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Abstract 
Hirschsprung’s disease (HD) is a congenital abnormality of unknown origin, 
characterised by a lack of ganglion cells in the distal colon which results in functional 
colonic obstruction.  The major cause of morbidity and mortality in these children 
results from an inflammatory condition called enterocolitis. 
Mucins are large glycoproteins produced by intestinal cells which are a vital part of the 
colonic defensive barrier to infection.  Previous work has found that this barrier is 
deficient in children with HD in the aganglionic colon and in the immediately adjacent 
ganglionic colon and that this is related to the risk of developing enterocolitis. 
This study aimed to further investigate the mucin defensive barrier in a greater region of 
the ganglionic colon in HD, to establish the extent of any mucin deficiencies and 
whether these were confined to a limited region close to the aganglionic colon. Mucosal 
biopsies were collected at intervals along the colon at the time of corrective surgery or 
colostomy closure in the controls.  Organ culture with radioactive mucin precursors was 
performed and the mucin produced was purified and analysed, results quantified by 
DNA content in the sample.  Lectin binding studies were also carried out. 
Patients were found to produce lower levels of new mucins most distally, but much 
higher levels five centimetres proximal when compared to controls.  The rest of the 
colon studied also showed changes in mucin production, with a lack of production of 
gel-forming mucins and sulphated secreted mucins in Hirschsprung’s disease higher up 
the colon. Lectin binding studies, which indicate the presence of existing mucins as well 
as those produced during organ culture, demonstrated greater levels of binding in 
patients compared to controls for wheat germ agglutinin and Maackia amurensis 
agglutinin. 
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Chapter 1:  Mucins 
1.0 Mucins – Basic Structure 
Mucus is a highly hydrated slippery gel containing many different constituents, 
including immunoglobulins, sloughed cells and bacteria.
1 , 2 , 3
  It is secreted by 
specialized epithelial cells lining the lumen of the gastrointestinal, respiratory and 
genitourinary tracts.  In the colon this gel layer serves as a lubricant in the passage of 
luminal contents, protects against mechanical trauma and acts as the first line of defence 
against potential colonic pathogens, foreign compounds and toxins by providing both a 
physical and a diffusion barrier.
4,5,6,7,8
  The thickness of mucus covering the mucosa 
gradually increases along the colon reaching
 
a maximum of 285 µm in the rectum. 
9
 
Mucus glycoproteins, otherwise known as mucins, are the main component of mucus.
10
 
They are very large, high molecular weight glycoproteins between 500,000 and 
30,000,000 daltons in size.
11
  Mucins can occur in secreted or membrane bound forms, 
the former being subdivided into gel-forming or non-gel forming.
11,12
  They are all 
identified by the abbreviation MUC. 
The basic structure of mucins consists of highly glycosylated repetitive sequences of 
threonine and/or serine residues.
11
 These oligosaccharide chains are linked via O-
glycosidic bonds, a linkage through an oxygen atom, a feature which characterises 
mucins and differentiates them from other glycoproteins.
13,12
 
Individuals make several structurally
 
different mucins and a given mucin may be found 
in more than
 
one organ.
14
 At least ten different mucin peptides are expressed in the 
gastrointestinal tract in a tissue-specific fashion, implying functional differences 
 17 
between different mucins.
15
  The main mucins expressed in the colorectum in humans 
from birth onwards are MUC2 and MUC4.
16
  MUC1 and MUC3 are also found in the 
colon but at lower levels.
17
  
To date at least twenty human mucin genes have been identified. 
10,18, 19
 The majority of 
these can be divided on the basis of their structural characteristics into three distinct 
subfamilies; membrane-bound, non-gel forming and gel-forming. 
Membrane-bound Mucins 
The membrane-bound mucin family is composed of eleven mucins. (Figure 1.1)  These 
mucins have a transmembrane domain, a short cytoplasmic tail, and an extended 
extracellular domain that forms the glycocalyx of epithelial cells.
11 
They are normally 
anchored to epithelial cells but can also be found in soluble form (proteolytic cleavage 
of the anchored form), secreted form (alternative splicing variants) and in a form which 
lacks the characteristic tandem repeat region (alternative splicing variants).
20,21,22
 
Because of shedding and direct secretion, cell-surface mucins can also be seen as 
components of secreted mucins.
23
 MUC3 is expressed in low levels in the colon but is 
more abundant in the small intestine.
14
 It is only expressed on mucosal surfaces and the 
upper parts of the colonic crypts.
24
 MUC4 is widely expressed in the colon and small 
intestine.
14
  
Membrane mucins appear to have several functions.  They form part of the cell-surface 
glycocalyx, protect the mucosa from pathogens, they can function as anti-cell adhesion 
molecules by virtue of their large negative charge and conversely can act as ligands (e.g. 
for P and E-selectins).
11,25,26 
 MUC1 may also aid in the maintenance of epithelial 
 18 
integrity, through its interaction with beta-catenin, which in turn interacts with other 
molecules important in cell-cell junction formation.
27,28
 
Secreted Non-gel Forming Mucin 
MUC7, MUC8 and MUC9 belong to this subgroup, although MUC8 has not been fully 
characterized.
19, 29
 These mucins have both a simpler structural organisation and lower 
molecular weight than the other human mucins.
30,31
  
Secreted Gel-forming Mucins 
This sub-family of mucins are secreted by goblet cells or other secretory cells and have 
the ability to form a gel which gives mucus its viscoelastic properties.  Five mucins 
make up this group.  (Figure 1.1)  These mucins are encoded by a cluster of four highly 
related genes on chromosome 11, region p15.5 and a similar gene on chromosome 
12.
32,19
   
MUC2 is the main gel-forming mucin in the colon
33, 34 
and immunohistochemistry has 
suggested that it is goblet cell specific.
14
 It is virtually absent from the soluble mucin 
fraction,
35
 but is almost the sole component of the insoluble mucin in the human 
colon.
36
 
In general all mucins share a common basic structure and this is crucial in conferring on 
them their functional characteristics.
12 
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Mucin Distribution Locus Reference 
Membrane-bound 
MUC 1 
Colon, stomach, breast, gall bladder, cervix, 
pancreas, respiratory tract, duodenum, 
kidney, eye, B & T cells, dendritic cells, 
middle ear 
1q21-24 
37, 10
 
, 38
  
MUC 3A/B 
Colon, small intestine, duodenum, gall 
bladder, middle ear 
7q22.1 
19, 39, 40
  
MUC 4 
Colon, stomach, respiratory tract, cervix, 
eye, middle ear 
3q29 
19, 41
 
MUC 11 
Colon, respiratory tract, reproductive tract, 
urinary tract, liver, thymus 
7q22.1 
42
 
MUC 12 
Colon, small intestine, stomach, pancreas, 
lung, kidney, prostate, uterus 
7q22.1 
42 
MUC 13 
Colon, small intestine, stomach, appendix, 
trachea, kidney, middle ear 
 
23 
MUC 15 
Colon, small intestine, spleen, thymus, 
prostate, testis, ovary, peripheral blood 
leukocyte, bone marrow, lymph node, tonsil, 
breast, foetal liver, lungs, middle ear 
11p14.3 
29 
MUC 16 
Peritoneal mesothelium, reproductive tract, 
respiratory tract, eye, middle ear 
19p13.2 
43
 
MUC 17 
Colon, small intestine, duodenum, stomach, 
middle ear 
7q22.1 
44
 
MUC 18 Melanocytic naevi  
45, 46
 
MUC 20 
Colon, kidney, placenta, lung, prostate, liver, 
middle ear 
 
46 
Gel-forming 
MUC 2 
Colon, small intestine, respiratory tract, eye, 
middle ear 
11p15.5 
19, 47, 48
 
MUC 5AC 
Stomach, respiratory tract, cervix, eye, 
middle ear 
11p15.5 
48, 49
 
MUC 5B 
Respiratory tract, salivary glands, cervix, gall 
bladder, seminal fluid, middle ear 
11p15.5 
48, 50
 
MUC 6 
Colon, Stomach, duodenum, gall bladder, 
pancreas, seminal fluid, cervix, middle ear 
11p15.5 
48, 49,
,
51
 
MUC 19 
Sublingual gland, submandibular gland, 
respiratory tract, eye, middle ear 
12 
52 
Non-gel forming (soluble) 
MUC 7 Salivary glands, respiratory tract, middle ear  
53, 54
 
MUC 8 Trachea/bronchus (not fully characterized)  
19, 55
 
MUC 9 Fallopian tube 1p13 
29, 56
 
 
Table 1.1: Human mucins identified to date   
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1.1 Mucins – Polypeptide Structure 
Mucins are polymers containing many subunits.  Each subunit consists of a central 
polypeptide core surrounded by radially attached oligosaccharide chains, giving a 
structure which has been likened to a bottle brush.
13
  (Figure 1.2) The polypeptide 
region is coded for by MUC genes 
57
 and consists of central domains and flanking 
domains.
10
 
 
Figure 1.1: A schematic representation of a MUC2 subunit showing the 'bottle brush' appearance.
58
 
The heavily glycosylated nature of mucins has made determination of their polypeptide 
structure very difficult due to the fact that the conditions necessary to deglycosylate 
them also cause a significant degree of proteolysis.
4
 Most of the information on mucin 
polypeptide sequencing has been obtained from recombinant DNA methods.
12 
The first central domain is characterised by tandem repeat peptide sequences.  These 
sequences are rich in threonine and/or serine amino acids, creating potential sites for 
oligosaccharide attachment 
31,38,40,59,60
 and contain at least one proline residue per repeat 
and normally many more.
11
  Proline appears to be important in governing the specificity 
of the initial galactosamine transferase responsible for mucin oligosaccharide 
synthesis.
61
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Different mucins exhibit variability in both the length and sequence of these domains. 
Tandem repeat sequences may be as short as eight residues as in MUC5AC, or as long 
as 169 residues in MUC 6.
34, 62
   Repeat sequences may also differ in their content of 
threonine and serine; from 75% in MUC5AC to only 25% in MUC 1.
11
  A lower 
percentage of these amino acids results in fewer potential sites for glycosylation and 
affects the mucin’s physical properties by making it less rigid.11 MUC2 contains two 
different tandem repeat regions, the central one containing 23 amino acid tandem 
repeats and a second upstream 347 residue domain of irregular repeats.
60, 63, 64
  The two 
domains are rich in threonine, serine and proline.
60, 64
 
In addition to variations between different mucins in the nature and length of their 
tandem repeat domains, individual mucins can also exhibit polymorphism in the number 
of their tandem repeats.
65, 66
 In MUC1 mucins, tandem repeat domains as short as 20 
nucleotides and as long as 125 nucleotides have been reported.
38 
Mucin genotype may 
confer different physical properties on the resulting mucin by varying the underlying 
structure of its protein product.
 11
 Tandem repeats can also vary in their repeatability. 
Some mucins have identical sequences, for example MUC7,
67
 whereas others 
demonstrate a more degenerate repeat sequence.
12
  In those mucins whose genomic 
organisation is known, the tandem repeat domain is encoded by a unique exon varying 
in size from 2.2kb (MUC7) to 21kb (MUC4).
68, 69
 
Secreted Gel-forming Mucins 
The other type of central domain is found in gel-forming mucins. These domains are 
rich in cysteine, poor in threonine and serine and may be interspersed by further tandem 
repeat domains.
63, 70
  In MUC2, two of these sequences have been identified flanking its 
second upstream repeat region,
64
 whereas in MUC5AC and MUC5B, these domains are 
 22 
more numerous and are separated by further repeat domains.
51, 70
  These ‘cysteine-rich’ 
domains in MUC2 contain potential N-glycosylation sites.
63
  N-linked glycosylation 
occurs between an oligosaccharide group and the amide nitrogen of an asparagine 
residue.  It can only occur if this residue lies within the tripeptide sequence Asn-X-Ser 
or Asn-X-Thr, where X can be any amino acid except proline.
61
 These linkages confer 
stability on secreted mucins and may assist in ensuring correct tertiary protein 
formation.
61 
Central domains are flanked on either side by other types of polypeptide regions.
63
 
Domains found particularly in gel-forming mucins are known as disulfide-rich D-
domains.  These were first described in von Willebrand’s factor (VWF) and have since 
been found in several other proteins.
71 , 72
  They can occur at either end of the 
polypeptide chain and are found in a similar number, position and size to those in 
prepro-VWF.
11, 63 
 MUC2, MUC5AC and MUC5B 
73
 contain four of these regions at the 
amino terminal end (N), designated D1, D2, D’and D3 and also one, D4, at the carboxyl 
(C) terminal.
12, 74,75
   The D domains have far fewer carbohydrate links than the tandem 
repeat domains and contain up to 30 ½ cysteines.
12
 (Figure 1.3) 
Downstream of D4 at the C-terminal in MUC2, MUC5AC and MUC5B are three other 
domains which show homology to further domains found in VWF namely, B-domain, 
C-domain and a cystine-knot (CK)-domain.
10, 56
 (Figure 1.3)  The C-domain consists of 
100-130 residues and has a similar make-up to those in the nearby tandem repeat 
domains, for example MUC2 contains 29% threonine, 18% serine and 20% proline.
63
 
This region is therefore sometimes known as  ‘mucin-like’.  The terminal 90-120 
residues are rich in cysteine and show sequence identity to those in the CK-domain in 
 23 
VWF in common with transforming growth factor β2, nerve growth factor and platelet 
derived growth factor.
12, 73
   
 
Figure 1.2: A schematic representation of the polypeptide domains of gel-forming mucins and their 
similarities to von Willebrand's factor (VWF), porcine sub maxillary mucin (PSM) and frog 
integumentary mucin (FIM-B.1) 12  
 
The ability to form mucin-type gels results from oligomerization of mucin core proteins 
mediated by D-domains.
76, 77
 Disulphide bonds form between cysteine residues; dimers 
at the C-terminal end and trimers at the N-terminal end.
78,79
  N-glycosylation in the 
region of the CK-domain influences the folding rate of mucin monomers to allow the 
structural maturation and stability of MUC2 dimers.
80
 Cysteine domains may also be 
involved in other intermolecular bonds through non-covalent linkages.
81
   The gel-
forming properties of this group of mucins is due to the complex, branching network of 
covalently linked mucin molecules and can be destroyed by reduction of disulphide 
bonds.
77 
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Within the cysteine-rich D4-domain of the MUC2 protein is an autocatalytic protein-
cleavage site at the motif GDPH (G = glycine, D = aspartic acid, P = proline, H = 
histidine).
77, 81
  Cleavage here produces a subunit called a ‘link protein’ and produces a 
new, reactive C-terminal which has the potential to link to O-glycans of other mucin 
molecules.
81
 This may explain the previously uncharacterized non-disulphide covalent 
bonds found between MUC2 monomers.
81
  This cleavage site is also found in those 
mucins containing D4-domains, MUC5AC and MUC4.
81
  It can be speculated that 
MUC4, a membrane bound mucin, could link to the gel-forming mucin complex via this 
linkage method aiding the complexity and viscosity of the mucus gel layer.
77 
Membrane-bound Mucins 
Membrane-bound mucins also contain tandem repeat domains but have neither D-
domains nor cysteine domains.
82
 However, they do exhibit two other regions, a 
transmembrane domain and a relatively short cytoplasmic tail which associates with 
cytoskeletal elements and cytosolic adaptor proteins and may participate in signal 
transduction.
74 
There are also domains in the extracellular juxtamembrane region.  One of these is the 
SEA domain (sperm protein, enterokinase, agrin), a long extracellular O-glycosylated 
region.
83
  During intra-cellular post-translational processing, a cleavage occurs at the 
SEA domain yielding two subunits.
84
  Although these subunits remain associated during 
biosynthesis, the α-subunit can be shed from the cell surface.85  The other domain found 
is one with close homology to the epidermal-growth-factor (EGF) family.
86
  Its function 
is not established but they are postulated to allow the interaction between cell-surface 
mucins and members of the EGF receptor family in regulation or signalling of functions 
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such as inflammation or differentiation.
86,
 
87
  Other domains which have been described 
include P-domains and domains similar to those found in the trefoil factor family.
88
  
The separation of mucins into membrane-bound and secreted is not absolute. In addition 
to membrane-bound mucins being able to link with gel-forming mucins, as discussed 
above, cell-surface mucin genes appear to undergo alternative splicing and encode 
isoforms, lacking transmembrane and cytoplasmic domains.
21,
 
89
  Due to secretion of 
these isoforms and the ability of subunit shedding, membrane-bound mucins can also be 
considered to be components of secreted mucins.
19, 23 
1.2 Mucins - Oligosaccharide Structure 
Oligosaccharides not only account for 80% of the dry weight 
90
 of a mucin molecule, 
they play a crucial role in its function, gel-like properties and stability. The highly 
glycosylated protein domains form long extended structures, which have a much greater 
solution volume, giving aqueous mucin solutions a higher viscosity than unglycosylated 
proteins.
12 
 It is the oligosaccharide chains which aid this structural formation by 
limiting the rotation around peptide bonds and also by mutual negatively charged 
repulsion forces between groups.
12
  The dense array of oligosaccharides also helps to 
protect the underlying polypeptide core from proteolysis by bacterial enzymes. 
Although there are variations in oligosaccharide chain length and antigenic structure 
between different mucins, they all share a similar basic structural pattern.
91
  
Mucin oligosaccharide chains contain, on average, 8-10 monosaccharide residues of 
five different types; fucose (Fuc), galactose (Gal), N-acetylglucosamine (GlcNAc), N-
galactosamine (GalNAc) and sialic acid.
44
  All mucin monosaccharides form six-
membered pyranose ring structures.
44
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Oligosaccharides of both secreted and cell surface glycoproteins, are classified by the 
nature of their linkage to the protein core. 
92
  They can be N-linked, via an amide 
nitrogen of an asparagine residue, (N-acetylglucosamine-asparagine) or O-linked, a 
linkage through an oxygen atom.
13,
 
93, 94
  In mucins the majority of the oligosaccharides 
are O-linked, the O-glycosidic linkages occurring between N-acetylgalactosamine and 
the hydroxyl amino acids of threonine and serine of the protein core.
91 
O-glycans form a very heterogeneous group with an extremely large potential for 
structural diversity.
94,
 
95
  Monosaccharides can undergo substitution at one or more of 
positions 2, 3, 4 and 6 of their pyranose ring with either an α or ß linkage.44 When this is 
considered alongside the possible differences in chain length, chain branching and 
combinations of individual monosaccharides, the resulting potential for variety is 
enormous.
44, 94, 95
  
Detailed studies on the composition of colonic mucin oligosaccharides have been 
achieved through cleavage of the O-glycosidic linkage by alkaline degradation of 
mucin. 
96, 97
  Many different distinct oligosaccharides have been identified but, despite 
the enormous heterogeneity this reveals, most represent variations on a limited number 
of basic structural types.
96, 97 
O-linked oligosaccharides can be described in terms of their core, backbone and 
terminal regions.
95
 Core structure refers to the primary linkage to the polypeptide chain 
and backbone to the subsequent monosaccharide sequence. Eight types of core structure 
have been classified depending on the branching and binding of the initial N-
acetylgalactosamine residue at position 3 and/or 6 (Figure 1.4).
95,
  
98
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Core 1 Gal β(1-3)-GalNAc α(1-O)-Ser/Thr 
Core 2 Gal β(1-3)-[GlcNAc β(1-6)]-GalNAc α(1-O)-Ser/Thr 
Core 3 GlcNAc β(1-3)-GalNAc α(1-O)-Ser/Thr 
Core 4 GlcNAc β(1-3)-[GlcNAc β(1-6)]-GalNAc α(1-O)-Ser/Thr 
Core 5 GalNAc α(1-3)-GalNAc α(1-O)-Ser/Thr 
Core 6 GlcNAc β(1-6)-GalNAc α(1-O)-Ser/Thr 
Core 7 GalNAc α(1-6)- GalNAc α(1-O)-Ser/Thr 
Core 8 Gal α(1-3)- GalNAc α(1-O)-Ser/Thr 
Figure 1.3: Difference O-linked oligosaccharide core structures found in mucins.
95, 98 
In human colonic mucins the majority are based on a core 3 structure, although 1, 2 and 
4 core-based oligosaccharides have been described, as well as small amounts of core 5 
and core 6 mucins.
99
   
Colonic mucins have backbones composed of repeating galactose and N-
acetylglucosamine units (Gal-GlcNAc) either linear or with branching side chains at the 
galactose residues.
95, 100 
  Backbones can be defined as either type 1 chain (Galβ1-3-
GlcNAc) or type 2 chain (Galβ1-4-GlcNAc) and consist of one or more of these 
disaccharide repeats.
101,
 
102
 
Mucin oligosaccharide chains are terminated by blood group substances.  These are 
specific carbohydrate complexes identified on the surface of red blood cells and are 
classified as either type 1 or type 2.
102 
 The underlying backbone structural type dictates 
which blood group substance type is attached and the variability within types is 
genetically determined, centring on the Lewis and the Secretor genes.
102 
 Type 2 is 
predominant in secretory mucins and includes the substances A, B, H, Le
b
, Le
a
 and 
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Sle
a
.
102 
Other intestinal mucins are predominately type 1 and include Lewis x and y 
(Le
x
, Le
y
) and SLe
x
 and show little expression in the normal gastrointestinal tract.
102
 
Sialylation precedes the final and terminating step of fucosylation in the biosynthesis of 
the blood group substances Sle
a
 and Sle
x
.
102
  Other blood group determinants include 
Sd
a
/Cad antigens which are other major structural features in human colonic mucin 
glycans.
24, 99 
Blood group probes and lectins have been used to identify terminal residues.
103,
 
104,
 
105
  
Lectins are proteins isolated from animal, plant and microorganisms which bind to 
specific non-reducing terminal monosaccharides determinants.  They include wheat 
germ agglutinin (WGA), Ulex europaeus agglutinin (UEA) and Maackia amurensis 
agglutinin (MAA) which bind to sialic acids and N-acetylglucosamine residues, fucosyl 
residues and α(2-3) linked sialic acids respectively.103, 106, 107 A terminal sugar can be 
part of a blood group determinant or a O-sulphate ester or sialic acid residue which has 
been added to a terminal blood group substance.
95, 100 
Mucins can be classified into neutral and acidic subtypes. The
 
latter are further 
differentiated into sulphated (sulfo or sulpho mucins) or
 
non-sulphated (sialomucins) 
groups. Neutral mucins appear to be
 
the predominant subtype expressed in gastric 
mucosa, whereas acidic
 
mucins are expressed throughout the intestinal epithelium and
 
dominate in the large intestine. 
108
 
Colonic mucin is particularly rich in sialic acids (sialomucins) which differ from other 
sugars within mucin oligosaccharides by having an acidic carboxyl group and a three 
carbon side arm which can exist in a number of variant forms.
102 
 Sialic acid is largely 
limited to the secretory mucins of the small and large intestine where it can be added to 
short core structures, the backbone or terminal blood group substances. 
102
 The most 
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common form of sialic acid in humans and the common precursor for all sialic acids, is 
N-acetylneuraminic acid (Neu5Ac), a nine carbon pyranose amino sugar which has a 
carboxyl group at its anomeric carbon.  This monosaccharide is found in many variant 
forms including O-acetylated and N-glycolyl. 
109
   
Neu5Ac is most commonly is found as a single terminal residue joined to an underlying 
galactose or GalNAc by an α-2,3- or α-2,6- glycosidic linkage.99, 100 Exceptions to this 
usual pattern are α-2,8- linked sialic acids which can be attached to an underlying α-2,3 
sialic acid residue.
99
 Almost 50% of mucin sialic acids are O-acetylated, approximately 
30% substituted by di-or tri-O-acetyl esters and 15% as mono-O-acetyl esters.
100
  O-
acetyl groups can be substituted within the carbon side arm at C4, C7, C8 or at C9. 
110
 
Differing levels of O-acetylation between individuals is likely to be due to genetic 
variation in the gene coding for O-acetyl transferase (OAT). Approximately 9% of 
Caucasians, for example, are homozygous for the inactive version of this gene and 
consequently only produce non-O-acetylated sialic acids.
102 
Mucus glycoproteins are also rich in carbohydrate O-sulphate esters (sulfomucins). 
111
  
Sulphation is most frequently found on Gal and GlcNAc residues in N-acetyl-
lactosamine sequences, specifically at the 3-position of Gal and the 6-position of 
GlcNAc of O-glycan cores and their elongated structures, either as a terminal residue or 
in a more internal position.
44, 112
 The majority of oligosaccharides in the colonic mucosa 
consist of between 4 – 12 monosaccharides and are both sialylated and sulphated, 
sulphation being particularly characteristic of colonic mucins.
100
  Sulphation not only 
adds negative charge to mucins, it also protects the mucin from bacterial degradation.
111, 
113
  Sulphate can also be added to the mannose residues of N-glycan chains 
114
 and to 
sialyl Lewis
x
 determinants attached to core 2 O-glycans.
115
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Sialic acids and sulphate esters ionise at all but the lowest pH values resulting in 
negatively charged residues.  In colonic mucins the high density of sialic acids and 
sulphate esters and the resulting repulsion between these negatively charged groups 
causes the expansion of their tertiary structure and a rise in their viscous properties.
44 
1.3 Mucins - Multimeric Structure and Assembly 
It has proved difficult to elucidate the multimeric structure of mucins. Their large 
molecular size and high carbohydrate content mean that conventional protein chemistry 
investigative tools do not work.
12
  As previously mentioned, mucins show significant 
homology to VWF in their terminal regions, the D-domains, where a high cysteine 
content creates potential for di-sulphide linkages.
116,117
  The combination of information 
obtained from work on porcine sub maxillary mucin (PSM) using mucin encoding 
plasmids with assumptions based on what is already known about VWF tertiary 
structure has led to a proposed model for mucin polymerization.
116, 117, 118 ,
 
119
   
The assembly of mucin multimers involves several stages, some in the endoplasmic 
reticulum (ER) and some in the Golgi apparatus.  The current model for mucin 
oligomerization is that mucin monomers undergo dimerization in the endoplasmic 
reticulum by the formation of disulfide linkages between their CK-domains within 
minutes of their biosynthesis.
48, 79, 117
 This occurs preceding or concomitant with N-
glycosylation which also takes place in the ER and is thought to be important in 
ensuring the correct folding of mucin dimers.
19, 79
 
The incorporation of O-linked oligosaccharides begins after dimerization and N-
glycosylation.
 69  
In cells expressing secreted mucins, e.g. intestinal goblet cells, O-
glycosylation is initiated in the cis-Golgi, although in other mucin-producing cell lines 
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this starts in the ER.
 79, 120
 This process continues in the medial- and trans-Golgi 
compartments, where the glycosyltransferases necessary for elongation and termination 
of the oligosaccharides are located.
12 
Glycosyltransferases transfer sugar residues from 
an activated donor substrate, usually a nucleotide sugar, to a growing carbohydrate 
group.
121
  Terminal glycosylation sequences are likely to reflect the glycosyltransferases 
which are expressed in the cell.
121 
The control of O-glycan biosynthesis is not well understood but is thought to involve 
many different factors.
15
 Heterogeneity of O-glycans is likely to be dictated by various 
factors: regulation of glycosyltransferase genes, availability of acceptor and sugar 
nucleotides, enzyme competition for acceptor intermediates and 
compartmentalization.
15, 94, 95
  
The first stage in mucin O-glycosylation is the α link addition of N-acetylgalactosamine 
to the hydroxyl group of a serine or threonine residue in the polypeptide core.
95, 122
  The 
enzyme involved in this process is UDP-GalNAc:polypeptide GalNAc transferase and 
the presence of proline in a triprolyl sequence nearby appears to be important .
61
  
The next stage is elongation, where further O-linked oligosaccharides are added 
individually to the polypeptide chain, the initial elongation step determining the type of 
core the oligosaccharide will have.
95  
 In O-glycosylation all the sugars are added by 
individual transfers (glycosyltransferases) from their nucleotide derivatives on the 
luminal surfaces of the ER and/or Golgi complex, in contrast with N-linked 
oligosaccharides which require preformed oligosaccharide intermediates.
94, 95
  The 
expression and compartmentalization of glycosyltransferases may be the predominant 
factor in determining final oligosaccharide structure, although the position and structure 
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of previously added oligosaccharides is also known to influence subsequent 
glycosylation.
123,
 
124
 
Sugars are sequentially added until a terminal sugar residue (to which no other sugars 
can be added) ends the process. This is commonly sialic acid (Neu5Ac), sulphate or 
fucose, but can be N-acetylgalactosamine, α-galactose or a blood determinant.95  
In common with all monosaccharides, the formation of Neu5Ac begins with glucose 
125
 
which is phosphorylated to glucose-6-phosphate. (Figure 1.5) This is then converted to 
fructose-6-phosphate by the action of an epimerase and an amino group is transferred 
from L-glutamine to create glucosamine-6-phosphate; the precursor for N-acetyl 
glucosamine, N-acetyl galactosamine and N-acetyl neuraminic acid.  Radiolabeled [H
3
]-
glucosamine, used in organ culture, can be incorporated during these stages.
126
    
 
 
Figure 1.4: Metabolic pathways for the generation of nucleotide sugars including sialic acid. 
(Modified from Varki, 1994) 127 
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The addition of sialic acid to an O-glycan chain occurs in the trans-Golgi.  The 
sialyltransferases which mediate this action require the sialic acid to be in its sugar 
nucleotide form, CMP-Neu5Ac, which is first formed in the nucleus before being 
transported into the Golgi apparatus.
128
  
A particular feature of colonic mucins is the presence of sulphate esters with the most 
highly sulphated mucin population being found in the rectum.
112
  In secreted mucins 
core structures 1 - 4 and 6 can serve as potential substrates for sulphotransferases 
(STs).
129, 130
   Two families of sulphotransferases have been identified which transfer 
sulphate from 3’-phosphoadenosine 5’-phosphosulphate (PAPS) to either the 3-position 
of Gal (Gal3ST) or the 6-position of GlcNAc (GlcNAc6ST) residues within N-acetyl-
lactosamine sequences.
112, 
 
131
  This is the most frequently found form of sulphation in 
mucins.
112
  In addition other sulphated epitopes may be found on mucins, catalysed by 
different sulphotransferases, for example GalNAc 4-sulphate and Gal 6-sulphate 
linkages and can be added to core sugars or to N-glycan chains.
112 
Sulphotransferases are located in the trans-Golgi.
112
 Sulphation can block certain 
pathways and prevent oligosaccharide branching and elongation e.g. once core 1 is 3-
sulphated, core 2 cannot be formed.
112, 132
 
High molecular weight mucin multimers are created from dimers after N-glycosylation 
and initial O-glycosylation.
133
  Interchain disulphide bonds form between cysteine 
residues in the amino terminal D-domains of dimers.
116, 117
  All of the amino terminal D-
domains in continuity appear necessary for multimerization although the disulphide 
bridges are actually established between two D3 domains.
118
  The other D-domains are 
thought to prevent inappropriate multimerization in the ER and the cis- and trans-
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Golgi.
12
  Instead of a linear polymer structure, MUC2 appears to form into trimers via 
its N-termini suggesting that it will form branched networks.
78  
Once in a polymerized state, mucin gels can exist in either a condensed phase or an 
expanded hydrated phase.
134
  Condensing granules bud off the trans-Golgi apparatus 
and form into mature secretory granules within the apical cytoplasm.
135
 While in a 
secretory granule mucins exist in a condensed state.  As the secretory granule docks on 
to the plasma membrane, a secretory pore is formed and Ca
2+
 from inside the pore is 
exchanged with extracellular Na
+
, driving water into the granule and converting the 
mucin to its hydrated phase.  The resulting massive swelling of the granular content 
drives the release of the mucin into the extracellular space and its formation into a 
gel.
134 
The dense glycosylation causes an extended conformation allowing the 
molecules to occupy large volumes.
12, 78
  
MUC2 occurs as an insoluble complex that resists
 
extraction with guanidinium chloride 
unless disulfide bonds are
 
cleaved.
35,
 
36, 
  The formation
 
of insoluble MUC2 gel is likely 
to involve "cross-links"
 
in addition to those that join mucin monomers into
 
larger 
structures.
136
  Within the polypeptide C-terminus of MUC2 is an autocatalytic protein-
cleavage site between the D and P residues.  Cleavage at this point yields a subunit 
which is believed to have a role in cross-linking mucin core proteins to the 
oligosaccharide side chains of MUC2, establishing higher order structures in the mucus 
gel.
81
  Further intra and intermolecular disulphide bonds are also likely to be involved.
81
 
Proposed other intermolecular interactions include hydrogen bonding, hydrophobic 
interactions and physical entanglements.
137
   
Different forms of MUC2 have been identified; N-glycosylated protein core in 
monomeric or dimeric forms in the cell layer, partially glycosylated oligomerized 
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intermediates and the fully glycosylated oligomerized form in both the secreted medium 
fraction and the cell layer.
138
  
Exocytosis involves two distinct processes,
 
baseline secretion and compound 
exocytosis. Baseline secretion or simple exocytosis which occurs under normal 
conditions involves a continuous low rate release of newly synthesized mucin granules, 
present in the apical regions of the goblet cells.
139
 Compound exocytosis is an 
accelerated secretory event regulated by endocrine, paracrine, neurocrine and immune 
pathways.
135 
 It results in the acute release
 
of centrally stored mucin granules and occurs 
in response to a stimulus which may be a neuroendocrine agent (e.g. vasoactive 
peptide), a cytokine (e.g. interleukin 1) or other compounds (e.g. adenosine 
triphosphate.
135, 140 , 141
  Only a certain fraction of the total mucin produced in the 
colonocyte and the goblet cells in a twenty four hour period is secreted out of the cell.   
1.4 Mucins - Role and Function 
The colonic epithelial barrier consists of a highly specialized columnar cells arranged in 
a single layer lining the crypts and flat mucosal surface.  These cells have several 
functions as well as providing a simple physical barrier to infection and damage.  They 
secrete water, ions and macromolecules, the constituents of mucus, which washes away 
and dilutes potentially harmful agents.
135
  
Mucus is produced mainly by goblet cells, specialised secretory epithelial cells, but also 
by enterocytes.
24
 Mucus consists of water (up to 95% by weight), mucins (no more than 
5% by weight), inorganic salts, carbohydrates and lipids.
142
  In the colon the mucus 
barrier consists of an inner insoluble layer, next to the goblet cells, almost completely 
devoid of bacteria and an outer viscous soluble layer containing a mixture of bacteria, 
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mucins and cell debris.
9, 143
  In addition, a layer of surfactant lipids secreted by epithelial 
cells coats the surface of the mucus gel preventing penetration by water soluble 
toxins.
144
 
One of the main roles of mucus is to provide a protective barrier between the gut lumen 
and the epithelium by physically covering cell surface glycoconjugates thereby 
preventing the adhesion of enteric pathogens.
145
 Within this layer a stable 
microenvironment is formed which, while being readily permeable to ions and low 
molecular weight solutes, is a physical barrier to larger molecules, such as proteases and 
toxins, which could cause epithelial damage.  Pathogens must bind to the mucus layer 
and then penetrate through it to gain access to the epithelial cells.
146
 
The mucus matrix can also serve as a highly selective barrier possibly by locally 
concentrated oligosaccharide chains functioning in a similar way to ion-exchange or gel 
filtration and facilitating or restricting diffusion.
77
 In the stomach bicarbonate ions 
secreted by the epithelium are held within the mucus creating a pH gradient from pH 2 
at the stomach lumen to pH 6-7 at the cell surface.  At a pH above pH 4, hydrochloric 
acid (HCL), can form channels within mucus, allowing it to pass through.  However, 
below pH 4 it cannot penetrate the mucus layer.  This allows secreted HCL to pass into 
the stomach lumen while simultaneously preventing luminal HCL access to the 
epithelium.  This function may be in part influenced by sialic acid structure.
77, 
 
147
  
Mucin gels bind other biologically active molecules.  One important group of such 
molecules is the trefoil factors (TF), a family of peptides containing the trefoil motif.
148
  
They are expressed by most mucin-producing epithelia, including the gastrointestinal 
tract, and bind to the D domains of mucins.
149
  As well as contributing to mucus 
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viscosity they also promote cell motility and differentiation, have an anti-apoptosis 
effect and promote wound healing and mucosal repair.
150, 151
  
Cytokines are also found in mucus gels bound to oligosaccharides.  Disruption to the 
mucin barrier, by physical or chemical means, could cause their release, leaving them 
free to instigate an inflammatory reaction.
77
  Secretory immunoglobulin A (sIgA) is 
retained at high concentrations within mucus where it can trap the progress of 
pathogens.  The exact nature of this binding is not clear but mucin integrity is important 
for its efficacy.
19
 Mucins also bind antimicrobial molecules (e.g. histatin-1) and their 
oligosaccharides may even have direct antimicrobial activity.
152, 153
 
Many pathogens need to bind or penetrate epithelial cells in order to cause pathology.  
This is reflected by the widest diversity of cell-surface mucins being found in the colon, 
the most microbe rich environment.
19
  Membrane bound mucins are likely to be able to 
provide signals to epithelial cells in response to alterations in the mucin layer, through 
changes in conformation or ligand status of their extracellular domains.  This may cause 
changes in epithelial cell proliferation, differentiation or cell-adhesion.
77
 It is also 
probable that these cell-surface mucins act as releasable decoy ligands for microbes 
trying to attach to the glycocalyx.
19
 Individuals with MUC1 alleles which have smaller 
extracellular domains have a greater risk of developing gastritis after Helicobacter 
pylori infection.
154
 
Secreted mucins express many oligosaccharide structures which are also found on the 
epithelial cell surface which could allow mucins to act as decoys for bacterial 
adhesins.
19 
  Streptococcus pyogenes and enteroviruses bind to sialic acids which are 
found on the epithelial surface and on mucins.
19, 155
  Some mucins also act as viral 
agglutinating agents.
19 
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Mucus offers several ecologic advantages to intestinal bacteria. Colonization of mucus 
may allow the bacteria to avoid rapid expulsion and confer a growth advantage.
19
   
Nutrients such as vitamins and minerals may be available within the mucus matrix as 
well as the enzymatic digestion of mucins providing a potential source
 
of carbohydrates 
and peptides.
145
 Bacterial colonization may also confer advantages to the host by 
retaining pathogens in the mucus layer, away from the epithelium and by providing a 
favourable environment prevent pathogenic bacteria gaining a niche.
19
   
Mucus secretion is typically enhanced in response to intestinal
 
microbes.
156
  Cholera 
toxin
 
of Vibrio cholerae, triggers massive mucin release via
 
a cAMP-dependent 
mechanism
157
 but conversely, Clostridium
 
difficile toxin A exerts an inhibition
 
of 
compound mucin exocytosis, although without altering baseline (constitutive)
 
mucin 
secretion when added to HT29-Cl.16E cells.
158
  Bioactive factors released by mucosal 
immune cells also regulate the composition of mucins.
19
   For example TNFα increases 
α-2,3-sialyltransferase expression in HT29 cells suggesting that it triggers an increased 
synthesis of sialomucins.
159
   Other factors which seem to enhance mucin secretion 
include pro-inflammatory cytokines and prostaglandins.
160, 161
 
At the level of the mucus barrier there is a constant dynamic equilibrium between mucin 
synthesis and mucin degradation. The normal enteric bacterial flora secrete a range of 
enzymes which act to continually break down the mucin gel as more mucus is 
produced.
100 
  A balance between these conflicting processes is necessary to maintain a 
functional defensive barrier at the mucosal surface.
90
 While mucus shedding and 
degradation rates exceed colonization rates, pathogenic bacteria are eliminated.
146 
  The 
structure of colonic mucins is specifically adapted to cope with the degrading activity of 
the micro flora.   
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The breakdown of mucins occurs in a stepwise manner that begins with proteolysis
 
of 
the non-glycosylated "naked" regions of the mucin glycoproteins
 
by host and microbial 
proteases.
162
  This initial step markedly
 
reduces mucin gelation and viscosity and results 
in the accumulation
 
of highly glycosylated subunits (>500 kDa) that are resistant
 
to 
further proteolytic attack.
163
  Before the remainder of the protein core can be 
hydrolysed, the oligosaccharide chains must first be broken down.
90 
 Bacterial enzymes 
breakdown the mucin oligosaccharide chains sequentially, starting from the peripheral 
non-reducing end of the chain.
90
  The rate of further degradation is therefore dependent 
on the efficient removal of these terminal residues.
100 
In colonic mucins up to 50% of these terminal residue positions are occupied by O-
acetylated sialic acids.
24, 164 
  Bacterial sialidases act to remove sialic acids but they are 
slowed down or blocked by the presence of two or more O-acetyl esters on the C7-C9 
tail of these monosaccharides.
24, 165
   These specific terminal residues acting in this way 
control the overall rate of mucin degradation. Removal of these O-acetyl esters, by 
sialic acid O-acetyl esterase, allows the abundant sialidase activity, normally present in 
the colon, to desialylate the oligosaccharide chains thus freeing up sites for further 
degradation by other glycosidases.
166
   Some enteric bacteria secret a specific sialic O-
acetyl esterase to overcome this block.
167
  
The other type of acidic mucins, sulfomucins, may also protect against bacterial 
activity.  Sulphated
 
mucins appear less degradable by bacterial glycosidases and
 
host 
proteases.
168
  Sulphate esters may mask antigenic or lectin binding sites, may also 
regulate the biosynthesis, half-life and biological roles of glycoproteins and may control 
lymphocyte homing and inflammation, so sulphation is also an important regulatory 
feature in colonic mucins.
112, 169  
  The presence of mucin oligosaccharide-specific 
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sulphatases in the colon has been established 
170
, in particular bacterial enzymes with 
specificity for galactose-6-O-sulphate and GlcNAc-6-O-sulphate.
100 
Sulphated glycans add negative charge to mucins which affects their physical and 
chemical properties including hydration and metal ion binding.
113
 They are also 
involved in functions such as cell signalling, cell adhesion and inflammation.
171
  
The highly heterogeneous nature of O-glycans may be an important aspect of mucosal 
defence.  O-glycans may mediate specific binding of antibodies and microbes and be 
important in host-pathogen interactions as well as inflammation and cancer metastasis.
24 
  
Oligosaccharide chains are known to mimic cell surface receptors and microbes bind to 
them, rather than reaching the mucosal surface.
91
  Their diverse nature means that they 
are able to trap a broad diversity of microorganisms and the terminal residues are the 
primary targets for this interaction.
24, 94, 101
   In pathogenic bacteria their ability to bind 
to a target residue appears to be related to its enzymatic capability. For example, 
Salmonella typhimurium binds
 
preferentially to a glycoprotein containing sialic acid
 
and 
possesses a sialidase.
172,
 
173
 
Binding to specific O-glycans by commensal bacteria could also aid mucosal defence by 
facilitating their mucus colonization and therefore providing them with a growth 
advantage over pathogenic bacteria.
174
  Multiple potential attachment sites for 
commensals may be a further way in which mucin structure acts as a major influence in 
dictating the composition of the enteric bacterial flora.
15
  
Different glycosylation patterns are known to exist along the length of the intestine. A 
gradient has been demonstrated from ileum to rectum with a pattern of decreasing levels 
of fucose and ABH blood group expression and increasing levels of sialic acids and 
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acidity.
24 
 Sd
a
/Cad antigens are absent in the ileum and increasingly expressed along the 
length of the colon.
24,  99 
  This gradient of variability may help to explain the region-
specific bacterial colonisation in the colon, the different glycans available enabling a 
given microbe to establish a niche that it can occupy.
24 
 In a similar way, resident 
colonic flora may differ among individuals because of variations in the specific
 
carbohydrate composition of their intestinal mucins.
175, 
 
176
 
Increased concentrations of sulphated mucins have also been found in the more distal 
areas of the large bowel.
104, 177, 178
  This increase in the proportion of acidic mucins 
along the intestine appears to mirror the increase in microbial population.
179
  
It has been shown that the structure of mucins, in particular their post translational 
modifications, are crucial in limiting their own degradation.  The rate of mucin 
breakdown must equal the rate of mucin production in order to maintain mucosal 
defence. Alterations in mucin structure and composition may therefore be integral in the 
pathogenesis of gastrointestinal disease. 
1.5 Mucins – Alterations in Disease 
Mucins are an important area of study for many diseases.  Quantitative and qualitative 
alterations have been documented.  Changes in mucins structure and production have 
been implicated in the pathogenesis of conditions as varied as cystic fibrosis and gastric 
cancer.
37, 180
  
A reduction in the ability to produce mucus will lead to a thinner protective layer.  In 
ulcerative colitis which affects the colorectum, there is a reduction in the thickness of 
the mucus layer compared to the normal healthy colon.  This appears to be a 
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consequence of a depletion of the number of goblet cells in the affected mucosa.
57, 
 
181
  
The inner layer of mucus also appears to be reduced over the surface of colonic 
carcinomas and polyps, allowing closer contact between epithelium and luminal 
contents, including lectins which are known to affect mucosal proliferation.
182 , 183
 
Mucin derived from inflamed rabbit colons shows a reduced inhibition of adherence of  
Escherichia Coli, using an in vitro binding assay, compared to mucin derived from 
normal colons.
156
   
Differing levels of mucin gene expression is one of the ways that disease may manifest.  
In normal stomach mucosa MUC1, MUC5AC and MUC6 are ordinarily expressed.  In 
the transition from early to later stages of intestinal metaplasia, there appears to be a 
gradual change in mucin type, from the additional of MUC2 to the normal mucin make-
up, to the replacement of stomach mucins with MUC2 and MUC3 alone.
37 
  In 
ulcerative colitis it seems that alterations in MUC2 expression are closely related to 
inflammation as during active disease. Reduced levels of biosynthesis of MUC2 
precursors and total MUC2 are found, while normal levels are detected during 
remission.
184
  MUC2 is the most prominent mucin in the colon but in colonic 
adenocarcinoma, MUC5AC is in abundance.
185
   Some microbes can directly alter 
mucin gene expression, e.g. H. pylori suppressing MUC1 and MUC5AC gene 
expression in a human gastric cell line.
186
 
Mucin production is altered in a similar way in the inflammatory bowel condition 
Crohn’s disease.  This has not only been found in the diseased bowel, where MUC1 is 
reduced, but also in healthy ileal mucosa, which expresses lower levels of MUC3, 
MUC4 and MUC5B than normal controls.
187
  As Crohn’s disease often involves or 
starts in the terminal ileum and MUC3 and MUC4 are the main mucins expressed in this 
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region of the intestine, this may represent a primary, or at least very early, mucosal 
defect in these patients.
187
    
In gastrointestinal disease, changes are found at the level of mucin oligosaccharide 
chains. Mucins produced by colorectal cancer cells have a reduced number and length 
of carbohydrate chains, suggesting a general decrease in glycosylation or premature 
terminal of the glycan chains.
188
 Alterations in the length of oligosaccharides can result 
in the formation of new antigenicities, for example Tn, T and sialyl Tn.
57, 102
  All three 
of these epitopes are expressed in over 90% of colorectal cancers but are absent from 
normal mucosa.
189
  There appears to be a progression in their appearance with T antigen 
being found in well and moderately differentiated tumours and Tn in more poorly 
differentiated carcinomas.
57 
  However, other authors have found no strong evidence for 
the presence of T antigen in either normal colon or adenocarcinoma.
190
 
Differences in amounts of sulphated and sialylated mucins and alterations in the levels 
of O-acetylesterase and sulphatase activity are associated with gastrointestinal 
pathology.
191, 192
  The terminal oligosaccharide, sialyl-Lewis
x
,
  
has also been associated 
with malignancy and metastases.
77, 193
  This antigenic site is normally masked by O-
acetylation.
191 
 Loss of sialic  acid O-acetylation occurs throughout the whole sequence 
of transformation from adenoma to carcinoma and is present at the earliest stages of 
premalignancy.
126 
  It is therefore likely that the appearance of the sialyl-Lewis
x
 epitope, 
as well as other epitopes, is secondary to these changes.
102 
  S-fimbriated Escherichia 
coli which cause sepsis and meningitis in newborn infants have been shown to bind to 
certain sialic acid containing structures on human erythrocytes.
194
      
Loss of colonic mucin sulphation has been found in ulcerative colitis.
192
  Lack of 
sulphation may affect the viscoelastic properties of the mucins and increase the rate of 
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bacterial degradation.
100
   Increased levels of faecal sulphatase activity, in particular 
those which cleave 6-sulphated sugar linkages, has been documented and may 
contribute to the reduced sulphation found in this disease.
164 
 Reduced turnover of 
sulphate in ulcerative colitis has also been demonstrated 
111
 and this, in combination 
with a reduction in fucosylation, is found in European colitics with severe disease.
181 
Alterations in enzyme activity are key features underlying mucin changes in colonic 
cancers. Reduced levels of mucin sulphation is a common finding in adenocarcinoma.
111
 
Cultured cancer cells have shown a loss of sulphotransferase activity suggesting that 
this may be the primary defect.
100
  Further detailed work on colonic cancer cultured cell 
lines has shown typical changes in the activity of a number of key 
glycosyltransferases.
192
  
The normal pathway in colonic mucin production is through core 3 and core 4 
pathways. In malignancy, alterations of these key glycosyltransferases  block certain 
pathways  resulting in a switch from core structure 3, to core 1 and  core 2.
196 
 
Alterations in core structure can have a knock-on effect on the rest of the 
oligosaccharide structure and a reduction in branching and a modification of sialylation 
have also been noted.
102, 
 
195
  Increased expression of specific glycosyltransferases can 
also lead to the aberrant expression of blood group determinants in gastrointestinal 
malignancies. One example is fucosyltransferase-4 which is associated with increased 
expression of the Ley blood substance.
196
  
Mucin alterations appear to play a major part in pathogenesis of many diseases, whether 
as a primary defect or as a consequence of a pathological process.  
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1.6 Mucins – Alterations in Children 
There is little information known about the role of mucins in disease of childhood and 
the variations which occur with age. 
Immediately after birth, the gut is practically sterile but during the first 12 to 24 hours of 
extra uterine life becomes colonised with maternal and environmental flora.
143
 
Escherichia coli and Enterococcus sp appear first followed by obligate anaerobes, 
Bifidobacterium and some Bacteroides sp in breast fed babies. In babies fed formula 
milk, the opposite occurs: Bacteroides sp. predominate and are accompanied by some 
Bifidobacterium sp.
143
   The infantile flora gradually evolve toward a normal adult flora 
during the next two years of life but during this time the flora are not stable or diverse 
and so are easily subject to disturbances and imbalances which is reflected in the highest 
incidence of enteropathies and food allergies occurring between 0 and 2 years of life.
143
 
The first bacteria to colonize the neonatal gastrointestinal system depend on the innate 
repertoire of bacterial adhesion sites, which varies according to genome.   If these 
bacteria have glycolytic potential, new binding sites will appear so new bacteria can 
colonize, resulting in every person having their own unique intestinal flora.
143
   Resident 
bacteria can also influence the carbohydrate repertoire of mucins by sending messages 
to host cells which interfere with the expression or activity of cell 
glycosyltransferases.
197
 
Mucin genes and mRNA have been found to be expressed in the early stages of the 
development of the human gastrointestinal system.
76 
  The MUC5AC gene is not 
normally expressed in the adult intestinal tract and the MUC4 gene is only found in low 
levels in the adult small bowel.
76
   However, both have been detected in foetal gut, 
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MUC5AC at 12 to 13 weeks gestation and again at 27 weeks and MUC4 at high levels 
in foetal small intestine at 12 and 13 weeks gestation.
76 
   Some authors have suggested 
that mucin genes may be involved in the development of enterocytes.
76 
  The adult 
pattern
 
of major MUC2 and MUC4 gene expression and low to background MUC1
 
and 
MUC3 predominates from birth onwards.
198
  
In situ hybridisation studies have shown the pattern of mucin mRNA expression in the 
foetal colon.
198, 199
  MUC2 mRNA was seen by 12 weeks gestation in the colon, MUC3 
and MUC4 at around 13 weeks, the former at high levels, the latter low levels.
199
 These 
decreased towards term and by 18 weeks MUC1 was detected in the colon.
198, 199
   
MUC5AC mRNA was also transiently seen in colonic goblet cells at week 17.
199 
Mucin sulphation within the colon starts as early as the 14
th
 gestational week in the 
lower crypts and at 20 weeks in the upper crypts, but O-acetylated sialomucins do not 
appear
 
until after the 23 week.
200, 201
   In the foetus and at birth, colonic goblet cells are 
mainly sulphated.
163 
 Glycoprotein synthesis appears to be completed by 23 weeks 
gestation.   No affinity for the lectin UEA has been detected in foetal or neonatal 
colon.
201 
In the mouse colon from day 14 of life, sialylated mucin containing goblet cells were 
only found in colonic crypts and sulphated mucin containing goblet cells were found on 
colonic cuffs.
163 
  Acidic mucins predominate at birth and the ratio of neutral to acidic 
mucins increases between birth and weaning and decreases after weaning.
163
 However, 
under germfree conditions, the ratio of neutral to acidic mucins
 
in the mouse colon is 
higher, and sulphated mucins appear to increase at
 
the expense of sialylated mucins 
which suggests that exposure to bacteria may influence mucin structure.
 163
   The human 
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adult pattern of sialylated mucins in goblet cell crypts and sulphated mucins in the cuffs 
becomes more distinct in the distal infantile colon after weaning.
163
   
Studies on weaning pigs have found an increase in mucin secretion with age as well as 
an increase in the sulphate content of the mucins in the older animals.
202
  Further lectin 
binding studies on the structure of membrane bound mucins in these animals have 
shown differences.  The expression of membrane glycoconjugate moiety Neu5Ac α-2,6 
recognized by Sambucus nigra agglutinin-1, was high in newborn pigs, declined in 
suckling animals and was very low in weaned animals.  Conversely, the expression of 
the membrane bound moiety Neu5Ac α-2,3 recognized by Maackia amurensis 
agglutinin-2 was low after birth but increased in the older animals.
203
   
Robbe-Masselot et al looked at lower gastrointestinal foetal oligosaccharides and found 
that the majority were based on core 2 structures and in contrast to adult mucins, 
Sd
a
/Cad determinants were not expressed on foetal O-glycans and there was not an 
acidic gradient along the intestinal tract.
204
   During foetal life there is expression of 
type 2 blood group substances A, B, H and Le
b
 by secretory mucin throughout the 
gastrointestinal tract. 
102
   After birth these blood group sequences are restricted to the 
foregut and midgut. 
102
  
Organ culture experiments measuring mucin production by colonic mucosal biopsies 
have shown that older children incorporate a greater proportion of sulphate compared to 
glucosamine, especially in the secreted mucin fraction.
205
   Children under 3 months 
produced the greatest amount of mucin per unit DNA and those children between 3 
months to 3 years the lowest.  Further studies measuring both radiolabeled and 
unlabeled mucins have shown similar results with a high turnover in the youngest 
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children, a drop in turnover in the middle age group followed by a rise in the oldest 
children.
205 
Looking at these age groups further, there was a statistically significant increase in the 
ratio of mucin sulphation incorporation between the youngest and the oldest age groups 
and a linear increase in the sulphation with increasing age.  Other experiments have 
shown that this was due to an increase in sulphate and not a reduction in glucosamine 
incorporation. 
205
   O-acetylation of sialic acids appears to occur at similar levels to 
adults.
169 
Mucins are an important part of mucosal defence and their alterations in quantity and 
quality have been implicated in many different disease processes.   Colonic mucin 
defence evolves during infancy and childhood so it is logical to assume that the 
pathogenesis and disease progression of conditions affecting the colon in children may 
be influenced by changes in mucin integrity.  One such condition is Hirschsprung’s 
disease. 
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Chapter 2:  Hirschsprung’s Disease 
and the Enteric Nervous System 
Hirschsprung‟s disease (HD), or congenital intestinal aganglionosis, is a congenital 
condition of unknown origin characterised by an absence of ganglion cells in the distal 
colon. It usually presents in childhood and can cause considerable morbidity and even 
mortality in those children affected.   
2.0 Hirschsprung’s Disease – Historical Background 
In 1691, Frederick Ruysch a Dutch anatomist, described a child with intestinal 
obstruction who was probably suffering with HD.  However, it was not until almost two 
hundred years later in 1886 that this condition was formally characterised by Harold 
Hirschsprung.  He initially presented the case of two children to the Paediatric Congress 
in Berlin, the title of his presentation being “Constipation in newborns due to dilatation 
and hypertrophy of the colon”.  He described the post mortem findings of colonic 
distension and muscular hypertrophy occurring proximal to a smaller normal size 
rectum.
206
  The two patients described died at eight and eleven months respectively, 
with unrelenting constipation, malnutrition and enterocolitis.
207, 208
   Hirschsprung went 
on to describe the clinical consequences of this disease in ten additional children in case 
reports in 1904 calling the condition congenital dilatation of the colon.   
The pathogenesis of this disease was not immediately apparent and three basic theories 
were proposed.  The first suggested that there was a malfunction in the hypertrophied 
colon; the second that there was a mechanical obstruction in the colon or rectum.  The 
last theory was the spastic theory, where the distal colon contracted spastically leading 
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to a functional obstruction.  Tittel first proposed that the distal colon was the actual site 
of the abnormality and not the more proximal dilated colon and he identified an absence 
of ganglion cells in a Hirschsprung‟s child as far back as 1901.  Unfortunately 
confusion remained as to the cause of the disorder until the late 1940s due to the failure 
to separate Hirschsprung‟s children from those with primary constipation.207, 208 
Ehrenpreis in 1946 was the first to appreciate that the colon became dilated as a 
secondary process to the distal functional obstruction and two years later two separate 
groups definitively documented the absence of ganglionic cells in the myenteric plexus 
and normal innervation in the proximal dilated colon was also described. 
209, 210
    
In the late 1940s the clinical observation was made of improved health in children with 
HD after a colostomy in the ganglionic bowel followed by deterioration when the 
colostomy was later closed.
211
 The combination of this observational evidence with the 
histological findings established the absence of ganglion cells as the main abnormality 
in the pathogenesis of HD.
212
 This led to the development of rectal biopsy as a 
diagnostic test and a treatment strategy aimed at removing the abnormal segment of 
colon.
213, 214
  
The first description of a reconstructive operation was by Swenson, the principle being 
resection of the abnormal aganglionic rectum and re-establishment of bowel continuity 
by a pull-through operation which brought the normal ganglionic bowel down to the 
anus, where an anastomosis was performed.
214, 215
  In subsequent years a variety of 
surgical procedures have been developed, the commonest being variations in pull-
through technique, most notably by Duhamel and Soave.
216, 217
    
The Duhamel procedure was designed to prevent dissection anterior to the rectum and 
as a method appropriate for use in infants. It involves bringing the ganglionic bowel 
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down to the anus behind the aganglionic rectal stump, an anastomosis being formed 
with the back wall of the anal canal above the dentate line.
216
  Martin‟s modification, 
commonly used today, adds a proximal suture anastomosis between the rectal stump 
and the pulled-through bowel. The resulting septum between the two lumens is either 
crushed, as in the original description, or nowadays divided with a stapling device. 
218
  
This creates an expanded rectum, the anterior wall aganglionic and the posterior wall 
ganglionic.   
In the Soave procedure the mucosa is stripped off the aganglionic bowel leaving the 
muscular sleeve of aganglionic rectum in situ.  The normal ganglionic colon is then 
pulled-through the rectum wall and either left hanging out of the anus to form adhesions 
with the anal canal as originally described 
217   
or sutured to the anus.
219
   
2.1 Hirschsprung’s Disease – Incidence and Aetiology 
Hirschsprung‟s disease occurs in approximately 1:5000 live births.208, 220   The male to 
female ratio varies depending on the length of colon affected,  being 4:1 for the most 
common type,  rectosigmoid Hirschsprung‟s disease, and  2:1 to 1:1 for longer segment 
disease. 
221,222, 223
  In the majority, approximately 75-80%, the area of aganglionosis is 
limited to the rectosigmoid region 
3, 224, 225, 226
  but it can occur throughout the colon, 
extending proximally in continuity and in a few cases involves the small bowel.
3, 223, 224,
 
227
  Total colonic aganglionosis occurs in about 15% of cases.
222, 228
   
Eighty percent of HD cases are sporadic but the remaining twenty percent are inherited 
as an autosomal dominant trait with incomplete penetrance and variable expression.
229,
 
230, 231
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Children with HD can also be affected by other congenital abnormalities, these being 
present in 18-29% of patients.
221, 232
  In premature infants the incidence of other 
congenital abnormalities is higher, up to 47%.
233
   In particular Hirschsprung‟s disease 
is known to have an association with congenital heart disease and Down‟s syndrome, 234 
as well as trisomy 18, Ondine‟s curse, Currarino‟s triad and Smith-Lemli-Opitz 
syndrome. 
235,236,237
  Intestinal atresias, in particular colonic atresias, have been found in 
Hirschsprung‟s patients.238 
2.2 Hirschsprung’s Disease – Clinical Presentation 
Hirschsprung‟s disease results in a functional obstruction of the colon which can 
manifest clinically in several ways.  The commonest presentation is a failure to pass 
meconium within 48 hours of birth.  Around 90% of neonates with Hirschsprung‟s do 
not achieve this compared to 98% without the disease who do.
225, 239, 240
  Failure of 
meconium passage can progress to acute intestinal obstruction with abdominal 
distension and bilious vomiting. Consequently obstructive enterocolitis can occur or 
even bowel perforation if the condition is not diagnosed and treated. 
232 
Not all children with HD present as neonates in this manner. In 5% of patients 
constipation is the sole symptom 
232
 with these children tending to be diagnosed later, in 
infancy or early childhood, with chronic constipation. 
232
 Often these children only open 
their bowels with the aid of suppositories or enemas and classically produce an 
explosive passage of faeces after rectal examination.  Late presenters may also have a 
history of vomiting, abdominal distension and failure to thrive. 
232
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2.3 Hirschsprung’s Disease – Pathophysiology 
The underlying abnormality in Hirschsprung‟s disease is an absence of enteric ganglion 
cells in the distal intestine.  (Figures 2.1 & 2.2) This results in the failure of relaxation 
of the affected bowel causing it to remain in a contracted state.  The proximal 
ganglionic bowel consequently dilates and hypertrophies, becoming thicker and longer 
than normal. The taeniae disappear and the longitudinal muscle appears to completely 
surround the intestine. 
241
 The distal aganglionic colon appears macroscopically normal. 
 
 
Figure 2.1: Histology section from a rectal biopsy from normal bowel demonstrating ganglion cells 
(arrows). (Farr G. The Autonomic Nervous System. BecomeHealthyNow.com.) 
 
 
 
Figure 2.2: Histology section from a rectal biopsy from a Hirschsprung's patient showing no 
ganglion cells and thickened nerve trunks (arrow). (Farr G. The Autonomic Nervous System. 
BecomeHealthyNow.com) 
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The mechanisms which lead to the development of HD are unclear and probably multi-
factorial.  A disruption in one of the many pathways necessary in the development of 
the enteric nervous system could result in an absence of ganglion cells. Cells may fail to 
migrate to the intestine correctly or once there may not be able to proliferate, 
differentiate or survive.  A familiarly with the normal function and development of the 
enteric nervous system is necessary in order to appreciate the different factors involved 
and how these may be altered in HD.  
2.4 The Enteric Nervous System – Structure 
The enteric nervous system (ENS) is defined as the system of neurons and their 
supporting cells within the walls of the gastrointestinal tract.
242
  It is part of the 
autonomic nervous system which also includes the parasympathetic and sympathetic 
nervous systems. The ENS is the most complex of the autonomic systems in terms of 
the number of different functional types of neurones found, their interconnectivity and 
in their expression of neurotransmitters.
243,
 
244
 ENS neurones can differ in the direction 
their axons project (orally, anally, radially or circumferentially) in the target of their 
axon (e.g. other neurones, smooth muscle) and in the neurotransmitter that they use.
245
 
The ENS not only mediates gut motility, it also plays an important role in the secretory 
activity and water and electrolyte transport by the mucosa and in the regulation of 
intestinal blood supply.
246
  Many ENS neurones receive input from the para and 
sympathetic nervous systems but there are also complex systems within the ENS which 
allow it to function independently.
242 
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Figure 2.3: Schematic representation of the layers of the intestine showing the nerve plexi. 
247 
The basic organisation of the ENS is numerous ganglia connected by bundles of nerve 
fibres, called internodal strands, lying in two main plexuses.
248
 The intermuscular 
myenteric (Auerbach‟s) plexus, lying between the circular and longitudinal muscles and 
the submucosal (Meissner‟s) plexus internal to the circular muscle layer.242, 248 (Figures 
2.3 & 2.4) These are continuous around the circumference and along the small and large 
intestine.
248
 There is also a much smaller mucosal plexus.
248
  Each enteric ganglion is a 
cluster of many different neurones and all ganglia contain similar types of neurones, 
although there is some regional variation in this as well as in ganglia size and 
connectivity.
242
   
Functionally the neurones of the ENS can be divided into three subgroups; sensory, 
which receive information from the gut lumen, inter-neurones which process this and 
pass it to the third subgroup, motor neurones, the effector cells which innervate the 
smooth muscle and secretory glands.
249
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Figure 2.4: Histological section showing the layers of the intestine wall and their relation to 
Auerbach's plexus.  M = mucosa, S = submucosa, C = circular muscle, L = longitudinal muscle. 
(The Digestive System. www.med.mun.ca/anatomyts/digest.digtut.htm) 
 
Within the ENS are networks of cells associated with the external muscles of the gut 
and with the nerve fibres innervating the intestine.  These are called interstitial cells of 
Cajal (ICC) and form into subpopulations with differing physiological functions.
250
  
They are derived from local gut mesenchyme and not from neural crest cells.
251
 Some 
ICCs act as „pacemaker cells‟, generating slow electrical waves that cause rhythmical 
muscle contractions and others are intermediaries in neuromuscular transmission.
250
  
ICCs expression the receptor tyrosine kinase (Kit) and their development is dependent 
on the stem cell factor-Kit signalling pathway.
252
  Their absence or lack in 
Hirschsprung‟s disease is unclear as separate studies have demonstrated contradictory 
results.
253
 
, 254,  255, 256
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These elements act together in an integrated manner to control the functions of the gut, 
primarily independently, but also under the influence of the extrinsic nervous system.   
2.5 The Enteric Nervous System – Function 
The ENS is composed of adrenergic and cholinergic nerves and also non-adrenergic, 
non-cholinergic nerves.
248
 The main inhibitory non-adrenergic, non-cholinergic 
neurotransmitter is nitric oxide (NO).
257
   NO is released in response to nerve 
stimulation of the myenteric plexus causing smooth muscle relaxation. It is synthesized 
by the activation of NO synthase.
258
 
Many other nerve fibres of intramural origin have been identified with various different 
neurotransmitters and messengers, mainly neuropeptides, including substance P, 
vasoactive intestinal peptide (VIP) etc.
259
 In normal circumstances there is a fine 
balance of those forces controlling relaxation and contraction of smooth muscle, with a 
state of relaxation predominating.
241
 An intrinsic gut reflex allows intestinal content to 
travel to the anus as the mild distension the bolus causes initiates a contraction 
proximally and a relaxation distally.  In the absence of ganglion cells this fails to 
occur.
241
   
Extrinsic control is through both preganglionic cholinergic fibres and postganglionic 
adrenergic fibres.  Parasympathetic cholinergic fibres release acetylcholine and cause 
muscle contraction.  Sympathetic adrenergic fibres mainly inhibit contraction, although 
may also act via some excitatory pathways and use norepinephrine as their mediator.
259 
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2.6 The Enteric Nervous System - Hirschsprung’s Disease 
In Hirschsprung‟s disease histological examination of the affected segment shows an 
absence of intramural ganglion cells in Meissner‟s and Auerbach‟s plexuses.239 The loss 
of ganglion cells results in the loss of the intrinsic, predominantly inhibitory, enteric 
nerve function.   The major mediator of this system is nitric oxide and a loss of the 
enzyme required for its production, nitric oxide synthase, has been found in the 
myenteric plexus of aganglionic bowel.
258
 It has been suggested that this is due to a 
decreased or absence expression of neuronal nitric oxide synthase gene at the mRNA 
level.
260
 
The extrinsic nervous system seems to respond to this by markedly increasing its 
innervation of adrenergic and cholinergic nerve fibres in the aganglionic segment of 
bowel.
261, 262
  Thickened nerve trunks are also seen in between the smooth muscle layers 
and extend into the submucosa.
208
 These fibres are detected by acetylcholinesterase 
staining.
260 
Several other neuronal abnormalities in aganglionic colon have been reported, 
especially in peptide-containing fibres.  There is a virtual absence of enkephalin and 
gastrin-releasing peptide (GRP) – containing nerve fibres in the aganglionic colon 263 
and a markedly reduced supply of others such as substance P and vasoactive 
peptide.
263,264
  A release of substance P can cause vasodilatation, an inflammatory 
response and modulate mucosal secretion.
265
  In contrast a hyper-innervation of 
neuropeptide Y-containing fibres in aganglionic colon has been found.
266
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Other documented abnormalities include an increased level of neuroendocrine cells 
267
 
and altered gene expression of certain types of muscarinic acetylcholine receptors in the 
smooth muscle of aganglionic bowel.
268
 
It appears that the combination of a loss of the intrinsic inhibitory nerves coupled with 
an excess of excitatory extrinsic stimulus leads to an imbalance of normal smooth 
muscle contractility resulting in a failure of the distal bowel to relax and dilate, resulting 
in a functional obstruction.
241
 The proximal bowel dilates with faeces and appears 
abnormal but has normal innervation and occurs as a consequence to the contracted 
aganglionic bowel.  Proximal to the aganglionic bowel is an area of hypoganglionosis 
called the transition zone. 
2.7 The Enteric Nervous System – Development 
In normal embryologic development the enteric nervous system arises from the 
migration of neural crest cells.
269
 These arise between the neural plate and the epidermal 
ectoderm, along the whole length of the body axis.
245
 Ablation studies in chick embryos 
at various axial levels by Yntema and Hammond revealed that only disruption in one 
small region prevented enteric nervous system development.  This they termed the vagal 
level which was level with somites 1-7. They concluded that vagal neural crest cells 
gave rise to the ENS.
269, 270   
This was confirmed by studies transplanting neural 
segments between chick and quail.
271
  
The contribution of neural crest cells from the lumbosacral region to the ENS has been 
contentious but recent work has concluded that this is the source of some hindgut ENS 
neurons and glial cells.
272
  As vagal crest cells are able to give rise to a range of 
differentiated neurones and glial cells, this suggests that the purpose of cells originating 
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from the sacral region, is to perform a specific function not fulfilled by vagal derived 
cells.
245
 Other recent work has suggested that cells caudal to the vagal crest also 
contribute to the foregut. 
273
 
Neural crest cells migrate to the upper end of the alimentary tract and proceed in a distal 
direction.
274
 The first nerve cells arrive in the oesophagus at the fifth week of gestation, 
the midgut by the seventh week and have migrated to the distal colon by the twelfth 
week.
245
 After these cells have colonised the gut, they must migrate radially to form 
firstly the myenteric plexus and then subsequently the submucosal plexus.
275
 
Neural crest cells appear to be guided in their migration by glycoproteins, including 
fibronectin and hyaluronic acid (laminar protein). The development of these 
glycoproteins precedes neural crest cell migration and these supporting fibres progress 
down the gastrointestinal tract, through the basement membrane and end in the 
muscular layer.
276
 Neural crest cells then use these structures to migrate to the correct 
destination.   
Once neural crest cells have reached the correct region of the gut they need support to 
survive there which may be provided in the form of trophic factor signalling.  Next they 
need to proliferate in order to form the vast number of cells necessary for the entire gut 
from a relatively small population of neural crest cells and then differentiate with 
accurate orchestration so that the ENS can acquire the appropriate number and types of 
neuronal and glial cells.
249
 These cells then cluster to form ganglia. The normal 
distribution of ganglion cells is present by 24 weeks gestation and these continue to 
develop in utero and into childhood. 
277
  Failure of one component during any of these 
processes could lead to aganglionosis.  
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RET is a cell surface molecule encoded by the RET proto-oncogene. It contains an 
extracellular ligand-binding domain, a transmembrane segment, a cytoplasmic kinase 
domain and a carboxy-terminal.
249
 All classes of RET have been shown to play a critical 
role in a variety of developmental processes and some have been implicated in human 
disease.
278, 279
  RET transcripts are detected in enteric neural crest cells prior to invasion 
of the foregut mesenchyme and are maintained at high levels throughout migration and 
colonisation of the gut wall.
271
   Studies looking at the site of  RET expression in the 
developing embryo clearly suggest that  RET encodes for a receptor which interacts 
with a growth factor involved in the survival, proliferation, migration and differentiation 
of neuronal cell lineages.
249, 280,  281
  
Glial cell line-derived neurotrophic factor (GDNF) is a distant member of the 
transforming growth factor – β super-family. It is GDNF which acts via its receptor, 
RET and co-receptor GFRα1 on neural crest cells, activating the tyrosine kinase domain 
of RET.
249, 282
  It is not only a mitogen and survival factor for these cells but it also 
induces their differentiation into neurones.
244, 283
  GDNF is widely expressed during 
embryogenesis by gut mesenchyme cells.  Neurturin (NTN), a member of the GDNF 
ligand family, also activates RET by binding to GFRα2 and plays a role in the support 
and proliferation of a subset of enteric neurones.
284
 (Figure 2.5) 
The caudal directional movement of crest cells is thought to be due to a least two 
factors.  Firstly the response of these cells to contact with each other tends to stimulate 
movement in a direction away from that contact, i.e. towards a region with a lower 
density of cells.
285
  Secondly crest cells are chemotactically attracted to GDNF in vivo 
and if these cells use up GDNF as they migrate this could produce a gradient for 
chemotaxis to occur.
245,  286
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SOX-10 (Sex-determining Region Y (SRY)-box 10) is a member of the SRY-related 
family of HMG -containing transcriptional regulators (high-mobility
 
group). It appears 
important for neural crest cell survival as absence leads to apoptosis of peripheral 
ganglia derived from these cells.
287,288
  PAX-3 (paired box 3) is another transcription 
factor involved in ENS development.  It functions with Sox-10 to regulate RET 
expression in mice.
289
  Initially those neural crest cells destined for the ENS express 
SOX-10. They are then induced to express RET and under the influence of GDNF they 
maintain their multi-potential capacity, proliferate and colonise the entire bowel.
249 
Another important system in ENS development is the ETB/ET-3 signalling system.  The 
endothelins are a family of 21-amino acid peptides (ET-1,-2,-3) which act on two cell-
surface receptors, ET-A, ET-B, coded for by EDNR-A and EDNR-B genes 
respectively.
242, 249, 290
 They are intercellular local messengers and are first produced as 
precursors called pre-proendothelins which are cleaved by endothelin-converting 
enzyme 1 (ECE -1) to their biologically active forms.
290
 The ETB receptor gene is on 
chromosome 13q22 and codes for a G protein-coupled receptor with seven 
transmembrane domains.
242
 In adults this system is important in the regulation of blood 
pressure by controlling tone in the microvasculature but is also involved in regulating 
morphogenesis during early embryologic development.
242
  
Animal studies by Baynash et al found evidence for the involvement of ET-3 in ENS 
development by demonstrating that in mice, targeted disruption of the gene encoding 
ET-3 caused a phenotype of white spotting and megacolon and that in the lethal spotting 
mouse ET-3 is mutated. 
277, 291
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The ETB receptor is expressed on neural crest cells before their emigration and 
throughout their migration.
292
 ET-3 and its activating enzyme ECE-1, are produced by 
gut mesenchyme cells and act via this receptor as a brake on the differentiating role of 
GDNF without affecting the proliferative role.
293
 ET-3 may therefore maintain cells in 
the mitotic and migratory pool, thus allowing a large pool of enteric neuronal precursor 
cells to build up.
294
  (Figure 2.5) 
 
Figure 2.5: Schematic representation of some of the signalling pathways involved in enteric nervous 
system development. Receptors are shown in dark blue. 
 
As the cell population in the gut increases, cells are allowed to mature and aggregate to 
form ganglia, perhaps due to reduced amounts of neurotrophic factors or reduced 
response by the cells.
249
   ET-3 may exert this action by inhibiting the activity of the 
transcription factors SOX-10 and PAX-3 as these act synergistically to promote 
differentiation in ENS neurones.
245
   ET-3 also promotes the development of enteric 
smooth muscle and this pathway is also intrinsic to melanocyte development.
293
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There are many other signalling pathways thought to be important in ENS development. 
MASH-1 (mammalian achaete-scute homologue 1) is a member of a family of 
transcriptional regulators involved in peripheral nervous system cell differentiation. It 
appears to be required for the development of the serotonergic sub-lineage of the 
ENS.
249, 295
  Other transcription factors intrinsic to ENS formation include PHOX-2a 
and 2b, HOX-1, and IL-1. 
241, 248, 296
  
NT3 is a neurotrophin synthesized by intestinal epithelial and mesenchymal cells.
297
 It 
is thought to regulate the survival and differentiation of enteric neurones mainly by 
interacting with TrkC receptor tyrosine kinases.
297,
 
298
   Studies have suggested that 
GDNF and NT3 are components of two independent signalling systems which operate 
sequentially during embryogenesis to promote neurogenesis of the gut, GDNF being 
needed earlier in the sequence.
249
   
Hedgehog proteins are secreted proteins which participate in development processes and 
are known to influence ENS development in models.
242
 Indian hedgehog (Ihh) and 
Sonic hedgehog (Shh) in particular seem to influence ENS development. Shh is thought 
to be important for the radial patterning of the gut so that the smooth muscle cells and 
neurones differentiate in the outer layers.
242
 
Recent work has also suggested a role for bone morphogenetic proteins (BMP), as these 
were strongly expressed in the ENS and their inhibition led to hypoganglionosis and 
failure of enteric ganglion formation, with crest cells unable to cluster into 
aggregates.
299
 
The development of the ENS from neural crest cells involves many different pathways.  
It is also a very interactive process with signalling occurring between mesenchymal 
cells and enteric neurones. For example, ICC are seen in the absence of enteric neurones 
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but at much lower levels suggesting that neurones produce substances which play a role 
in ICC development.
300
 
Mutations within any of these pathways could affect the stem cells ability to migrate, 
proliferate, differentiate or survive. Defects could occur within the cells themselves or 
within their environment; at their site of origin, along their migration pathway or at their 
destination, within the intestine.
242
 Many of the genes coding for key peptides at various 
stages of these pathways are associated with Hirschsprung‟s disease.277 
2.8 Hirschsprung’s Disease - Pathogenesis  
Neural crest cells contribute to many other structures throughout the body.  They 
differentiate into diverse cell types including neurons and glia of the sensory, 
sympathetic and parasympathetic ganglia, pigmented cells, neuroendocrine cells, 
adrenal medulla and facial cartilage.
301
  Diseases which arise from the neural crest are 
grouped together and given the name neurocristopathies.  These are divided into two 
basic forms; simple involving a single pathological process, which are generally 
unifocal and localized and the more complex neurocristopathy syndromes which are 
multifocal.
183
 HD is classified as a simple neurocristopathy and can occur in isolation or 
associated with other conditions, for example Shah-Waardenburg syndrome, which 
involve other systems originating from abnormal development of the neural crest.
183
    
In 1967 Okamoto et al suggested that the absence of ganglionic cells in HD was due to 
failure of neural crest cell migration.  Evidence for this came from animal studies where 
transection of a chick embryo at the hindgut level resulted in distal aganglionosis, which 
could be corrected by subsequent implantation of pigeon ganglion cells distal to the 
transection level.
241 
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Although migration failure may be part of the underlying mechanism, neural crest cells 
must also proliferate, survive and differentiate in order to give rise to fully fledged 
enteric ganglia.
230
 The intestinal environment must be conductive to these processes.   
HD has a strong genetic component. The risk of the disease in a further sibling is 4% 
compared to 0.02% in the general population and this risks increases with the length of 
the affected bowel.
242
 Several specific gene mutations have been identified in human 
and animal models of HD but many cases remain unexplained.  Known gene mutations 
account for less than 50% of distal aganglionosis cases 
302
 suggesting that some cases 
are either not genetic in origin or their genetic basis is still unknown.  To date at least 
eight HD genes have been identified but it remains a complex inheritance disorder.
291
 
Often a single mutation may not be enough for the disease to manifest. Clinical 
expression of HD appears to require the interaction of multiple susceptibility genes. 
Two of the important signalling systems involved in ENS development have been 
implicated in the pathogenesis of HD.  These are the GDNF-RET/GFRα1 and ET-3-
ETB. Mutations affecting any of the aspects of the RET/GDNF system could affect 
neural crest cell migration, differentiation and survival.   
RET was first implicated in the pathogenesis of HD by linkage studies showing that an 
autosomal dominant gene for HD mapped to a region where RET had been previously 
localised. Subsequent mutational analysis showed that around 50% of patients with the 
inherited form of HD had mutations in RET and they were found in 70-80% of those 
with long segment disease.
226, 277, 291  
Mutations identified range from whole gene 
deletions to missense mutations, base pair deletions and splicing alterations and are the 
commonest forms of mutations found in HD patients.
279
 Further mutations may 
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indirectly affect the production of RET, for example those involving promoter or other 
regulatory regions. 
Mutations in the GDNF component of the RET signalling system have also been 
reported in HD in up to 4.6% of patients.
291
  In functional assays the absence of GDNF 
or GRFα1 results in a reduction or absence of RET signalling.303  There is also some 
evidence that the expression of GDNF may be reduced in the absence of an identifiable 
genetic mutation.  Martucciello et al demonstrated an absent immunoreactivity for 
GDNF in the aganglionic segment compared to the normoganglionic segment in HD 
patients.
291
   This could represent an important co-factor in the pathogenesis of HD, 
where even in the absence of a mutation in the RET or GDNF genes, a lack of GDNF 
expression may prevent the necessary RET activity and cause neuroblast migratory 
arrest.
291
  
Much of the information on ENS development and the genetic basis of HD has come 
from animal studies.  As melanocytes are also derived from the neural crest, many of 
these models also exhibit pigmental changes. The lethal spotting (ls) and piebald lethal 
(S
l
) mouse strains have aganglionic colons and pigmentation defects, the former allows 
reproduction, so as a consequent has been more extensively studied. 
304
 The rat model 
of spotting lethal (sl) also demonstrates total colonic aganglionosis. 
305
 The dominant 
megacolon (Dom) mouse has an autosomal dominant inheritance, the homozygous 
genotype being lethal in early embryogenesis, the heterozygote dying early in life and 
exhibiting distal aganglionosis.
306
  
Homozygous mice with defects in RET, GDNF or GFRα1 die at birth and have kidney 
agenesis and intestinal aganglionosis.
307
 Studies on knock-out mice, where the gene 
encoding for GFR 1 was missing, resulted in the absence of all mid and hindgut 
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neurones except for a few in the distal colon.
307
 Assuming these are neurones derived 
from the lumbosacral region, it indicates that the vagal neural crest cells are dependent 
on the GDNF/RET signalling system in a way that the sacral crest cells are not.
307
  
Approximately 10% of patients with HD have a mutation in one of the genes involved 
in these endothelin signalling pathways,
 277, 291
 about 3-5% of HD cases appear to stem 
from ETB mutations.
308
  This is a dominant effect with incomplete penetrance.  In the 
piebald S
l
 mouse and also the sl rat, there is a mutation in the ET-B receptor gene.
291
 
The main ligand for the receptor in the gastrointestinal tract is ET-3.
309
 Mutations in the 
ET-3 gene, on chromosome 20q13.2-13.3, are found in about 5% of HD patients as well 
as in the ls mouse model.
310
 The gene encoding for endothelin converting enzyme 
(ECE-1), necessary for production of active ET-3, has been found to be mutated in 
certain complex abnormalities which involve aganglionosis.
311
 
Mutations within the endothelin system appear to affect specific subpopulations of 
enteric neural cells and do not cause the catastrophic elimination of the entire ENS as 
occurs in GDNF/RET mutations. Two groups have proposed the theory that deficiencies 
in the ET-3/ET-B system may cause premature differentiation of the neural crest cells, 
resulting in a smaller population to migrate and proliferate in the distal intestine.
293, 312
  
Animal studies looking at blocking this pathway and its affect on distal colonization 
have been contradictory.
292, 313
  
Transcription factors are proteins which bind to regulatory elements of DNA, thereby 
promoting or repressing the transcription of the gene.  In this way they regulate gene 
expression.
242
 Phox2a and Phox2b are transcription factors which are expressed in 
enteric neurons, some parasympathetic neurons and all noradrenergic neurons.
314
 Both 
regulate the expression of RET as well as the noradrenaline synthetic enzymes, tyrosine 
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hydroxylase and dopamine β hydroxylase.315, 316 In Phox2b knock-out mice, neural crest 
cells failed to migrate beyond the foregut and certain polymorphisms of this gene in 
humans have been associated with HD.
315, 317
  
Other transcription factors have been linked with HD. In the Dom mouse model, a 
mutation of the gene encoding Sox-10 results in distal aganglionosis.
287
 Sox-10 gene 
targets are unknown but mutations affecting its function have been reported in HD. 
318
  
Pax-3 is also thought to be needed for the initiation of RET expression by enteric 
neuron precursors.
289
 Mash-1 appears to be necessary for neuronal cell differentiation 
but not their migration and this shows very close homology to the human version Hash-
1.
295
   Other possible candidates for involvement in ENS development and HD 
pathology include the Hox transcription factor family and SIP1, a repressor of 
transcription.
319
 
Defects in the neurotrophin (NT) family of neurotrophic factors may also play a role in 
HD aetiology.  Targeted mutation of the genes encoding NT-3 and its receptor, TrkC, 
resulted in a decreased number of enteric neurones in mice and reduced levels of TrkC 
expression have been described in HD.
298, 320
  Other genes which have been implicated 
include PMX2B.
321
 
There are other abnormalities that have been reported in HD which could influence 
neuroblast migration. Abnormal distributions of fibronectin and laminin have been 
demonstrated in the aganglionic intestinal wall and these are thought to provide a 
framework for neural crest cell movement.
322, 323
   In order for neuroblasts to migrate, 
they must also adhere to the intestine cells.  Neural cell adhesion molecule (NCAM) has 
been found to be reduced in the aganglionic colon compared to both controls and 
ganglionic tissue from Hirschsprung‟s patients.324 
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Vascular anomalies have been documented in HD. Abnormal arteries have been found 
in the HD colon where there was a proliferation of smooth muscle cells in a thickened 
adventitia.
325
  Functional defects of vascular endothelin B receptor have also been 
found. 
326
  Vascular defects resulting in ischemia may interrupt ganglion cell migration 
or affect their survival once migration has occurred.  
HD is a multigenic disorder, principally caused by dysfunction in either of the two main 
signalling pathways involved in ENS development; RET/GDNF and ET3/ETB. A single 
mutation in ones of the genes involved is likely to add a variable contribution to the 
final disease phenotype, each one adding a degree of genetic susceptibility.
291 
2.9 Hirschsprung’s Disease – Treatment   
The underlying principle of management of Hirschsprung‟s disease is to relieve the 
functional obstruction caused by the aganglionic segment.
239
 The definitive treatment is 
surgical and there are two main ways of surgical management.  The first option is to 
perform a diverting colostomy in ganglionic bowel, confirmed by intra-operative frozen 
section, soon after birth, once the diagnosis has been confirmed by rectal biopsy. 
327
   
Following this at the age of 3-6 months the definitive corrective surgery is performed.  
This is called a „pull-through‟ procedure and involves the removal of part of the 
aganglionic section and suturing of the ganglionic colon to the rectum.  During surgery 
intra-operative sections are sent for immediate histological examination to confirm that 
only ganglionic colon is being used.  This is referred to as a staged pull-through.  The 
colostomy is either closed at this point (two stage) or in a separate operation at a later 
date (three stage). 
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The second option is known as a primary pull-through.
328
  This dispenses with the 
intermediate colostomy and instead relies on regular rectal wash outs to keep the colon 
deflated and clear of a build up of faeces until the child is old enough (usually 3 
months) for pull-through surgery.  Some surgeons perform a primary pull-through 
within weeks of birth although this is not one of the management methods practiced at 
the centres involved.
329,
 
330
 
Several difference pull-through procedures have been described and are used in 
difference institutions but all employ the same underlying principles of relieving the 
functional obstruction without impairing rectal continence or damaging pelvic 
nerves.
214, 215, 239 
  The most widely used are the retrorectal transanal pull-through 
(Duhamel) operation where a neorectum is created with an anterior aganglionic half and 
a ganglionic posterior half and the endorectal pull-through where the proximal normal 
colon is pulled through the aganglionic segment from within after first stripping it of its 
mucosa.
216, 217, 219, 239
 (Figure 2.6) 
 
Figure 2.6: Schematic representation of the different types of pull-through procedure for 
Hirschsprung's disease.  The dark lines represent the retained aganglionic bowel.  (Modified from 
Teitelbaum DH. Hirschsprung’s disease) 331 
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2.10 Hirschsprung’s Disease – Outcome  
Corrective surgery for Hirschsprung‟s disease can cause complications, resulting in 
morbidity and occasional mortality in some children.
241  
These can be classified into 
early, occurring soon after surgery and late.  Some of the more common early 
complications include anastomotic leak or breakdown (2%), rectal pouch problems, 
faecal fistula, intestinal obstruction which requires further surgery (8–13%) and anal 
stenosis (10-20%) which can often be managed by rectal dilatations.
241, 332, 333
  The 
overall reported incidence of these early complications ranges from 1.1- 20%.
241, 332,333
 
Post operative deaths (within 30 days of procedure) have been reported at between 0 to 
1.5% and late deaths due to either complications of the operation or post operative 
enterocolitis from 1-2.1%.
332 
Surgical correction of HD should ideally allow normal stooling but despite corrective 
surgery many children have ongoing problems with faecal continence or constipation.  
Long term outcome is variable and establishing reliable data is problematic due to 
different criteria being used by different authors.   
Typical incontinence rates seem to range from between 3-8%, 
241
 although higher rates 
have been reported, 
334
 but these seem to improve as the patients become older 
335
 and if 
neurologically impaired children are excluded, continence rates are similar to age-
matched controls. 
241, 336
 
In one study the outcome was reported as very satisfactory in 67%, in 27% occasional 
enemas and laxatives were needed and 8% had constipation or soiling.
335
 They also 
found that function improved with time and at 15 years follow-up 88% were considered 
to have normal bowel function.
335
 Yanchar and Soucy found similar improvements with 
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only 8% having fair to poor continence in those over 15 years compared to 50% in 
younger children.
334 
Soave reported the outcome as 83% good and 17% as unsatisfactory.
337
  The 
constipation rate after the various procedures has been recorded as 54% after a 
Duhamel, 43% after a Soave and 4% after a Swenson. 
338
  Others have found that only 
64% of patients had a normal stooling habit but 90% of parents were moderately or very 
satisfied with their child‟s outcome.334 Continence in children over five years of age has 
been reported at 86%. 
339 
2:11 Hirschsprung’s Disease - Transitional Zone 
In the colon of HD patients there exists a region of hypoganglionosis in between the 
aganglionic and ganglionic colon.
209
 This is referred to as the transition zone (TZ) and 
usually extends over a few centimetres.
209
 This area is known to be abnormal and is 
characterized by diminished numbers of ganglion cells.
209
 Other documented 
abnormalities include changes in Auerbach‟s plexus which grows more irregular, 
tapering towards the aganglionic colon 
340
 and occasional acetylcholinesterase staining 
hypertrophic bundles of extrinsic nerves.
227, 340
 
The histological features of the TZ are subtle 
341
 and its margins along the bowel are not 
symmetrical.  White and Langer demonstrated that the circumferential distribution of 
the TZ is uneven and has a leading edge of ganglion cells which extends into the 
aganglionic bowel.
342
  This leading edge was most often seen on the anti-mesenteric 
border and ganglion cells tended to cluster within it, in contrast to a complete absence 
of such cells in the remainder of the circumference.
341
 A single biopsy could therefore 
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give misleading results.
343
  In order to ensure the best surgical results the TZ should be 
included in the resected specimen.
341
   
The remaining colon with its complement of ganglionic cells is considered to be 
„normal‟, however this distal section can retain other structural and functional features 
which may be abnormal or suboptimal.   
Sandgren, Larsson and Ekblad compared the number of enteric neurons and the 
expression of various neurotransmitters along the ganglionic sections of colon in the 
homozygous (short rectal aganglionosis) and heterozygous (phenotypically normal) 
lethal spotted mouse model of HD.  They reported many differences including a 
reduction in number of total neuron cell bodies and an increase in VIP expression in 
both plexi in the homozygous mice.
256
 
Abnormalities have also been reported in humans. Neuropeptide nerves are found in 
normal numbers in the proximal ganglionic colon in HD but in a disordered 
arrangement.
264
 Others have found that proximal ganglionic samples have little 
immunoreactivity for general neuropeptide markers.
344
 It appears that even where 
ganglionic cells are present other neuronal elements may be deficient resulting in 
abnormal function of the enteric nervous system. 
RET mRNA expression levels were examined in HD patients.
260
 Compared to the 
ganglionic colon, a significantly lower signal was found in the aganglionic segment and 
also in the hypoganglionic transitional zone, although this signal was higher than that of 
the aganglionic.
260
  Levels of mucin production have also been found to be low in the 
ganglionic colon nearest the aganglionic colon. 
345
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2.12 Hirschsprung’s Disease – Enterocolitis 
Enterocolitis (EC) is the most serious and potentially life-threatening complication 
which can affect children with HD.  The incidence in the literature varies considerably 
affecting from 17-50% of HD children, with a mean incidence of 25% and can be the 
presenting feature of HD.
346, 347, 348, 349, 350, 351
 Reported mortality figures also widely 
differ ranging from 0–39%.332, 349 Although the mortality for EC has fallen over time, 
presumably due to improved recognition and critical care, it still remains the major 
source of morbidity and mortality for HD patients and can lead to lengthy and 
complicated hospital admissions.
352,
 
331, 346, 
 
353
 
The association between HD and enterocolitis was first recognized in 1956, 
354
 but the 
clinical aspects of EC were first accurately characterized by Bill and Chapman who 
described the classic features of abdominal distension, fever and foul-smelling stools.
346
 
Symptoms and signs can range from mild to life-threatening and there still remains 
some discrepancy in the diagnostic criteria used.
348
   The natural progression of the 
disease does, however, show discrete histological phases which have been used to 
establish a grading system based on the pathological severity.
355
 Within the 
histopathological changes noted, the retention of mucin is particularly characteristic.
355
 
The greatest risk of developing EC is before diagnosis of HD and can be the presenting 
feature of the disease.
332, 351
 A delayed diagnosis of HD beyond the first week of life 
substantially increases the risk of EC.
347
 Other factors have also been associated with 
increased risk of EC.  Some authors have found a higher incidence of EC in children 
with long segment aganglionosis,
347
 although other studies have refuted this.
332, 346
   
Children with HD who also have associated anomalies appear to have a higher risk of 
developing EC, an incidence of 29% compared to 47% in some studies. 
349
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Genetic factors may be important as there is an increased risk of EC occurring in 
children with a family history of HD 
332, 356
 although long-segment disease is known to 
be associated with both a family history and greater risk of EC and these variables have 
not been studied independently.
351
   Once a child has had an episode of EC, their risk of 
further episodes may be greater.
357
 
The aetiology of EC remains unknown.  One of the earliest theories postulated was that 
functional obstruction of the aganglionic bowel led to stasis of faeces causing bacterial 
overgrowth and infection leading to epithelial destruction, ulceration and subsequent 
bacterial translocation.
351
  However, the fact that EC occurs in 5-35% of patients after 
corrective surgery, even in the absence of post operative stenosis, 
145
 and even, if only 
rarely, in the presence of a defunctioning colostomy, suggests that there must be other 
factors involved.
339, 346, 347
 
Several studies have found evidence for an infectious aetiology, both in abnormal 
pathogen carriage and impaired immunity. Clostridium difficile (C. difficile) is one such 
bacterium which has been implicated.  An increased incidence of C. difficile in the 
stools of patients with EC compared to those without and to controls has been 
reported.
358
 Also this bacterium has been detected in the stools of HD patients beyond 
12 months of age, demonstrating prolonged carriage, unlike the typical absence of this 
organism in the gastrointestinal tract of normal children at this age.
359
  A further study 
found that in 39% of children with pre-pull-through EC had enterocyte adherence by 
bacteria on histological examination, the organisms involved being Escherichia coli, C. 
difficile and Cryptosporidium.
353
  
Despite this evidence the significance of C. difficile in the aetiology of EC remains in 
doubt.  Not only is the bacteria and its toxin found without ill effect in the faeces of 
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healthy infants and children but other studies have not replicated these results, finding 
no variation in stool bacterial flora in children with or without enterocolitis.
355, 360, 
 
361
  
Another proposed infectious candidate is rotavirus, increased levels being found in 
those children affected with EC by Wilson-Storey et al.
360
 It is possible that several 
different infectious agents have the potential to cause EC in the presence of defective 
mucosal integrity and immunity. 
An impairment in host immunity could increase susceptibility to EC. Infants with 
Down‟s syndrome (trisomy 21) and HD have a 50% risk of developing EC compared to 
29% in all other HD children.
356
   Children with trisomy 21 are known to have reduced 
levels of humoral and cellular immunity, suggesting that immunodeficiency may be 
involved in the aetiology of EC.
347, 
 
362
 
Various impairments in cellular and humoral immunity have been described in HD 
patients.
351
  Alterations in neutrophil response and decreased serum complement levels 
have been reported.
123
   Wilson-Storey and Scobie measured immunoglobulin A (IgA) 
levels in HD patients. The presence of secretory IgA in saliva was presumed to indicate 
its presence at the luminal surface of the bowel.  Those patients who previously or 
subsequently developed EC, had increased levels of IgA in the colonic mucosa, lower 
serum IgA levels and virtually all had an absence of salivary IgA.
363
  They hypothesized 
that a failure of transport of IgA from its point of manufacture across the mucosal cell 
and into the gut lumen resulted in a susceptibility to EC.
363
  
Further studies have also shown a reduction in luminal staining of IgA in EC.
363, 364
  
Other groups have found low levels of IgA in colonic mucosa.
365
   Studies on the 
piebald mice found higher levels of immunocytes and IgA containing cells in those 
mice with EC compared to controls.
366
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Natural killer (NK) cells have anti-tumour and antiviral activity as well as potentially 
being regulators of antibody production.
364
 An increase in NK cells infiltrating the 
ganglionic bowel in EC compared to aganglionic bowel and ganglionic bowel in 
controls has been reported.
364
 This may be related to abnormalities in peptidergic nerves 
causing regional abnormalities in neuropeptides.
364
 
Caudal type homeobox gene-1 and 2 (CDX-1, CDX-2) encode transcription factors in 
endoderm derived tissues of the intestine.
167
 CDX genes control proliferation and 
differentiation of intestinal mucosal cells.  The involvement of mucosal abnormalities in 
EC has already been suggested by presumed inefficient transfer of IgA across the gut 
mucosa.  The expression of both CDX genes has been found to be reduced in patients 
with EC which could result in a loss of mucosal integrity and function.
167 
A further feature which is important in mucosal integrity and immunity is the mucus gel 
layer and its main constituents, mucins.  Mucins have several functions including 
helping to prevent bacterial colonisation of mucosal cells.
5 
  Enterocolitis complicating 
HD is still a cause of morbidity and mortality.  Its aetiology remains poorly understood 
but is likely to be multi-factorial.
351
   The presence of a robust mucus defence barrier 
may be important in its prevention. 
2.13 Hirschsprung’s Disease - Mucin Alterations 
Alterations in the sulphate and sialic acid content of mucins can render the mucus layer 
more susceptible to degradation by pathogens.
164
 A reduced secretion of sulphated 
mucins allows bacteria to adhere more easily to enterocytes, thus facilitating bacterial 
invasion and infection.
164, 355
 Changes in mucins have been reported in HD.  Teitelbaum 
et al found a relative increase in neutral mucins and a decrease in acidic sulphated 
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mucins in those patients with EC compared to those without.
355
  Others have reported an 
increase in sulphated mucins in patients with HD, especially those with EC.
367
  
Animal studies on the piebald mice have also demonstrated mucin alterations in HD and 
EC.
366
 A marked depletion of sulphomucin and neutral mucins combined with an 
increase in sialomucin secretion was found in all piebald mice, those with and without 
EC, although the changes were greater in those mice without EC.
366
  
MUC2 is the main gel-forming mucin in the colon.
352
   Levels of MUC2 protein in stool 
have been shown to be much lower in children with HD compared to controls and 
undetectable in those who had a current episode of EC. 
368
  The fact that the levels were 
lower even in those without EC suggests that there is a true deficit in MUC2 production 
rather than a secondary response to an infective process. Although mRNA levels for 
MUC2 have not been found to be significantly different in HD compared to normal 
controls, posttranslational changes in mucins could result in the abnormal expression of 
this glycoprotein in HD.
16 
Episodes of enterocolitis are unrelated to the type or timing of surgery 
332
 and can occur 
after corrective surgery, 92% of children having their last bout of EC requiring hospital 
admission within two years of pull-through.
332, 369 , 370
   The frequency of these 
admissions tends to decrease with time. 
371
  That most children outgrow their episodes 
of EC could be explained by the fact that in normal children the mucus defensive barrier 
is at its weakest between 3 months to 3 years, an increased turnover of mucins occurring 
with increasing age.
205, 352
 
Neuroendocrine (NE) cells modulate gut function by endocrine, paracrine or neurocrine 
pathways.  Decreased levels of these have been found in the ganglionic colon of patients 
with EC compared to those without EC.
165 
 As mucus secretion is partly under the 
 80 
control of the ANS, the weakened mucus barrier could result from an underlying ANS 
abnormality and corresponding reduction in NE cell populations.
165, 364
  This would help 
to link and explain poor mucus secretion and motility disturbances which can persist 
after surgery.
351 
  Alternatively NE deficiencies may occur as a secondary response to 
infection.  
Studies by Aslam et al investigated the mucin turnover of the aganglionic and adjacent 
ganglionic colon in HD patients and in controls.
345
 The quantity of radioactive labelled 
mucins produced in 24 hours per µg DNA was measured and the ratio of incorporation 
of the labelled precursors determined.  Not only was the turnover of mucin in both the 
cellular and secreted fractions of the aganglionic samples reduced compared to controls, 
this was also the case in the „normal‟ distal ganglionic bowel.345  
What is not clear is whether this abnormal production of mucins is localised to a region 
close to the transition zone or reflects a more generalised deficiency.  Little is known 
about the mucin production of the „normal‟ ganglionic colon in HD.   If poor mucin 
turnover was found to only affect a short segment of ganglionic colon, this additional 
length could be resected along with the aganglionic colon and transition zone.  
Presuming that a defective mucin barrier is a major contributor to the development of 
enterocolitis, this alteration in surgical technique could result in fewer cases of post 
operative enterocolitis.   This hypothesis is strengthened by the finding that in those HD 
children who underwent corrective surgery, a correlation has been found between a low 
turnover of mucin precursors in distal ganglionic colonic biopsies and an increased 
incidence of post-operative enterocolitis.
372
 
 Further studies have looked in more detail at the colonic mucins in the distal colon in 
children with HD and have found that the protective modifications of mucins appear to 
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be present in similar amounts to controls, patients showing matching staining patterns 
for sulphated mucins within the colonic crypts and similar levels of O-acetylation. 
16
  
Similarly the expression of mucin genes has not been found to be altered in HD; in all 
age groups and in both ganglionic and aganglionic colon MUC1, 2, 3, 4 and 5B were 
detected in similar quantities.
16
 
Lectin binding study results with Maackia amurensis demonstrated 50-70% mucin 
binding with no significant differences seen between aganglionic bowel, ganglionic 
bowel and normal controls.
16 
 The aim of this study was to further investigate the ganglionic and presumably 
„normal‟ colon in children with Hirschsprung‟s disease. 
  
82 
 
Chapter 3 - Materials and Methods 
3.0 Subject Recruitment and Study Groups 
Local ethical approval for the study was obtained through the COREC system.  The 
study was approved for Research Governance purposes by the local Research and 
Development Directorate of Addenbrooke’s Hospital and of Norfolk and Norwich 
Hospital. All subjects were recruited from paediatric surgical units from one of two 
hospitals (Addenbrooke’s Hospital or Norfolk & Norwich Hospital). 
The study group consisted of children with a diagnosis of Hirschsprung’s disease made 
on clinical grounds and confirmed by an absence of ganglion cells on suction rectal 
biopsy specimens. 
The majority of controls were children born with an anorectal malformation who had a 
diverting colostomy sited soon after birth.   
Parents of suitable children were approached before surgery and given a parent 
information leaflet to read.  Consent was obtained using existing ethical guidelines. 
General practitioners were informed of participation in the study.  (Appendix 1 for 
copies of forms) 
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3.1 Retrieval of Specimens   
The children with Hirschsprung’s disease in this study underwent surgical correction, 
involving removal of the aganglionic segment of colon,
239 
 by one of two established 
management options; a three stage approach, with an intermediate colostomy, or by a 
deferred primary pull-through procedure.
328
   In the latter, the colon was kept 
decompressed by rectal washouts until the time of surgery.  
Mucosal biopsies were taken intra-operatively at the time of definitive pull-through 
surgery in the study group or at the time of colostomy closure in the control group.  
The most distal biopsy (A) was taken just above the transition zone.  In primary pull-
through cases this was assumed to be just above where the collapsed distal colon met 
the dilated proximal colon and in some instances was further identified by sequential 
intra-operative frozen sections.  In the control group and in those in the study group 
with a colostomy, the most distal specimen was taken from just inside the proximal 
end of the stoma.  Subsequent biopsies were then removed more proximally at 5cm 
intervals and lettered according to the diagram below. (Figure 3.1) 
 
Figure 3.1: Schematic representation of the distal colon and biopsy sites. 
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The investigator was present in theatre at operation to supervise the collection and 
labeling of specimens. In those patients recruited by the team at Norfolk and Norwich 
Hospital, this involved driving sixty miles there, with an appropriate tissue retrieval 
kit, collecting and labeling the specimens in theatre and then driving back a further 
sixty miles to the laboratory at Addenbrooke’s Hospital. The return journey took at 
maximum of 1 hour 40 minutes.  The laboratory bench space was set up in readiness 
prior to the journey in order to reduce the time taken to commence organ culture.  
Biopsies were transferred to the laboratory in PBS at room temperature, and placed 
into organ culture within a maximum of 2 hours. 
3.2 Reagents 
Reagents were supplied from Sigma (Sigma, Poole) unless otherwise stated. All tissue 
culture reagents were obtained from GIBCO (GIBCO, location). 
Culture Medium 
A working stock of 100mL of culture medium was prepared.    
88.9mL  Dulbecco’s modified Eagles medium 
10mL  foetal bovine serum (10%) 
1mL penicillin (10,000U/mL) invitrogen/gibco 
1mL streptomycin (10,000µg/mL) invitrogen/gibco 
0.1mL gentamicin (50mg/mL) invitrogen/gibco 
The tissue culture medium was sterilized using a 0.22m filter and stored in 10mL 
aliquots at -20
0
C. 
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Purification of Guanidine Hydrochloride 
Guanidine hydrochloride (reagent grade) was made up to an approximately 7M 
solution in phosphate buffered saline (PBS) by adding 1kg guanidine, HCl to 1.5L 
PBS (GIBCO) and stirring at room temperature for 24 hours. The guanidine solution 
was de-ionised by the addition of 15g activated charcoal and stirred at 4ºC for 24 
hours.  The suspension was filtered through two pieces of Whatman No 1 filter paper 
(Labsales, UK) and a further 15g of activated charcoal was added and stirred at room 
temperature for 24 hours.  The suspension was filtered as before and finally through a 
0.22m filter (Milipore).  The solution was diluted with sufficient extra PBS to give a 
final concentration of 6M. 
Tris Buffer 
A 0.5M Tris/HCL pH 8.0 buffer was prepared; 30.25g Tris base was added to 400mL 
of distilled water.  The pH was adjusted to 8.0 with addition of 50% HCL (v/v) and 
further distilled water was added to give a final volume of 500mL. 
Extraction Buffer 
0.5M Tris/HCL buffer 8.0 pH containing 6M guanidine HCL, 10mM dithiothreitol and 
5mM EDTA 
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Inhibitor Cocktail 
The cocktail was made up fresh in 10mL batches as required.   
15.4mg benzamidine    10mM 
6.3mg N-ethylmaleimide   5mM 
1mg soy bean trypsin inhibitor  0.1mg/mL 
100L 1M DTT    10mM 
100L 5M EDTA    3mM 
250L 6.8mg/mL PMSF in propan-2-ol 1mM 
    Final volume  10mL 
The cocktail was kept on ice and used immediately.  
Gel filtration buffer – 10mM Tris/HCl pH 8.0 
  Stock solution 5M 
  50 x dilution  = 1 mL in 50mL 
  Need 500mls  = 10mL 5M stock and 490mL water 
Gel filtration buffer – 0.5M guanidine HCL/PBS 
  Stock solution 6M 
  12 x dilution  = 1mL in 12mL 
     = 100mL in 1200mL 
     = 100mL 6M stock and 1100mL PBS 
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Preparation of Dialysis Tubing 
Dialysis tubing (visking size 1 inf dia 
8
/32: MWCO – 12-14,000 Daltons) was prepared 
by boiling the tubing for an hour in distilled water containing sodium bicarbonate and 
EDTA.  Subsequently the tubing was stored in 0.1% sodium azide (w/v) until use. 
3.3 Organ Culture 
Mucosal samples obtained at surgery were prepared for culture using established organ 
culture methods. 
372, 373, 345
  After initial dissection in theatre any remaining extra-
mucosal layers were dissected off using a sharp scalpel blade so that macroscopically a 
pure mucosal sample was obtained and this was further divided into 2mm
2
 pieces.   
These mucosal pieces were placed in a model type tissue culture dish, (Becton 
Dickinson) luminal surface up, on a raised steel grid covered with lens tissue overlying 
the culture dish well. (Figure 3.2) 
 
Figure 3.2: Schematic representation of the organ culture equipment. 
 
Two mL of culture medium was placed in the central well of the dish, in contact with 
the lens tissue and one mL of distilled water was added to the outer rim of the culture 
dish to prevent drying of the sample. Once the organ culture was assembled 10µCi of 
each of the radioactive precursors [3H]-glucosamine and [35S]-sulphate (Amersham) 
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were added to the medium. The mucosal cultures were incubated at 37ºC in a 
humidified atmosphere at 5% CO2 for 24 hours 
3.4 Cellular Fractionation 
Following incubation the culture medium was collected and the mucosal tissue was 
washed with 1mL ice cold PBS. The medium and PBS wash were combined and 
dialysed against 5L distilled water over 24 hours. The dialysis step was then repeated 
for a further 24 hours. 
The dialysate was centrifuged at 12,000xg at 4ºC for 10 minutes and the supernatant 
separated from any formed pellet; this formed the Secreted Soluble Fraction (SSF) 
and was stored at -80ºC until chromatography. Any remaining pellet was retained and 
was processed with the cellular soluble fraction.  
The mucosal tissue was homogenised in 1mL of PBS containing protease inhibitor 
cocktail along with any pellet remaining from the secreted soluble fraction. 
Homogenisation was carried out in a manual glass Potter-Elvejhem homogenizer. 
Approximately 20 strokes were required after which a smooth homogenate was 
obtained with only non-reducible connective tissue remaining visible. A 20L aliquot 
of the resulting homogenate was removed for DNA analysis.  The homogenate was 
centrifuged at 12,000xg at 4ºC for 10 minutes and the resulting supernatant retrieved 
formed the Cellular Soluble Fraction (CSF), which was stored at -80ºC until 
chromatography. 
The pellet was re-suspended in 1mL extraction buffer and incubated for 15 hours at 
room temperature.  Proteins were denatured by guanidine.  Remaining insoluble mucin 
89 
 
was solublised; firstly the disulphide bridges were disrupted by DTT and then their 
reformation prevented by reduction through the addition of solid iodoacetamide to give 
a final concentration of 25mM and incubated for 5 hours at room temperature in the 
dark. The sample was then centrifuged at 12,000xg at room temperature for 15 
minutes.  The supernatant was retrieved and any remaining pellet underwent a 
maximum of 2 further extractions in 1mL of extraction buffer for 2 hours.  The 
solutions were centrifuged at 12,000xg at room temperature for 15 minutes. The 
supernatants obtained at each step were pooled and collectively formed the Cellular 
Insoluble Fraction (CIF), which was stored at -80ºC until chromatography. 
3.5 Gel Filtration 
The fractions obtained after the various extraction procedures carried out on the 
mucosal samples were analysed by gel filtration.  Glass columns 1cm x 30cm (Dr 
Tony Corfield, Bristol Mucin Research Group) were packed with Sepharcryl S-500 
HR(Amersham) and equilibrated and eluted with the appropriate buffer. For the 
secreted soluble and cellular soluble samples the buffer used was10mM Tris/HCL pH 
8.0 and for the cellular insoluble samples 0.5M guandine/HCL/PBS. 
The stored fractions were thawed, centrifuged for 5 minutes at 12,000xg and loaded 
carefully onto the top of each column.  The total volume of the cellular soluble and 
cellular insoluble fractions and a maximum of 2mL of the secreted soluble fraction 
were used. The volume of the remainder of the secreted soluble was measured and re-
frozen at -80ºC.  
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A high molecular weight dye, blue dextran, which has a similar molecular weight to 
mucin molecules (2000 kD compared to 500 – 30,000 kDa) and is therefore too large 
to enter the gel, was run through the column to establish the void volume or exclusion 
volume (the volume of buffer that elutes from the column first which is too large to 
enter the gel). The fraction numbers in which the blue dextran appeared would 
correspond to the fraction numbers containing the mucin.  (Figure 3.8) 
Fractions of 1mL were collected manually to a total of 40mL.   The mucin samples 
were obtained at around fractions 13-16. All fractions were stored at 4ºC for later 
analysis.  Each column was washed through twice with the appropriate buffer after a 
gel filtration run and clamped and covered between experiments.  Columns were 
repacked after 5 runs. 
3.6 Determination of Radiolabel Incorporation 
A 100µL aliquot of each 1mL fraction obtained from gel filtration was placed in a 
scintillation vial (pico prias vials) with 1mL of scintillation fluid (Optiphase ‘Hisafe’ 
3) and the vials thoroughly mixed.  Counts were measured for up to 4 minutes per 
sample in a scintillation counter which was programmed to count disintegrations for 
35
S and 
3
H labels. Counts were automatically converted to disintegrations per minute 
(DPM) by the scintillation counter and the results retrieved from a print out of the data.  
Quenching curves were obtained to correct for any factors which cause energy loss in 
the scintillation solution by using 1µL of 
35
S with serial dilutions of acetone or by the 
manufacturer supplied quench curve for 
3
H. 
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Example calculation Patient L SSF sample A: 
Raw dpm H
3
 at fraction 13 = 70.13 
Decay corrected dpm 
= raw dpm ÷ ( exp ( - decay constant x ( 
date of count – incubation date ))) 
 = a 
Dilution factor corrected dpm = a x 10 
Volume SSF = 2.525mLs 
Volume corrected dpm = ( a x 10 ) x ( volume SSF ÷ 2 ) 
 = ( a x 10 ) x (2.525 / 2 ) 
 = a x 10 x 1.26 
DNA content sample A = 37.59ng/mL 
Final calculation for corrected dpm = a x ( 10 x 1.26 ) ÷ 37.59  
Radioactivity Calculations 
Mucosal samples were cultured in the presence of 10µCi of [3H]-glucosamine and 
10µCi of [35S]-sulphate.  [35S]-sulphate has a short half-life and therefore the volume 
of stock solution required needed to be recalculated for each experiment. 
Example Calculation: 
[35S]-sulphate stock = 250µCi on 03/05/2004 
Half-life = 87.4 days 
Experiment date = 06/05/2004 (i.e. 3 days from starting date) 
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Rt  = radioactivity at time of experiment 
Ro = radioactivity at initial date  
e  = exponential 
k  = constant 
t  =  time (days) 
ln  = log natural 
t½ = half-life 
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At start date there were 250µCi in 250µL solution, therefore 1µCi/µL. At time of the 
experiment there were 244µCi left in the stock. 
   
   
              
10µCi required for the experiment,  
        
  
    
            [   ]                 
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3.7 DNA analysis 
DNA analysis was carried out using 20µL aliquots of homogenized material from each 
of the samples.  A dye-binding fluorometric assay kit, PICO green (Invitrogen) was 
used.   
A stock solution of 2µg/mL DNA was made by diluting the standard stock dsDNA 
provided in the kit with TE (Tris/HCL, EDTA).   The solution was used to generate a 5 
point standard curve from 1ng/mL to 1µg/mL as recommended by the manufacturers.   
The dilutions were made to a final volume of 100µL as in the table below.  Each was 
placed in duplicate wells in a multi-well plate (Labsales, UK). 
Well DNA solution (µL) TE (µL) Concentration DNA content(ng) 
A 100 0 1µg/mL 200 
B 25 75 25ng/mL 50 
C 10 90 10ng/mL 20 
D 2.5 97.5 2.5ng/mL 5 
E 1 99 1ng/mL 2 
F 0 100 Blank 0 
 
Table 3.1 : DNA Content of Wells 
 
Each 20µl patient sample was run in four wells diluted with TE as follows: 
 2 x 5µl with 95µl of TE (total 100µl) 
 2 x 2µl with 98µl of TE (total 100µl) 
A 200 fold dilution of the PICO green reagent was prepared in TE.  100µL of this was 
added to each well.  The multi-well plate was placed in the fluorometer and the 
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Picogree.sec program was used.  The reading from the reagent blank was subtracted 
from all the results.  
The results from the standard DNA samples were plotted on a graph (x  axis = ng 
DNA, y axis = fluorometer reading). (Figure 3.3)  A linear trend line was produced and 
from the line equation the DNA content of the unknown patient samples was 
calculated.  This was converted into ng DNA/µL and a mean for each patient sample 
obtained. 
3.7.1 Example calculation - Patient Q @ sample C:   
Linear trend line equation:          
DNA standard sample gave results of  
m  =  2.81  c  =  4.95 
 
 
Figure 3.3: Standard DNA curve used with Patient Q 
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Fluorometer reading for Sample C of Patient Q = 450.26 
       
     
 
      
             
    
 
        = 158.47  ng DNA in Sample C 
 
3.8 Slot Blot Analysis of Gel Filtration Fractions 
The fractions obtained from gel filtration were subjected to slot blot analysis.  A 
standard protocol (Dr Tony Corfield, Bristol Mucin Research Group) was used as a 
starting point and adapted to a working format.  The development of the final 
methodology required several preliminary experimental stages.  
3.8.1 Establishment of Protocol 
Assembly and loading of slot blot apparatus 
The slot blot apparatus (minifold 2, Whatman) was assembled using nitrocellulose 
membrane (Amersham) on top of two sheets of blotting paper.  All were pre-soaked in 
PBS. Trial 600µL aliquots of PBS were loaded into the wells and vacuum was applied 
but the PBS remained in the wells even after one hour. 
The method was modified by using a more capable vacuum pump which improved the 
transference of samples through the nitrocellulose but only in those wells nearest the 
vacuum inlet.  Reduced resistance offered by the emptied wells compared to the 
remaining full wells, resulted in the vacuum acting preferentially through these.  To try 
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to counter this once the wells were empty they were covered.  Parafilm, plasticine and 
autoclave tape were all trialed, the latter being the most effective in promoting well 
clearance, through several wells still did not empty.  The final modification was to run 
the slot blot using a single piece of blotting paper.  This resulted in complete and rapid 
clearance of all the wells without the need to cover any of the wells.  
 
Trial Run of Slot Blot with Standard Mucins 
The slot blot was loaded as above with serial dilutions of serum and saliva.  
Nitrocellulose was separated from blotting paper using forceps and placed face up in a 
tray.  The membrane was blocked in PBS with 0.05% (v/v) polyoxyethylene sorbitan 
mondaurate (Tween-20 (Sigma, Poole)) and 1% bovine serum albumin (BSA) (Sigma, 
Poole) for 4 hours at room temperature on a rocking platform covered with cling film. 
Wheat germ agglutinin-horse radish peroxidase conjugate (EY laboratories Inc) was 
added to the blocking solution to give a final dilution of 1:15,000, covered with cling 
film and incubated for a further 4 hours at room temperature on a rocking platform.  
The nitrocellulose membrane was washed three times with 20mLs of PBS and 0.05% 
Tween-20 for 8 minutes and then a final wash with 20mLs of PBS for 9 minutes. 
The slot blot membranes were developed with a perioxidase reaction using 
diaminobenzamidine (DAB) reagent (Sigma) but no colour change signal was 
detected. 
  
97 
 
A failure at one or more stages was suspected: 
1. Mucin sample – failure to bind to the nitrocellulose or dilutions too weak to 
allow detection 
2. Lectin – failure to bind to mucin or inadequate amount of lectin present for 
detection 
3. Colour detection – DAB detection system not working 
 
Modifications to Slot Blot Method 
The efficiency of the DAB detection system was tested by applying neat lectin dots 
directly on to the nitrocellulose.  After blocking and washing as before, the membranes 
were developed with DAB.   The dots of lectin were found to stain although they 
appeared quite grainy. 
Higher concentrations of the standard serum and saliva mucins were used and these 
were loaded on to the slot blot in 4 sets of identical dilution series; neat, 1:2, 1:4, 1:6, 
1:8. The nitrocellulose was then divided into 4 pieces, blocked as before and then 
different concentrations of the lectin were added to each; 1:1000, 1:2000, 1: 5000, 
1:10,000.  These were incubated for four hours, washed and developed.  All samples 
stained although the appearance was grainy and non-uniform within each slot.  There 
was no improvement with the more concentrated WGA solutions so a concentration of 
1:10,000 was used for further experiments. 
The method above was tested for the ability to detect the lower mucin concentrations 
expected in patient samples.  Using the same WGA dilution, 20µL samples of serial 
dilutions of serum and saliva (neat to 1:3125) were added in triplicate to the blot.  
98 
 
Patient samples from gel filtration fractions representing the mucin peak and the eluted 
volume and a blank of PBS were also loaded.  The samples all stained with DAB, 
including the blanks, with no gradation between the serial dilutions.  The appearance 
of the blot remained very grainy. 
To try to improve the differentiation between mucin concentrations a different 
detection system, enhanced chemiluminescence was used.  As above serum and saliva 
dilutions were loaded in duplicate on to a blot, to yield two replicate membranes and 
these were blocked as before and WGA added.  One was developed with DAB and the 
other with chemiluminescence.  Both gave similar results showing a lack of 
differentiation between the dilution levels. 
PVDF membrane (Amersham), was compared to nitrocellulose.  PVDF was wet with 
methanol and then placed in PBS.  Serum and saliva dilutions were loaded in duplicate 
onto PVDF and nitrocellulose membranes.  The membranes were cut into two and 
were blocked and WGA added.  Half of each membrane was detected using the DAB 
system and half by chemiluminescence.   The nitrocellulose membrane showed better 
staining results. 
To try to improve the blot appearance a more purified form of BSA was used as the 
blocking agent (Sigma A9647).  Also concentrations of 0.05% and 0.5% Tween-20 
were compared.  Neither alteration made a significant difference. 
In the original protocol a small amount of bleach was added after the DAB detection 
system had caused a colour change, to stop the reaction.  The bleach was omitted and 
the blot removed from the DAB agent and washed instead.   This resulted in the 
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resolution of both the grainy appearance of the staining and a clear difference in colour 
uptake could be noted between the different mucin concentrations.   
Application of Method to Subject Samples 
Preliminary slot blots were performed to determine whether the peak of radioactivity 
coincided with the WGA staining peak.  Aliquots of 50µL were taken from each of the 
gel filtration fractions from 1 to 40 and loaded onto a blot.  A separate experiment was 
performed for each of the mucin fractions, SSF, CSF and CIF.  Peak staining occurred 
at the same gel filtration fractions as the peak radioactivity counts.  In order to 
determine the volume of sample required to give optimum staining, different volumes 
of sample were loaded onto a blot.  The optimal volume was found to be 300µL. 
3.8.2 Final Method Protocol 
A piece of blotting paper and a piece of nitrocellulose were cut to size and soaked in 
PBS at room temperature.  These were loaded into the slot blot apparatus (minifold 2, 
Whatman), care taken to only handle the nitrocellulose with forceps.   
A separate slot blot was performed for each subject.  The fractions obtained from gel 
filtration previously analysed for radioactivity resulted in a bi-peaked distribution. 
Pools were made from 200µL aliquots of each of the three highest front peak and back 
peak samples with the highest scintillation counts, resulting in each subject having 24 
separate samples, i.e.  
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A 
SSF Front peak CSF Front peak CIF Front peak 
SSF Back peak CSF Back peak CIF Back peak 
B 
SSF Front peak CSF Front peak CIF Front peak 
SSF Back peak CSF Back peak CIF Back peak 
C 
SSF Front peak CSF Front peak CIF Front peak 
SSF Back peak CSF Back peak CIF Back peak 
D 
SSF Front peak CSF Front peak CIF Front peak 
SSF Back peak CSF Back peak CIF Back peak 
 
 
Table 3.2: Samples used for slot blot analysis for each subject 
A mucin standard curve was loaded onto every blot in the following dilutions; 1:10, 
1:50, 1:100, 1:250, 1:500.  PBS was used as a blank.  Samples were loaded in 
duplicate in 300µL aliquots. 
The membrane was blocked in PBS with 0.05% Tween-20 and 1% BSA for 4 hours at 
room temperature.  The lectin was added to this solution in the appropriate dilution and 
was incubated for a further 4 hours at room temperature. The dilution of lectin required 
was determined by repeated experimentation and was 1:10,000 WGA, 1:100 MAA 
(EY laboratories Inc). UEA (EY laboratories Inc) was used in the following dilutions; 
1:10,000, 1:5000, 1:1000 and 1: 100.  
The membrane was washed with PBS/Tween-20 (0.05%) for three eight minute 
washes.  Just before use, 1 ml of the DAB reagent was added to 9 mLs of the DAB 
buffer and added to the membrane.  When a colour change had occurred the reagent 
was removed and the membrane washed in distilled water. (Figure 3.4) 
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Figure 3.4: Example of a slot blot obtained using WGA lectin. 
 
Slot blots were scanned and the densitometry was calculated using Image J (internet 
resource, National Institute of Health, USA, Research Services Branch). (Figure 3.5)  
Corrections for background reactivity were performed.  Inter-membrane variation was 
controlled for by comparison against the standard mucin curves present on each 
membrane.  
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Figure 3.5: Densitometry trace from a WGA slot blot obtained using the Image J program. 
 
 
The dot intensities were plotted on a graph and a logarithmic curve fitted. (Figure 3.6) 
The relative mucin concentration of the patient samples was interpolated from the 
curve equation. As each subject sample was loaded in duplicate a mean result was 
obtained. 
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3.8.3 Example WGA slot blot calculation - Patient H @ sample B:   
Logarithmic Curve equation:             
Standard Mucin Curve sample gave results of  
m  =  346.08  c  =  320.16 
 
 
Figure 3.6: Standard mucin curve obtained from a WGA slot blot. 
 
 
Densitometry reading for Patient H @ Sample B (CSF Fraction) = 1491 
        
     
       
             
       
        = 29.46 WGA Binding 
  
y = 346.08ln(x) + 320.16 
R² = 0.9599 
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3.8.4 Example MAA slot blot calculation - Patient T @ sample B:   
The slot blots performed with the lectin Maackia amurensis agglutinin (MAA) also 
had standard mucin dilutions run along side subject samples.  These generated a 
hyperbolic curve. (Figure 3.7) 
Standard MAA Curve sample gave results of  
a  =  2119.63  b  =  4147.56 
 
Figure 3.7: Example of a standard mucin curve obtained from a MAA slot blot. 
 
Densitometry reading for Patient T @ Sample B (CSF Fraction) = 1859 
       
 
     
      
       
              
   
     = 15.91 MAA Binding 
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3.9 Analysis of data 
Data obtained from the scintillation counter print out was manually entered onto Excel 
workbook sheets (Microsoft Office).  Disintegrations per minute were calculated 
separately for [3H] and [35S] for each of the 40 gel filtration fractions obtained from 
the secreted soluble, cellular soluble and cellular insoluble mucins fractions 
respectively.  DPM were corrected for the following; background radioactivity (by 
subtracting the mean DPM from the fractions collected prior to the void volume from 
the other fractions), radioactive decay and total DNA content of the mucosal sample.  
In addition the secreted soluble samples were also corrected for the fraction of the total 
volume run on the column.  The incorporation of label in each fraction was expressed 
as dpm/ng DNA.   
For each biopsy point a single set of incorporation values for each precursor was 
generated by adding together the figures for the secreted soluble, cellular soluble and 
cellular insoluble generated at fractions 1 to 40.  The incorporation results from the 
separate extraction fractions and the combined results were plotted graphically against 
the gel filtration fraction number giving three individual graphs and one combined 
graph for each patient or control for each biopsy taken and each precursor used. 
(Figures 3.8 & 3.9)   
The resulting graphs of disintegrations per minute for the gel filtration fractions showed 
a double peaked configuration.  Mucins are very high molecular weight molecules so 
are elucidated early on in the gel filtration process at a similar fraction number to blue 
dextran. 
11
   Slot blot analysis of samples taken from each of the gel filtration fractions 
with wheat germ agglutinin stained in the region of the first peak and also within the 
second peak.  Based on these confirmatory results and on previous similar work with 
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gel filtration columns, the front peak was designated the mucin peak and the other peak 
nominally called the back peak.
345, 372
    
 
Figure 3.8: Example of a Patient graph of gel filtration fraction number and incorporation 
 
Figure 3.9: Example of a Control graph of gel filtration fraction number and incorporation 
 
A single incorporation value for each precursor was calculated by taking the sum of the 
three highest values within each peak. 
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Example: Patient J @ Biopsy level A 
 
Total incorporation values (SSF + CSF + CIF) - peak values in red 
Fraction 3H 35S 
5 2.48 -3.95 
6 1.41 4.66 
7 -6.96 -0.53 
8 -7.46 -0.61 
9 -13.83 -6.23 
10 -13.16 0.31 
11 28.32 21.88 
12 502.92 228.02 
13 2127.13 1013.06 
14 1088.79 452.79 
15 383.78 120.96 
16 319.54 86.15 
17 316.82 84.99 
18 323.24 73.81 
19 342.54 69.63 
20 340.77 64.30 
21 372.43 55.37 
 
Table 3.3: Incorporation results from a subject demonstrating the mucin peak values 
Single figure results for patient J at point A are therefore: 
   3H = 502.92 + 2127.13 + 1088.79 
    = 3719 
   35S = 229.02 + 1013.06 + 452.79 
    = 1695 
The data for this analysis for each patient and control can be summarized thus: 
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 Patient J 
 A B C D 
 mucin back mucin back mucin back mucin back 
3H 3719 9628 1539 10853 2180 6175 1342 3464 
35S 1694 3615 428 4896 654 1289 491 786 
 
Table 3.4: Summary results for incorporation for a subject 
Mean values for the patient and control groups were calculated for total incorporation 
within the peaks and for incorporation within the separate extraction fractions peaks for 
each precursor and corrected for DNA content.  Relative incorporation was derived by 
dividing [35S]-sulphate incorporation by [3H]-glucosamine incorporation. 
Overall incorporation values were calculated by adding the result from each biopsy 
and dividing by the total number of biopsies taken to yield a single figure per subject.  
i.e. (A + B + C + D)/4 
Lectin binding results were calculated as mentioned above from the generation of a 
standard curve.  Mucin peak densitometry mean values were calculated for each 
separate biopsy level and for each separate extraction fraction studied for patients and 
controls.  Addition of the binding values for the separate extraction fractions gave total 
mucin binding values.  Overall densitometry results were calculated by adding the 
combined result from each biopsy and dividing by the total number of biopsies taken 
as above.  
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Densitometry results were further quantified by DNA content of the sample and 
expressed per 100ngDNA. 
3.10 Statistical Analysis 
Statistics were generated using the In Stat 3 program (GraphPad Software). An 
unpaired t-test was used where data passed a normality test, Kolmogorov and Smirnov 
method. Welch correction was applied when the difference between standard 
deviations was statistically significant. The Mann-Whitney test was used where the 
data did not follow a normal distribution pattern. A p value of < 0.05 was considered 
significant.  
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Chapter 4 –Results 
4.0  Study subject data 
A total of 10 patients with Hirschsprung’s disease and 6 controls were recruited over a 
period of 15 months.  There were no withdrawals from the study.   
All of the Hirschsprung’s patients had their diagnosis established by rectal biopsy and 
had histological confirmation of their diagnosis at operation.  None had any evidence of 
enterocolitis at the time of surgery or diarrhoea of unknown origin.   Eight had 
Hirschsprung’s disease affecting the rectosigmoid colon, two affecting the descending 
colon. (Table 4.1) None of the controls had diarrhoea at the time of surgery and none 
had any evidence of immunodeficiency.  
Six patients underwent the Duhamel operation as part of a two or three stage procedure 
328 
and four had a laparoscopic-assisted Soave procedure as a single stage procedure.
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(Table 4.1) Five controls had an anorectal malformation, one had sustained a rectal 
injury.  All had a colostomy performed as part of their initial treatment. (Table 4.2) 
Mean number of biopsies taken per patient was 3.6 and in the control group 3.3.  Within 
the patient group seven had four biopsies retrieved, two had three biopsies and one had 
two biopsies.  In the control group three had four biopsies taken, two had three biopsies 
and one had two biopsies.   
Gestation and birth weight were comparable between the two groups (p = 0.35 and p > 
0.99). There were five episodes of pre-operative enterocolitis affecting three patients 
and six episodes of post-operative enterocolitis affecting four patients.  Two patients 
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had pre and post-operative enterocolitis. (Table 4.1) There were no complications 
arising from the study.  Follow-up was ongoing in the majority of patients at the time of 
write up.   
Patient 
Identifier 
Demographics at 
operation 
Length of disease 
Type of 
Surgery 
Episodes of 
enterocolitis 
Pre-operative use of 
washouts 
Age 
(days) 
Weight 
(kgs) 
Pre - 
op 
Post - 
op 
Elective Emergency 
G 106 7820 Rectosigmoid Duhamel 0 0 No No 
H 349 8660 Descending colon Duhamel 0 0 No No 
J 169 6950 Rectosigmoid Duhamel 0 3 No No 
K 220 8200 Rectosigmoid Soave 2 0 Yes No 
L 502 14300 Rectosigmoid Soave 2 1 Yes Yes 
M 97 6920 Rectosigmoid Soave 1 1 Yes Yes 
Q 97 7010 Rectosigmoid Soave 0 0 Yes No 
R 78 6290 Rectosigmoid Duhamel 0 0 No No 
T 177 8790 Descending colon Duhamel 0 0 No No 
E 61 5160 Rectosigmoid Duhamel 0 1 No No 
 
Table 4.1: Demographics and clinical features of patients. 
 
Control 
Identifier 
Demographics at operation 
Underlying Diagnosis Type of Surgery 
Age (days) Weight (kgs) 
F 409 12300 Anorectal malformation Closure of colostomy 
N 92 8800 Anorectal malformation Closure of colostomy 
P 155 8270 Anorectal malformation Closure of colostomy 
S 212 8500 Rectal perforation Closure of colostomy 
X 345 8700 Anorectal malformation Closure of colostomy 
Y 186 7500 Anorectal malformation Closure of colostomy 
 
Table 4.2: Demographics and clinical features of controls. 
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 Patients Controls  
 Median Range Median Range p value 
Age at operation (days) 137.5 61 - 502 199 92 - 409 0.43 
Weight at operation (kg) 7415 5160 - 14300 8600 7500 - 12300 0.12 
 
Table 4.3: Age and Weight of Subjects 
 
 
4.1 Gel Filtration Graphs 
The incorporation of [3H]-glucosamine and [35S]-sulphate in each sub-fraction was 
expressed as dpm/ng DNA.  The majority of the graphs, especially those from the 
cellular soluble mucin fraction, showed a characteristic pattern of two peaks, the first 
at around 12-14 fractions and a second at around 28-31 fractions.  The two peaks for 
both radioactive precursors coincided and were separated by a region of minimal 
turnover.  In all graphs the back peak was higher than the mucin peak and the [3H]-
glucosamine incorporation peaks were greater than those of [35S]-sulphate.  Patterns 
yielded were similar in patients and controls. 
Two other patterns of graph were found to occur.  In some the first peak was minimal or 
absent.  This was the most common pattern found in the secreted soluble mucin graphs 
and occurred in both patients and controls.  The third pattern occurred predominantly in 
the cellular insoluble fraction where the two peaks were linked by levels of 
incorporation well above base line, giving rise to a continuous curve linking the two 
peaks.  Patients and controls again displayed similar patterns. 
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The number of the fractions where the two peaks was elucidated was slightly different 
in the three mucin samples.  In the secreted soluble the peaks tended to occur earlier at 
around 10-12 and 24-26 respectively, whereas in the cellular soluble and cellular 
insoluble they occurred at 12-14 and 29-31. This was true for patients and controls. 
The sum of the corrected incorporation for the three mucin sub-fractions was calculated 
for [3H]-glucosamine and [35S]-sulphate to give a single set of figures and a single 
graph for each radioactive precursor and for each point along the colon for every patient 
and control. 
These showed the same double peaked configuration. (Figures 4.1 & 4.2)  The front, 
mucin peak occurred at around fraction number 13 and was in most a sharp peak, with 
the highest value at the centre and the second and third highest values either side.  This 
was the same in patients and controls and for both precursors.  The back peak was of a 
similar configuration for [35S]-sulphate incorporation but more broad based for [3H]-
glucosamine incorporation. 
The front peak was designated the mucin peak due to confirmatory results using blue 
dextran and WGA binding as detailed in the methodology. 
Comparing the graphs along the colon from A to D for individual subjects, although 
there was no uniform pattern or progression, most controls showed a higher mucin peak 
at A compared to B whereas in most patients the reverse occurred.  (Figures 4.1 & 4.2) 
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Figure 4.1: Example Patient graph showing mucin and back peaks 
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Figure 4.2: Example Control graph showing mucin and back peaks 
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4.2 Total Mucin Peak Incorporation 
The incorporation of [3H]-glucosamine and [35S]-sulphate within the mucin peak was 
expressed as dpm/ng DNA and samples were incubated for 24 hours.  Any statistically 
significant results are shown in red. Overall incorporation values were calculated by 
adding the result from each biopsy and dividing by the total number of biopsies taken 
to yield a single figure per subject.  i.e. (A + B + C + D)/4 
 
Mucin Peak [3H]-glucosamine Incorporation 
 Mean Standard Deviation 
Patients 4079 ±1926 
Controls 3530 ±1037 
  (p value 0.53) 
 
Table 4.4: Mean Total Overall [3H] Incorporation within Mucin Peak 
 
 
 
Mucin Peak [35S]-sulphate Incorporation 
 Mean Standard Deviation 
Patients 1369 ±773 
Controls 1206 ±562 
  (p value 0.66) 
 
Table 4.5: Mean Total Overall [35S] Incorporation within Mucin Peak 
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4.2.1 Total Mucin Incorporation at the Different Colonic Points 
Total [3H] Incorporation 
Subject A B C D 
Patients 
G 2674.34 8348.31 6997.41 5001.91 
H 3819.74 3130.65 5085.69 3129.34 
J 3718.84 1538.66 2180.05 1342.48 
K 1854.52 3841.20 993.83 1164.83 
L 1267.47 7086.22 9261.22   
M 8057.17 9711.85 6413.25 6750.56 
Q 653.20 1955.63 7257.24 3074.48 
R 2544.99 2893.74 1919.16 1027.92 
T 5989.24 2633.88 5846.06 5019.56 
E 4348.98 2212.36     
      
Controls 
F 2914.30 3600.63 5332.45 3354.50 
N   5683.77 3658.90   
P 5612.37 3480.13 7979.81 1934.16 
S 6101.16 1839.79 272.68   
X 4909.98 1090.40 2755.43   
Y 5688.21 2108.42 511.16 897.50 
 
Table 4.6: Total Individual [3H] Incorporation within Mucin Peak 
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Figure 4.3: Individual subject graphs of total mucin peak [3H]-glucosamine incorporation 
(corrected disintegrations per minute/ngDNA) at colonic points A to D 
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Total [35S] Incorporation 
Subject A B C D 
Patient 
G 737.60 4047.10 652.05 2182.62 
H 1756.22   2648.70 1482.65 
J 1693.86 427.75 654.08 490.71 
K 673.72 1334.99 175.45 456.20 
L 194.42 649.95 2329.76   
M 2824.27 4289.38 1217.12 1083.05 
Q 34.68 144.18 240.59 568.07 
R 750.02 881.65 497.62 340.47 
T 1955.22 982.86 2425.80 1675.17 
E 2925.89 1691.79     
      
Control 
F 1581.61 1528.93 2313.99 1476.93 
N   1731.56 996.93   
P 976.18 481.97 714.54 49.96 
S 1783.08 483.61 111.39   
X 3393.15 462.09 2009.09   
Y 672.39 1844.03 321.85 545.21 
 
Table 4.7: Total Individual [35S] Incorporation within Mucin Peak 
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Figure 4.4: Individual subject graphs of total mucin peak [35S]-sulphate incorporation (corrected 
disintegrations per minute/ngDNA) at colonic points A to D 
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Figure 4.5: Scatter graph of Mucin Peak [3H]-glucosamine incorporation  
 
Figure 4.6: Scatter graph of Mucin Peak [35S]-sulphate incorporation  
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4.2.2 Mean Mucin Peak Incorporation at the Different Colonic Points 
Mean Mucin Peak [3H]-glucosamine Incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 3493 ±2242 5045 ±1266 0.18 
B 4335 ±2930 2967 ±1648 0.32 
C 5106 ±2814 3418 ±2943 0.28 
D 3314 ±2118 2062 ±1234 0.37 
 
Table 4.8: Mean [3H] Incorporation within Mucin Peak at the Colonic Points 
 
Mean Mucin Peak [35S]-sulphate Incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 1354 ±1031 1681 ±1057 0.58 
B 1606 ±1525 1089 ±679 0.39 
C 1205 ±996 1078 ±899 0.81 
D 1035 ±683 1011 ±725 0.48 
 
Table 4.9: Mean [35S] Incorporation within Mucin Peak at the Colonic Points 
 
4.3 Incorporation within the Sub-Fractions of the Mucin Peak 
The following tables show the incorporation results in dpm/ngDNA obtained from the 
three sub-fractions within the mucin peak of both patients and controls.  
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4.3.1 Secreted Soluble Fraction - [3H]-glucosamine incorporation 
Subject A B C D 
Patients 
G 11.00 271.34 100.47 124.44 
H 802.60 50.40 67.18 13.76 
J 9.22 372.28 250.78 41.03 
K 25.10 50.28 55.35 42.07 
L 55.90 176.52 1702.29   
M 175.52 614.60 163.24 586.77 
Q 2.88 25.57 23.78 5.75 
R 96.88 48.23 74.07 11.91 
T 11.06 7.55 7.41 0.00 
E 52.45 30.70     
      
Controls 
F 116.99 117.60 174.67 97.72 
N   72.01 194.37   
P 5.12 2.45 32.59 5.57 
S 11.77 191.93 13.14   
X 14.14 8.91 27.64   
Y 134.68 28.58 71.96 24.49 
 
Table 4.10: Individual [3H] Incorporation within SSF fraction 
 
 
Mucin [3H]-glucosamine incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 124 ±244 57 ±64 0.43 
B 165 ±200 70 ±74 0.20 
C 272 ±542 86 ±79 0.34 
D 103 ±199 43 ±49 0.63 
 
Table 4.11: Mean [3H] Incorporation within SSF fraction 
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4.3.2 Cellular Soluble Fraction - [3H]-glucosamine incorporation 
Subject A B C D 
Patients 
G 2555.38 7600.23 5509.65 4135.02 
H 3087.16 2853.23 4601.90 3350.00 
J 3450.07 1260.07 1828.75 1196.78 
K 1522.85 3119.51 809.50 846.47 
L 1155.89 6223.23 7056.73   
M 7522.55 9047.40 5578.06 6340.32 
Q 632.61 1897.96 7125.19 3011.62 
R 2394.73 2480.64 1732.11 988.53 
T 5691.78 2286.73 5514.69 4738.81 
E 3812.12 1769.94     
      
Controls 
F 2480.91 3294.10 4185.03 2736.29 
N   5183.10 3098.16   
P 5219.82 3206.38 6755.27 1382.07 
S 5094.39 1480.72 243.08   
X 4670.50 952.36 2142.72   
Y 5237.03 1877.98 404.35 797.23 
 
Table 4.12: Individual [3H] Incorporation within CSF fraction 
 
 
Mucin [3H]-glucosamine incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 3183 ±2108 4541 ±1174 0.21 
B 3854 ±2737 2666 ±1548 0.35 
C 4417 ±2372 2805 ±2464 0.23 
D 3076 ±1981 1639 ±995 0.27 
 
Table 4.13: Mean [3H] Incorporation within CSF fraction 
 
124 
 
4.3.3 Cellular Insoluble Fraction - [3H]-glucosamine incorporation 
Subject A B C D 
Patients 
G 132.59 785.83 1410.67 790.48 
H 214.87 450.50 703.36 345.79 
J 338.06 785.83 31.71 138.05 
K 311.49 777.36 187.81 287.41 
L 76.62 865.02 1220.20   
M 632.57 897.93 688.42 636.73 
Q 22.25 39.88 138.83 88.28 
R 79.18 358.50 98.09 35.12 
T 288.48 344.79 329.05 359.02 
E 625.51 297.18     
      
Controls 
F 367.29 421.65 1184.01 520.49 
N   428.66 336.83   
P 326.56 292.47 1334.88 610.94 
S 443.37 229.93 23.77   
X 319.14 42.40 592.50   
Y 316.50 159.48 36.63 73.80 
 
Table 4.14: Individual [3H] Incorporation within CIF fraction 
 
 
Mucin [3H]-glucosamine incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 272 ±216 355 ±54 0.28 
B 560 ±297 262 ±151 0.04 
C 534 ±506 585 ±565 0.86 
D 335 ±265 402 ±288 0.72 
 
Table 4.15: Mean [3H] Incorporation within CIF fraction 
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4.3.4 Secreted Soluble Fraction - [35S]-sulphate incorporation 
Subject A B C D 
Patients 
G 2.76 208.97 6.05 34.73 
H 320.78   9.76 0.00 
J 3.20 6.43 12.63 0.05 
K 0.00 0.44 5.42 3.79 
L 8.56 8.97 63.80   
M 7.67 137.68 15.16 4.04 
Q 2.09 2.67 11.50 0.00 
R 20.79 0.00 0.00 3.75 
T 1.52 0.00 0.00 0.00 
E 12.67 0.00     
      
Controls 
F 36.29 21.99 98.04 52.46 
N   0.00 0   
P 2.30 0.00 0.00 0.00 
S 0 0.00 0   
X 60.46 9.36 2.14   
Y 7.14 11.21 25.26 4.14 
 
Table 4. 16: Individual [35S] Incorporation within SSF fraction 
 
 
Mucin [35S]-sulphate incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 38 ±100 21 ±26 0.63 
B 41 ±77 7 ±9 0.23 
C 14 ±19 21 ±36 0.69 
D 6 ±12 19 ±29 0.53 
 
Table 4.17: Mean [35S] Incorporation within SSF fraction 
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4.3.5 Cellular Soluble Fraction - [35S]-sulphate incorporation 
Subject A B C D 
Patients 
G 716.41 3735.91 571.02 1977.53 
H 1458.70   2435.93 1563.11 
J 1576.99 421.87 619.64 443.45 
K 584.87 1170.39 155.57 367.37 
L 190.32 619.30 2147.60   
M 2665.32 4135.37 1066.89 1117.78 
Q 39.25 141.85 554.68 582.93 
R 708.29 836.93 526.37 345.74 
T 1892.13 899.09 2325.14 1626.43 
E 2632.85 1508.68     
      
Controls 
F 1407.45 1433.81 2084.21 1271.36 
N   1624.09 924.91   
P 937.30 459.67 686.43 39.36 
S 1535.04 509.76 121.10   
X 3245.15 442.70 1788.78   
Y 688.14 1739.63 291.53 488.00 
 
Table 4.18: Individual [35S] Incorporation within CSF fraction 
 
 
Mucin [35S]-sulphate incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 1247 ±948 1563 ±1001 0.56 
B 1497 ±1442 1035 ±626 0.41 
C 1156 ±893 983 ±797 0.71 
D 1003 ±654 600 ±624 0.38 
 
Table 4.19: Mean [35S] Incorporation within CSF fraction 
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4.3.6 Cellular Insoluble Fraction - [35S]-sulphate incorporation 
Subject A B C D 
Patients 
G 38.32 251.74 83.81 193.56 
H 101.69   316.46 156.05 
J 133.55 104.56 37.26 64.95 
K 94.75 214.27 35.33 94.98 
L 0.00 27.52 162.00   
M 227.74 429.37 155.95 207.72 
Q 0.00 1.81 15.26 15.46 
R 21.14 70.87 0.00 5.64 
T 63.23 88.05 103.14 74.65 
E 339.22 167.70     
      
Controls 
F 140.65 142.08 229.57 186.82 
N   124.37 93.04   
P 37.07 31.61 44.81 6.62 
S 106.24 0.00 0.00   
X 150.03 16.02 295.78   
Y 0.00 52.31 1.13 47.09 
 
Table 4.20: Individual [35S] Incorporation within CIF fraction 
 
 
Mucin [35S]-sulphate incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 102 ±109 87 ±66 0.78 
B 151 ±133 61 ±59 0.10 
C 101 ±100 111 ±124 0.87 
D 102 ±77 80 ±95 0.71 
 
Table 4.21: Mean [35S] Incorporation within CIF fraction 
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4.3.7 Ratios of [35S]/[3H] within Mucin Peak Sub-Fractions 
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Figure 4.7: Mean Ratio of [35S]/[3H] Incorporation within SSF 
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Figure 4.8: Mean Ratio of [35S]/[3H] Incorporation within CSF 
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Figure 4.9: Mean Ratio of [35S]/[3H] Incorporation within CIF 
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4.4 Total Back Peak Incorporation 
 
 
Mucin [3H]-glucosamine incorporation 
 Mean Standard Deviation 
Patients 11841 ±6459 
Controls 13022 ±5759 
  (p value 0.72) 
 
Table 4.22: Mean Total Overall [3H] Incorporation within Back Peak 
 
 
 
 
 
Mucin [35S]-sulphate incorporation 
 Mean Standard Deviation 
Patients 3100 ±2278 
Controls 3403 ±2406 
  (p value 0.81) 
 
Table 4.23: Mean Total Overall [35S] Incorporation within Back Peak 
  
130 
 
4.4.1 Total Back Peak Incorporation at the Different Colonic Points 
Total [3H] Incorporation 
Subject A B C D 
Patients 
G 6434.21 46247.05 7669.76 24944.47 
H 11368.60 9479.32 13168.95 10763.73 
J 9628.48 10852.93 6174.53 3464.17 
K 6262.98 8062.80 4506.99 4305.19 
L 2315.35 11225.50 34096.95 
 M 19632.45 30776.48 17542.04 19478.15 
Q 3416.82 4428.99 8263.71 4487.68 
R 9015.76 7516.07 5449.03 4921.01 
T 7790.02 6994.20 13577.41 16135.10 
E 
    
      
Controls 
F 6675.01 12154.93 14386.72 12730.60 
N 
 
12940.49 11004.03 
 P 8312.31 21363.22 41145.54 25027.81 
S 14447.36 14068.46 3442.42 
 X 15359.84 4769.28 19232.04 
 Y 9726.67 9896.37 2525.15 5591.24 
 
Table 4.24: Total Individual [3H] Incorporation within Back Peak 
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Figure 4.10: Individual subject graphs of total back peak [3H]-glucosamine incorporation 
(corrected disintegrations per minute/ngDNA) at colonic points A to D 
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Total [35S] Incorporation 
Subject A B C D 
Patient 
G 1664.26 20100.69 2194.36 9402.01 
H 2290.55 
 
1801.99 1793.81 
J 3614.96 4895.57 1288.71 785.63 
K 921.98 1731.73 1188.78 1558.75 
L 374.83 2270.62 8490.40 
 M 3300.63 8720.19 2478.31 3466.42 
Q 1291.14 1141.59 1705.81 1134.92 
R 1471.66 1221.25 795.39 903.38 
T 3091.87 1849.01 3098.59 3880.51 
E 
    
      
Control 
F 1106.71 3183.56 3456.66 3868.38 
N 
 
2231.52 1892.04 
 P 951.66 1178.61 2754.46 657.90 
S 3078.31 4463.11 592.52 
 X 5261.07 2251.80 16866.83 
 Y 4629.15 4508.87 1433.70 2336.01 
 
Table 4.25: Total Individual [35S] Incorporation within Back Peak 
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Figure 4.11: Individual subject graphs of total back peak [35S]-sulphate incorporation (corrected 
disintegrations per minute/ngDNA) at colonic points A to D 
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Figure 4.12: Scatter graph of Back Peak [3H]-glucosamine incorporation 
 
 
 
 
Figure 4.13: Scatter graph of Back Peak [35S]-sulphate incorporation 
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4.4.2 Mean Back Peak Incorporation at the Different Colonic Points 
Mean Back Peak [3H]-glucosamine Incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 8429 ±5093 10904 ±3821 0.36 
B 15065 ±13996 12532 ±5438 0.63 
C 12272 ±9273 15289 ±14188 0.62 
D 11062 ±8226 14450 ±9832 0.58 
 
Table 4.26: Mean [3H] Incorporation within Back Peak at Colonic Points 
 
Mean Back Peak [35S]-sulphate Incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 2002 ±1133 3005 ±1972 0.24 
B 5241 ±6532 2970 ±1335 0.37 
C 2560 ±2332 4499 ±6141 0.49 
D 2866 ±2882 2287 ±1606 0.75 
 
Table 4.27: Mean [35S] Incorporation within Back Peak at Colonic Points 
 
4.5 Incorporation within the Sub-Fractions of the Back Peak 
The following tables show the incorporation results in dpm/ngDNA obtained from the 
three sub-fractions within the back peak of both patients and controls.   
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4.5.1 Secreted Soluble Fraction - [3H]-glucosamine incorporation 
Subject A B C D 
Patients 
G 1163.30 3447.67 3963.91 4992.64 
H 2942.37 69.42 1518.92 1118.50 
J 1567.00 7400.46 4951.23 2111.40 
K 1615.80 2903.26 1734.63 1451.79 
L 1202.00 2498.91 11713.56 
 M 3550.58 7600.31 4142.52 5990.33 
Q 925.65 1193.26 2852.32 2076.20 
R 2518.04 3123.31 2008.43 1854.98 
T 1552.09 1123.96 3033.01 2471.00 
E 
    
      
Controls 
F 615.59 1256.73 2214.07 1203.31 
N 
 
3067.79 6500.23 
 P 2111.60 17816.81 32630.06 23199.01 
S 2881.20 10485.94 1631.43 
 X 3239.38 1969.24 3918.97 
 Y 4585.40 3539.42 2913.75 2585.64 
 
Table 4.28: Individual [3H] Incorporation within SSF fraction of the Back Peak 
 
 
Mucin [3H]-glucosamine incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 1893 ±900 2687 ±1464 0.23 
B 3262 ±2540 6356 ±6518 0.31 
C 3991 ±3121 8301 ±12041 0.43 
D 2758 ±1757 8996 ±12320 0.47 
 
Table 4.29: Mean [3H] Incorporation within SSF fraction of the Back Peak 
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4.5.2 Cellular Soluble Fraction - [3H]-glucosamine incorporation 
Subject A B C D 
Patients 
G 5878.40 44720.69 7018.35 23975.67 
H 9670.87 8346.52 10639.45 9294.72 
J 8156.44 8994.29 4153.43 2316.91 
K 5161.90 7120.29 4000.41 3860.47 
L 1652.28 8303.59 24416.50 
 M 17173.53 32609.90 15696.18 16166.94 
Q 2662.80 3158.56 4942.91 2868.45 
R 8238.62 5415.50 4487.33 2848.77 
T 7158.26 6422.46 11869.46 13896.44 
E 3812.12 1769.94 
  
      
Controls 
F 6376.51 10996.98 12113.09 11810.46 
N 
 
12031.01 10026.94 
 P 7636.90 8807.93 15357.96 4865.35 
S 13067.69 11815.99 1393.43 
 X 11526.02 4472.57 18250.78 
 Y 9208.61 8195.53 1994.98 5095.87 
 
Table 4.30: Individual [3H] Incorporation within CSF fraction of Back Peak 
 
 
Mucin [3H]-glucosamine incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 6957 ±4419 9563 ±2744 0.25 
B 12686 ±14173 9387 ±2877 0.49 
C 9692 ±6877 9856 ±6918 0.96 
D 9404 ±7972 7257 ±3945 0.67 
 
Table 4.31: Mean [3H] Incorporation within CSF fraction of Back Peak 
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4.5.3 Cellular Insoluble Fraction - [3H]-glucosamine incorporation 
Subject A B C D 
Patients 
G 591.70 2037.28 897.93 1263.90 
H 699.44 1090.54 1531.92 1211.43 
J 1439.57 2304.12 2067.55 873.27 
K 668.01 1029.67 292.59 469.04 
L 188.38 1311.68 2122.75 
 M 1718.79 1822.69 1519.01 2410.74 
Q 398.07 1052.10 994.42 914.16 
R 706.67 1120.01 715.32 613.14 
T 787.63 1060.43 1288.98 1479.11 
E 
    
      
Controls 
F 976.96 995.93 1597.64 1112.51 
N 
 
1492.64 975.23 
 P 977.53 957.17 2105.79 700.42 
S 1627.12 1606.11 135.32 
 X 1094.24 372.85 747.71 
 Y 586.98 572.10 86.61 325.39 
 
Table 4.32: Individual [3H] Incorporation within CIF fraction of Back Peak 
 
 
Mucin [3H]-glucosamine incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 800 ±483 1053 ±374 0.33 
B 1425 ±494 999 ±488 0.12 
C 1270 ±609 941 ±801 0.38 
D 1154 ±609 713 ±394 0.28 
 
Table 4.33: Mean [3H] Incorporation within CIF fraction of Back Peak 
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4.5.4 Secreted Soluble Fraction - [35S]-sulphate incorporation 
Subject A B C D 
Patients 
G 39.18 238.35 154.50 234.27 
H 555.60 
 
83.30 34.60 
J 23.54 74.36 116.15 37.60 
K 44.65 88.20 16.43 33.84 
L 21.42 26.60 222.25 
 M 166.93 246.84 117.53 81.56 
Q 16.04 45.22 87.37 10.74 
R 43.58 0.00 16.36 36.51 
T 76.53 36.12 121.43 80.12 
E 
    
      
Controls 
F 45.96 88.52 178.69 95.58 
N 
 
38.85 126.29 
 P 32.61 81.61 269.19 88.03 
S 58.82 319.28 49.02 
 X 226.33 89.32 98.68 
 Y 128.47 134.00 61.01 67.83 
 
Table 4.34: Individual [35S] Incorporation within SSF fraction of Back Peak 
 
 
Mucin [35S]-sulphate incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 110 ±173 98 ±80 0.89 
B 94 ±95 125 ±100 0.57 
C 104 ±64 130 ±83 0.50 
D 69 ±71 84 ±14 0.58 
 
Table 4.35: Mean [35S] Incorporation within SSF fraction of Back Peak 
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4.5.5 Cellular Soluble Fraction - [35S]-sulphate incorporation 
Subject A B C D 
Patients 
G 1717.41 20204.11 2157.14 9708.16 
H 2052.02 
 
1628.89 1627.84 
J 3575.16 4700.07 1252.02 730.46 
K 783.68 1566.20 1080.90 1449.39 
L 366.47 2206.53 8291.40 
 M 3003.91 10086.58 2588.13 3314.59 
Q 964.24 627.14 1534.91 830.51 
R 1838.72 1098.64 714.15 794.57 
T 2974.30 1846.53 2822.55 3130.43 
E 2632.85 1508.68 
  
      
Controls 
F 1160.19 2934.21 3199.46 3570.33 
N 
 
2187.96 1850.71 
 P 921.00 1144.11 2699.98 628.32 
S 2850.36 4200.59 545.17 
 X 4759.43 2232.26 16270.85 
 Y 4673.30 5071.99 1442.04 2254.65 
 
Table 4.36: Individual [35S] Incorporation within CSF fraction of Back Peak 
 
 
Mucin [35S]-sulphate incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 1991 ±1063 2873 ±1840 0.25 
B 4872 ±6452 2962 ±1444 0.41 
C 2452 ±2297 4335 ±5922 0.74 
D 2698 ±3009 2151 ±1474 0.78 
 
Table 4.37: Mean [35S] Incorporation within CSF fraction of Back Peak 
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4.5.6 Cellular Insoluble Fraction - [35S]-sulphate incorporation 
Subject A B C D 
Patients 
G 71.97 601.34 204.25 374.39 
H 152.56 
 
263.23 219.65 
J 142.42 352.08 269.84 106.32 
K 160.70 275.43 110.78 145.48 
L 57.21 220.46 383.59 
 M 314.72 494.83 304.03 299.12 
Q 326.71 670.42 332.98 346.50 
R 103.15 194.41 98.14 92.54 
T 256.83 415.52 337.68 447.59 
E 
    
      
Controls 
F 231.59 320.64 267.96 479.46 
N 
 
257.16 270.04 
 P 86.84 79.47 110.67 36.24 
S 461.31 253.94 17.04 
 X 316.57 224.55 605.38 
 Y 31.86 182.42 14.34 172.67 
 
Table 4.38: Individual [35S] Incorporation within CIF fraction of Back Peak 
 
 
Mucin [35S]-sulphate incorporation 
 Patients Controls  
 Mean SD Mean SD p value 
A 176 ±100 226 ±174 0.51 
B 403 ±175 220 ±82 0.04 
C 256 ±100 214 ±223 0.68 
D 254 ±133 229 ±227 0.82 
 
Table 4.39: Mean [35S] Incorporation within CIF fraction of Back Peak 
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4.5.7 Ratios of [35S]/[3H] within Back Peak Sub-Fractions 
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Figure 4.14: Mean Ratio [35S]/[3H] Incorporation within SSF  
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Figure 4.15: Mean Ratio [35S]/[3H] Incorporation within CSF  
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Figure 4.16: Mean Ratio [35S]/[3H] Incorporation within CIF 
Patients
Controls
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4.6 Lectin Binding 
Results were expressed in corrected densitometry per 100ngDNA. Slot blots performed 
with the lectins wheat germ agglutinin and Maackia amurensis agglutinin bound to the 
mucin samples.  Slot blots performed with the lectin Ulex europaeus agglutinin (UEA) 
did not show any binding in any control or patient samples.  Slot blots performed with 
WGA showed binding at the same fractions as mucin peak and back peak incorporation. 
4.6.1 Wheat Germ Agglutinin Mucin Binding 
Overall WGA binding within mucin peak  
 Mean Standard Deviation 
Patients 537.88 ± 752.14 
Controls 18.13 ±33.99 
  (p value 0.06) 
 
Table 4.40: Overall mean WGA Mucin binding 
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Figure 4.17: Mean [35S] Incorporation within CIF of Back peak 
Patients
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Subject A B C D 
Patients 
G 789.42 2661.13 3539.55 224.80 
H 2215.85 825.32 2813.37 574.82 
J 350.95 2082.46 1410.56 1759.80 
K 0.15 61.22 112.22 35.18 
L 513.28 556.10 198.43 
 
M 0.75 4.79 1.24 0.10 
Q 94.57 37.68 18.03 3.44 
R 2.20 3.45 3.55 1.33 
T 75.06 68.28 0.24 37.28 
E 7.42 0.49 
  
  
    
Controls 
F 43.43 55.52 146.85 98.33 
N 
 
2.47 0.01 
 
P 0.05 2.39 0.13 0.04 
S 1.10 2.68 0.00 
 
X 4.80 16.86 33.79 
 
Y 0.19 4.17 0.00 0.01 
 
Table 4.41: Total Individual WGA Mucin Binding Results 
 
 
 
Mean Total WGA Mucin Binding 
 Patients Controls  
 Mean SD Mean SD p value 
A 404.97 ±690.77 9.91 ±18.83 0.10 
B 630.09 ±968.87 14.02 ±21.09 0.08 
C 899.69 ±1378.43 30.13 ±58.76 0.10 
D 329.59 ±610.79 32.79 ±56.75 0.22 
 
Table 4.42: Mean Total WGA Mucin Binding Results 
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Figure 4.18: Individual subject graphs of total mucin peak WGA binding (densitometry per 
100ngDNA) at colonic points A to D 
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4.6.2 Wheat Germ Agglutinin Binding within Mucin Sub-Fractions 
Secreted Soluble Fraction 
 Patients Controls  
 Mean SD Mean SD p value 
A 3.22 ±9.95 0.14 ±0.31 0.35 
B 6.11 ±19.24 0.16 ±0.36 0.35 
C 27.18 ±80.38 0.39 ±0.94 0.35 
D 4.13 ±10.18 2.20 ±3.79 0.76 
Overall 10.03 ±40.89 0.53 ±1.52 0.10 
 
Table 4.43: Mean WGA Mucin Binding Results within SSF Fraction 
 
Cellular Soluble Fraction 
 Patients Controls  
 Mean SD Mean SD p value 
A 29.47 ±43.33 2.15 ±2.75 0.08 
B 23.02 ±39.86 7.01 ±6.76 0.25 
C 3.34 ±5.10 6.90 ±13.42 0.56 
D 8.82 ±14.60 1.24 ±2.13 0.20 
Overall 16.90 ±32.07 4.90 ±8.26 0.04 
 
Table 4.44: Mean WGA Mucin Binding Results within CSF Fraction 
 
Cellular Insoluble Fraction 
 Patients Controls  
 Mean SD Mean SD p value 
A 372.28 ±660.62 7.62 ±16.55 0.12 
B 600.97 ±973.76 6.85 ±16.76 0.86 
C 869.17 ±1338.96 22.84 ±55.83 0.95 
D 316.65 ±610.63 29.36 ±50.84 0.23 
Overall 542.92 ±929.56 15.21 ±36.21 0.002 
 
Table 4.45: Mean WGA Mucin Binding Results within CIF Fraction 
147 
 
4.6.3 Maackia Amurensis Agglutinin Mucin Binding 
Cellular Soluble Fraction 
 Patients Controls  
 Median Range Median Range p value 
A 2.51 0 – 140.49 0.00 0 – 2.22 0.24 
B 3.67 0 – 32.39 0.92 0 – 16.34 0.36 
C 4.48 0 – 143.61 0.08 0 – 19.83 0.17 
D 1.91 0 – 130.90 0.38 0 – 0.44 0.76 
Overall 3.83 0 – 143.61 0.08 0 – 19.83 0.03 
 
Table 4.46: Median MAA Mucin Binding Results within CSF Fraction 
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Figure 4.19: Scatter Graph for MAA Binding 
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Chapter 5 - Discussion 
The aim of the study was to investigate the biosynthetic activity of the distal ganglionic 
colon in patients with Hirschsprung’s disease and compare this to controls and to 
determine whether previously found deficiencies in mucin production in the ganglionic 
colon, close to the transition zone, persisted more proximally or were confined to a 
limited region.   
5.0 Gel Filtration Graphs 
The mucin peak elucidated at a similar fraction number and demonstrated a consistent 
pattern along the colon and in patients and controls. (Figures 5.1 & 5.2)  The peaks for 
both [3H]-glucosamine and [35S]-sulphate incorporation occurred at approximately the 
same fractions with the former consistently having higher peak values than the latter. 
This was to be expected as [3H]-glucosamine would be present in all newly synthesized 
mucins but not all would be sulphated.   
 
0
1000
2000
3000
4000
5000
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39
co
rr
ec
te
d
 d
is
in
te
gr
at
io
n
s 
p
er
 m
in
u
te
 [
3H
]-
gl
u
co
sa
m
in
e 
p
er
 n
gD
N
A
 
gel filtration number 
Figure 5.1 Example of [3H]-Glucosamine Incorporation Gel 
Filtration Graph 
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The precursors [3H]-glucosamine and [35S]-sulphate are not only incorporated into 
fully formed mucin molecules but also into many other different cellular 
glycoconjugates formed during the incubation period, including monosaccharides or 
oligosaccharides which would eventually form part of de novo mucin molecules.  All of 
these are of a lower molecular weight than mucins so will enter the gel beads and are 
elucidated later during gel filtration forming the back peak.  (Figures 5.1 & 5.2)  
The back peak is unlikely to consist of mucin degradation products, as the addition of 
broad spectrum antibiotics to the culture medium would reduce any bacterial activity on 
the newly produced mucin molecules. 
The back peaks of [3H]-glucosamine incorporation were more varied than the mucin 
peaks in their configuration and in comparison to back peaks of [35S]-sulphate 
incorporation, which had a narrower base. (Figures 5.3 & 5.4) This suggests that the 
[35S]-sulphate is incorporated into molecules of more defined molecular weight and 
that this is unaffected by colonic site, whereas [3H]-glucosamine is incorporated in a 
broader range of molecules, covering a greater variance in molecular weight and that 
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Figure 5.2 Example of [35S]-Sulphate Incorporation Gel Filtration 
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this range varies along the colon.   In particular the back peaks for the cellular insoluble 
fraction were very broad, covering a greater range of molecular weights.  
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Figure 5.3: Example of Patient [3H]-Glucosamine 
Incorporation Gel Filtration Back Peak Graph  
A
B
C
D
0
2000
4000
6000
8000
10000
12000
14000
16000
202122232425262728293031323334353637383940
co
rr
ec
te
d
 d
is
in
te
gr
at
io
n
s 
p
er
 m
in
u
te
 
[3
H
]-
gl
u
co
sa
m
in
e 
p
er
 n
gD
N
A
 
gel filtration number 
Figure 5.4: Example of Control [3H]-Glucosamine 
Incorporation Gel Filtration Back Peak Graph 
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Comparing the graphs obtained within individual subjects, there was not an obvious 
progression pattern identified moving along the colon from samples A to D for patients 
or controls.  However, within an individual subject, especially within the cellular 
soluble fraction, the graphs for [3H]-glucosamine and [35S]-sulphate incorporation 
demonstrated the same relative variances within the mucin and back peak along the 
colon.  This was found to be the case in both patients and control subjects.  This 
suggests that mucin production is closely allied to the production of the back peak of 
and that uptake of both precursors is altered in a similar way.  
5.1 Incorporation within the Mucin Peak 
Glucosamine-6-phosphate is the precursor for N-acetylglucosamine, N-
acetylgalactosamine and N-acetylneuraminic acid (sialic acid).
126, 127
   The first two in 
particular are common to all mucins so the amount of [3H]-glucosamine incorporation 
within the front peak reflects the amount of newly produced glycosylated mucin 
synthesized within the time of incubation.
44
  
Within the mucus barrier there is a constant dynamic equilibrium between mucin 
synthesis and mucin degradation. The normal enteric bacterial flora secrete a range of 
enzymes which act to continually break down the mucin gel as the mucosa produces 
newly formed and secreted mucins.
100 
  A balance between these conflicting processes 
allows the host to maintain a functional defensive barrier at the mucosal surface.
90
   
Sulphation of mucins is particularly characteristic of colonic mucins and is one of the 
mechanisms which helps reduce bacterial degradation.
113, 168
  
 
   
Sulphate esters may also regulate the biosynthesis, half-life and biological roles of 
glycoproteins so sulphation is also an important regulatory feature in colonic mucins.
112, 
152 
 
169
   The amount of incorporation of [35S]-sulphate within the mucin peak and the ratio 
of [35S]-sulphate to [3H]-glucosamine incorporation reflects the degree of modification 
of mucins and may reflect their robustness.
100, 111
 
Previous research has shown that mucin production in the colon, close to the transition 
zone, is reduced in patients.
345 
  One of the aims of this research was to determine 
whether this deficiency extends to a greater region of colon. Therefore the overall mucin 
incorporation for the fifteen centimeters of colon studied was calculated as a mean for 
each study group.  Patient values for both precursors were higher than control although 
this was not statistically significant, p = 0.53 [3H] and p = 0.66 [35S].  This suggests 
that the overall ganglionic mucin production is not impaired in Hirschsprung’s disease. 
The thickness of the mucus layer is known to increase along the colon towards the 
rectum
9 
and under normal circumstances colonic mucins should become more sulphated 
distally.
104, 112, 172, 177, 178
 Therefore an increasing amount of mucin production, using 
both precursors, from D to A would be expected in the normal bowel. 
Mean values for the control subjects were calculated for [3H]-glucosamine 
incorporation and [35S]-sulphate incorporation for each colonic level.  Levels of 
incorporation in the mucin peak of both precursors were greatest most distally and 
lowest most proximally and showed a similar pattern for both precursors. (Figures 5.5 & 
5.6)  These results agree with what would be expected with an increase of mucin 
production D to A. 
153 
 
 
 
An increase in the sulphation of colonic mucins, proximal to distal, would show in the 
ratio of [35S]-sulphate to [3H]-glucosamine incorporation in controls. However, there 
was no obvious increase in the percentage of sulphated mucins moving distally. (Figure 
5.7) 
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Figure 5.5 : Control Mean Mucin [3H] Incorporation A-D 
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Figure 5.6 : Control Mean Mucin[35S] Incorporation A-D 
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Patients, in contrast, demonstrated low incorporation values distally, closest to the 
transition zone, compared to control subjects (Figure 5.8). This is in agreement with the 
previous research.
345 
  This low mucin productivity did not persist further away from the 
transition zone as the patient values were only lower than controls at point A. The 
patient values at the other points were greater than controls, with the lowest mucin 
productivity occurring most proximally at D.  (Figure 5.9) 
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Figure 5.7 : Ratio of Control Mean [35S]/[3H] Incorporation 
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Figure 5.8 : Patient Mean Mucin [3H] Incorporation A-D 
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These differences distally in the two groups were also reflected in the individual gel 
filtration graphs, as in the majority of controls the mucin peak at A was higher than at B 
whereas in patients the reverse was true.  Ratios of incorporation were similar in the two 
groups showing that the overall proportion of newly formed mucins which are sulphated 
was not markedly altered in Hirschsprung’s disease (Figure 5.10)   
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Figure 5.9 : Patient and Control Mean[35S] Incorporation A-D 
Patients Controls
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Figure 5.10: Ratio of Patient Mean [35S]/[3H] Incorporation 
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These results show that in HD mucin production is low in the ganglionic colon closest 
to the transition zone when compared to normal controls.  Mucus secretion is partly 
under the control of the autonomic nervous system, of which the enteric nervous system 
is a component.
242
 In HD the enteric nervous system of the aganglionic colon is 
abnormal 
239 
and the region of the transition zone is characterized by diminished 
numbers of ganglion cells as well as other reported ENS abnormalities.
209, 227, 339 
   The 
margin of the transition zone is known to be asymmetrical and it is possible that some of 
the biopsies taken at A could be in a region of hypoganglionosis where the abnormal 
ENS causes lower than normal mucin production.
342 
Neural crest cells migrate to the upper end of the alimentary tract and proceed in a distal 
direction.
274 
The more proximal the colonic biopsy the further it is from the abnormal 
aganglionic colon and therefore should have an ENS closer to normality and levels of 
mucin production similar to control values.  Instead, moving proximally, the patient 
levels increased to above what is expected in controls.   
It may be possible that poor mucin production distally stimulates a compensatory 
elevation in the adjacent colon.  It is known that membrane bound mucins are likely to 
be able to provide signals to epithelial cells in response to alterations in the mucin layer 
through changes in conformation or ligand status of their extracellular domains.
77 
  
Other factors known to influence mucin secretion are prostaglandins, cytokines and 
intestinal microbes.
156, 160, 161
   Bioactive factors released by mucosal immune cells also 
regulate mucin.
19 
  For example TNFα increases α-2, 3-sialyltransferase expression in 
some cell lines potentially causing an increased synthesis of sialomucins.
159 
  One or 
more of these mechanisms may be able to influence mucin production in the adjacent 
regions of the colon. 
157 
 
The low mucin production at A demonstrated in patients could therefore be a result of 
persisting ENS abnormalities within the distal ganglionic colon.  Low mucin levels at 
this point may trigger compensatory higher mucin production in the adjacent colon, 
resulting in patient values at this point being greater than controls. 
Patient incorporation values can also be considered within smaller subgroups with 
certain clinical features which could potentially affect mucin production.  Intestinal 
microbes can lead to increased mucus secretion
156 
so those patients who had episodes of 
pre-operative enterocolitis were compared to those who did not.  Mean incorporation for 
both precursors was similar in these groups along the colon with the exception of point 
B where incorporation was higher in the subgroup of patients who had had at least one 
episode of EC. (Figure 5.11) 
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Figure 5.11:  Patient Subgroup Mean [3H] Incorporation A-D 
Pre-operative enterocolitis
No pre-operative enterocolitis
158 
 
Comparing these two patient subgroups to the control group revealed that incorporation 
at point A was still greater in the control group than either patient group with the 
converse pattern occurring at point B, but incorporation was much higher than controls 
in those patients with pre-operative EC at point B. (Figures 5.12 & 5.13) 
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Figure 5.12: Controls and Patient Subgroups Mean [3H] 
Incorporation 
Patients EC Controls Patients No EC
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Figure 5.13: Controls and Patient Subgroups Mean [35S] 
Incorporation 
Patients EC Controls Patients No EC
159 
 
It does appear that those patients who had an episode of EC did skew the data at point 
B.  Despite there only being three patients within this subgroup, they accouted for two 
of the three highest [3H]-glucosamine incorporation results but only one of the highest 
[35S]-sulphate incorporation results. (Figure 5.14)  The small numbers in the study 
make it difficult to draw any firm conclusions from this, especially any link between 
susceptibility to EC and greater mucin production at point B.   
If overall mean values (A-D) are compared between these patient groups and controls, 
both patient subgroups have higher incorporation of [35S]-sulphate than controls but 
only those patients with pre-operative EC demonstrated greater [3H]-glucosamine 
incorporation, the other patient subgroup having very similar mean incorporation to 
controls. EC may persistently stimulate an increase in mucin productivity but why this 
should be more pronouced at one colonic sample point is difficult to explain.  Sampling 
difficulties (see page 189) may have contributed to this result.   
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Figure 5.14: Scatter Graph of Individual Patients [3H]-
glucosamine Incorporation at Colonic Point B 
Patients EC Patients No EC
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Colonic washouts were given to those patients who developed enterocolitis as part of 
their treatment. The effect, if any, of washouts on mucin levels is not known and could 
be the cause of differences in incorporation levels rather than EC persay.   In addition to 
those patients who developed EC, patients who had a single stage corrective procedure 
underwent regular colonic washouts pre-operatively in order to decompress the bowel.   
Unfortunately due to the small size of this study the separate effect of washouts could 
not be established as the only children who developed EC were also having elective 
washouts, only one child of the four with a delayed primary pull-through did not have a 
single EC episode. 
Only two patients did not have HD restricted to the rectosigmoid colon, but extending 
into the descending colon.  These small numbers again make it difficult to analyse the 
data separately but at points A and B, control incorporation values were very similar to 
patients with descending colonic HD but at points C and D these patients had much 
higher values.  (Figure 5.15)  Mucin production should increase proximally to distally. 
9
 
Those with descending colonic HD are likely to have more proximal biopsies compared 
to those with rectosigmoid HD.  Control samples may also be more proximal when 
compared to patients with rectosigmoid disease as their colostomy may have been sited 
higher up the sigmoid colon.  This could explain why patients with descending colon 
Hirschsprung’s disease incorporation levels are similar to controls at A and B and 
greater than rectosigmoid disease patients at B, but does not explain the greater 
incorporation levels more proximally at C and D.  Larger study samples would be 
needed to further investigate any differences. 
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5.2 Incorporation within the Mucin Peak Sub-Fractions  
The biosynthetic products, including mucins, created during the incubation time were 
extracted in three phases, namely a secreted soluble fraction, a cellular soluble fraction 
and a cellular insoluble fraction.  
The soluble secreted fraction contained those mucins within the culture medium which 
were readily soluble.  This would not have included the secreted non-gel forming 
mucins MUC7, 8 or 9 as these are not found in the intestine.
52, 54, 56
   This fraction may 
include some membrane bound mucins which can exist in secreted and soluble forms
 20, 
21, 22
  and also some MUC2 molecules which have yet to form the intermolecular bonds 
which would render it insoluble.   
The cellular soluble fraction was obtained after homogenization of the mucosal tissue 
and contained those mucins with an intra-membrane component, e.g. MUC1.
37 
  In 
addition contained within this fraction would be those mucins soluble in PBS which had 
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Figure 5.15: Controls and Patient Subgroups Mean [3H] 
Incorporation 
Patients Rectosigmoid HD Controls Patients Desc Colon HD
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not entered into the culture medium and were still intracellular. These could include 
immature secreted and gel-forming mucins or different forms of MUC2 which can be 
present in the cell layer.
138
    
The cellular insoluble fraction contained only those mucins which had formed into an 
insoluble gel which require the disruption of disulphide bonds in order to become 
soluble.  In particular this would include mature MUC2 and may also contain some 
membrane-bound mucins which are able to link with gel-forming mucins.
89
  
These individual mucin fractions were therefore studied to ascertain whether a 
particular form of mucin production was altered in HD. The vast majority of mucin 
incorporation occurred in the cellular soluble fraction.  This was true for both patients 
and controls and for all points A-D. (Figures 5.16 & 5.17) The reason for this is likely 
to be the length of the incubation period.  Although high molecular weight mucin 
multimers are created from dimers early in biosynthesis,
 133 
within 24 hours only some 
of the newly formed mucins produced in the mucosal cells would have reached the stage 
where they would be secreted or formed into an insoluble gel.
205 
  
In both study groups the least amount of incorporation of either precursor was found 
within the secreted soluble mucin. (Figures 5.16 & 5.17)  The main mucins expressed in 
the colorectum in humans from birth onwards are MUC2 and MUC4, along with lower 
levels of MUC1 and MUC3.
17, 243
   Three of these are membrane-bound and one in its 
mature form is gel-forming so a predominance of cellular and cellular insoluble mucins 
would be expected.
19, 37  
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In patients [3H]-glucosamine incorporation within both cellular fractions showed a 
similar pattern to total mucin incorporation, with lower levels compared to controls at A 
and greater levels than controls at B, which was a statistically significantly result within 
the cellular insoluble fraction, p = 0.04, unpaired t-test. (Figure 5.18) Control values for 
the cellular soluble mucin were greatest distally and lowest proximally (Figures 5.16 & 
5.17) 
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Figure 5.16 : Mean Control [3H] Incorporation A-D within the three 
mucin containing fractions 
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Figure 5.17 : Mean Patient [3H] Incorporation A-D within the three 
mucin containing fractions 
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[35S]-sulphate incorporation within the cellular soluble fraction was lower at A in 
patients than controls and greater at B than controls. 
Different glycosylation patterns are known to exist along the length of the intestine. A 
gradient has been demonstrated from ileum to rectum, with a pattern of decreasing 
levels of fucose and ABH blood group expression and increasing levels of sialic acids 
and acidity.
24 
  Increasing distal values of glucosamine incorporation found in controls 
overall and in the cellular soluble mucins could reflect greater numbers of newly formed 
mucins but could also indicate greater levels of sialylation within individual 
molecules.
126, 127
    
Levels of O-acetylation of sialic acids in colonic mucins have been shown to be 
unaltered in HD and sialic acid is largely limited to the secretory mucins of the large 
intestine.
16, 102
 As the secreted soluble and cellular insoluble fractions do not show this 
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Figure 5.18: Mean [3H] incorporation A-D within CIF mucin fraction 
Patient Control
165 
 
pattern of high control values at A compared to patients, it is more likely that it is a 
reflection of greater mucin production rather than greater sialylation.  
It appears that the deficiency in total mucin production demonstrated by patients distally 
(Point A) is due to a lack of cellular soluble and insoluble mucins.  Secreted soluble 
mucin production showed some interesting variation between the two groups.  Patients 
had much higher levels of [3H]-glucosamine incorporation than controls at all points 
within the secreted soluble fraction, although these differences were not statistically 
significant. (Figure 5.19) [35S]-sulphate incorporation within the secreted soluble 
fraction was highest distally, being greater than controls, and lowest proximally.  
 
Although total mucin incorporation in patients was not deficient compared to controls at 
the more proximal colonic levels, the relative proportion of the different mucins were 
altered in patients.   In controls the relative proportion of cellular insoluble mucins, 
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Figure 5.19: Mean [3H] Incorporation A-D within SSF mucin 
fraction 
Patients Controls
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incorporating both precursors, increased distally to proximally at the expense of the 
cellular soluble proportion.   (Figure 5.16) 
The proportion of [35S]-sulphate incorporation within the secreted soluble fraction in 
patients also decreased higher up the colon and the ratio of [35S]-sulphate to [3H]-
glucosamine was much lower than controls, demonstrating a reduction in the proportion 
of these mucins which were sulphated. This was in direct opposition to controls and 
could result in mucins produced proximally in patients being more susceptible to 
bacterial degradation. (Figures 5.20 & 5.21) 
 
 CIF  CSF  SSF 
Figure 5.20: Proportion of [35S] incorporation within the mucin fractions at A and D 
Patient A Control A 
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One theory to explain the different mucin fractions found in the two groups involves the 
main gel-forming mucin in the colon, MUC2.
77, 352 
Levels of MUC-2 protein in stool 
have been shown to be much lower in children with HD despite mRNA levels for 
MUC2 being found at similar levels to controls.
16,
 
368 
  MUC2 is known to exist in 
different forms, commonly gel-forming, due to a complex, branching network of 
covalently linked mucin molecules. This makes it almost the sole component of the 
insoluble mucin in the human colon.
36 
  It can also be found as partially glycosylated 
oligomerized intermediates or in the fully glycosylated oligomerized form within the 
cell layer.
138
 
The soluble fraction may include MUC2 prior to forming its gel state and the greater 
levels in patients may indicate an abnormal expression of this glycoprotein resulting in a 
problem forming the completed complex mucin gel within the incubation period.
138 
  
Mucosal turnover could be more efficient higher up the colon in controls, meaning more 
of the mucins produced being of a sufficient maturity to form into an insoluble gel. This 
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Figure 5.21: Mean Ratio of [35S]/[3H] in SSF fraction 
Patients Controls
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would be reflected by the increase in cellular insoluble mucins and secreted mucins at 
the expense of cellular soluble mucins.  
Abnormalities of mucin production seem to persist in HD at least up to 15 centimetres 
of proximal ganglionic colon, with a reduction in mucin production being most 
consistently found just above the transition zone.   These changes are unlikely to be 
simply due to differences in mucin gene expression as these have been found to be 
unaltered in HD, with MUC1, 2, 3, 4 and 5B being detected in similar quantities in all 
age groups and in both ganglionic and aganglionic colon.
16
 Abnormalities of the ENS 
have been found in the ganglionic colon in HD including reduced immunoreactivity for 
general neuropeptide markers and disordered arrangement of neuropeptide nerves in the 
proximal ganglionic colon in HD.
264,
 
344 
  These could affect mucin secretion further up 
the colon. 
Alterations in mucin production could be due to abnormalities within mucin specific 
biosynthetic pathways or could reflect more widespread changes.  The biosynthetic 
activity of the tissue is reflected by the mucin and back peak totals.  Analysis of back 
peak incorporation in comparison to mucin peak incorporation could indicate whether 
alterations in mucin synthesis reflect more global mucosal productivity changes.  
5.3 Incorporation within the Back Peak 
Overall back peak incorporation for the colon samples studied was therefore calculated 
as a mean for each study group.  The incorporation of both precursors was slightly 
higher in controls but this was not statistically significant, for [3H]-glucosamine 
incorporation p = 0.72 and [35S]-sulphate incorporation p = 0.81 and the spread of 
values and the ratio of incorporation of the two precursors were similar. This suggests 
169 
 
that overall mucosal synthetic activity within the distal colon is unlikely to be 
diminished in HD.   
Mean values for the control subjects were calculated for [3H]-glucosamine 
incorporation and [35S]-sulphate incorporation for each colonic level.  Back peak 
glucosamine incorporation showed a completely reversed pattern to mucin 
incorporation with lowest levels distally, higher levels proximally.  (Figure 5.22 & 5.5) 
Conversely patient back peak values of [3H]-glucosamine incorporation demonstrated a 
similar pattern to that in the mucin peak in patients, with low levels at A, higher levels 
at B and C and then lower levels again at D.  Control values for incorporation of both 
precursors were greater than patients at point A with patient values being higher at point 
B, as with the mucin peak results.  None of these differences were statistically 
significance. Back peak incorporation of [35S]-sulphate was lower at A in patients 
compared to controls with patients having higher values at B than controls. 
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Figure 5.22: Mean Control [3H] Incorporation A-D in Back peak 
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These results suggest a relationship between [3H]-glucosamine incorporation in the 
mucin peak and back peak in the normal colon.  As discussed above, part of the contents 
of the back peak are likely to include the mucin precursors.  Therefore, at point A, the 
low back peak and the corresponding high mucin peak could be explained by an 
increased efficiency of the conversion of mucin precursors to completed mucin 
molecules.   
In HD patients the situation appears different, with both mucin and back peak levels of 
[3H]-glucosamine being low distally. This suggests that all mucosal productivity 
involving glucosamine subunits is reduced.  If a large proportion of the back peak 
consists of mucin precursors this could reflect globally diminished mucin synthesis of 
both precursors and fully formed mucin molecules.  Alternatively, if the back peak is 
more varied in its constituents, low levels of incorporation may reflect a more 
widespread deficiency in glyco-conjugate synthesis in patients. 
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Copy of Figure 5.5 : Control [3H] Incorporation A-D in Mucin Peak 
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5.4 Incorporation within the Back Peak Sub-Fractions 
As with the mucin peak, the biosynthetic products were extracted in the three phases. 
The data from the individual fractions was examined. Most of the back peak 
incorporation was contained within the cellular soluble fraction, as found in the mucin 
peak.  In controls [3H]-glucosamine incorporation within the cellular soluble fraction 
followed the pattern shown in the mucin peak, namely the amount increasing distally. 
This suggests increasing levels of membrane bound mucins are matched by increasing 
levels of smaller intracellular or membrane bound molecules.   
The cellular soluble fraction may contain mucin precursors or mucin related molecules, 
for example, during intra-cellular post-translational processing of membrane-bound 
mucins a cleavage occurs at the SEA domain to yield two subunits.
84 
  As greater 
numbers of fully-formed mucin molecules are produced within the incubation period 
more of these smaller subunits will be generated. 
In controls [3H]-glucosamine incorporation within the secreted soluble fraction 
increased from A to D. (Figure 5.23)   In both patients and controls the secreted soluble 
and cellular soluble fractions appeared to be inter-related, the proportion of one 
increasing at the expense of the other.  (Figure 5.24) This is different to the mucin peak 
where the cellular insoluble and cellular soluble fractions altered in tandem. 
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The cellular soluble fraction of the back peak includes newly formed smaller molecules 
which have not been secreted into the culture medium, so are either membrane-bound or 
intracellular.  Decreases in the proportion of cellular soluble fraction with a concurrent 
rise in secreted soluble fraction may be due to greater subunit shedding into the  
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glycocalyx from the membrane-bound structures, or secretion of different isoforms 
which are soluble.
19, 23
   
The proportion of [35S]-sulphate incorporation within the back peak fractions remained 
similar along the colon and ratios of [35S]-sulphate to [3H]-glucosamine incorporation 
were similar in the two groups and shown less variation along the colon. However, 
patients did show statistically higher levels of [35S]-sulphate incorporation in the 
cellular insoluble fraction at B. 
5.5 Lectin Binding 
Oligosaccharides of both secreted and cell surface glycoproteins, are classified by the 
nature of their linkage to the protein core.
92 
  In mucins, the majority of the 
oligosaccharides are O-linked 
91
 and can be described in terms of their core, backbone 
and terminal regions.
91, 95
   Terminal residues in mucins are often sialic acid residues, 
with secretory colonic mucins being particularly rich in sialic acids.
102 
Sialic acid is 
most commonly found as a single terminal residue joined to an underlying galactose or 
GalNAc by an α-2,3- or a α-2,6-glycosidic linkage.99, 100   Exceptions to this usual 
pattern are α-2,8-linked sialic acids which can be attached to an underlying α-2,3 sialic 
acid residue.
99 
Lectins are proteins isolated from animal, plant and microorganisms which bind to 
specific non-reducing terminal monosaccharides determinants and can be used to 
identify terminal residues.
103, 104, 105
  Lectins used to study mucins include wheat germ 
agglutinin (WGA) which binds to sialic acids and N-acetylglucosamine residues, 
Maackia amurensis agglutinin (MAA), which is more specific, only binding to α-2,3  
174 
 
linked sialic acids and Ulex europaeus agglutinin (UEA) which binds to fucosyl 
residues.
103, 106, 107 
 
5.5.1 Wheat Germ Agglutinin  
Earlier work with lectins and mucins shows that colonic mucin oligosaccharides contain 
either a terminal sialic acid residue or an N-acetylglucosamine residue accessible for 
WGA binding.
96, 97
 Measurement of WGA binding gives an indication of total mucin 
present, both the newly synthesized and therefore radioactively labeled, as well as 
mucin already present prior to incubation.
103 
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WGA binding at all points A to D of the mucin peak was much lower in controls 
compared to patients but within the patient group there appeared to be two subgroups, 
one with low binding levels similar to controls and another showing much higher levels 
of WGA binding (>100 densitometry per 100ngDNA).  (Figure 5.25)  These patients 
did not have correspondingly higher or lower amounts of either [3H] or [35S] 
incorporation.  
At each individual colonic biopsy level WGA binding was much higher in patients 
although these differences were not statistically significant. (Figure 5.26)  Control 
values increased A to D, whereas patient values were low at A and D, a similar pattern 
to mucin incorporation results.  Dividing the patient group into these two subgroups still 
resulted in mean control values being lower than both patient subgroups at all colonic 
points. (Figure 5.27) 
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Figure 5.26: Mean WGA binding within Mucin Peak 
Patients Controls
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The greatest amount of binding was found within the cellular insoluble mucin fraction 
and overall binding levels were statistically higher in patients in this fraction, p = 0.002, 
and in the cellular soluble fraction, p = 0.04. This is different to incorporation which 
showed greatest results in the cellular soluble fraction.  The lowest level of binding was 
found within the secreted soluble fraction. Controls had a higher proportion of binding 
within the cellular soluble compared to patients. 
Newly formed mucins, which would have incorporated the precursors, would not all 
have reached sufficient maturity to be in the form of a gel within the twenty four hours 
of incubation.
205
 WGA binds to all mucins, including any mucins present prior to the 
incubation period which would not be radioactively labeled, i.e. those mucins produced 
by the mucosa in vivo which had not degraded. Any such mucins would have had more 
time to form the cross-linking bonds to create the gel-forming mucins and would 
therefore remain in the cellular insoluble fraction. 
Patient levels of binding within the secreted soluble fraction showed a similar pattern to 
the cellular insoluble fraction, with highest values at point C and low values at A and D.  
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Figure 5.27: Mean WGA Binding within Low Patient Subgroup 
Low Patient Subgroup Controls
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In contrast binding levels within the cellular soluble fraction were lowest at C.  At all 
points patients showed greater binding than controls. (Figures 5.28 & 5.29)  
Previous work has shown very different results with controls having higher levels of 
WGA binding than patients in both the secreted and cellular fractions.
345
 This could be 
partly due to differences in methodology.  The gel-forming insoluble mucins, which 
demonstrated the greatest amount of WGA binding, resist
 
extraction with guanidinium 
chloride unless the disulfide bonds are
 
cleaved.
35,36, 
  The method used with this research 
included disruption of these disulphide bridges by DTT, allowing them to be extracted 
into a further fraction. This additional step was not undertaken by the previous work, 
and hence any cellular insoluble mucins would not have been included in those lectin 
studies.  
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5.5.2 Correlation between Incorporation and Wheat Germ 
Agglutinin Binding 
It is interesting that whereas patients had much higher levels of WGA binding compared 
to controls, corresponding incorporation levels were much more similar between these 
two groups.  WGA binding and incorporation data were compared.  
Comparing an individual subject’s incorporation data with their WGA binding data did 
not reveal any obvious pattern with the exception of control F whose scatter graphs for 
mucin incorporation and WGA binding were similar. (Figures 4.3, 4.4 & 4.18) However 
when patient and control mean values for incorporation and WGA binding were studied 
some interesting patterns emerged. 
Patient levels of incorporation appeared to mirror those of WGA binding with lower 
values at A and D and higher values at B and C.  This was more obvious when 
comparing [3H]-glucosamine incorporation to WGA binding than with [35S]-sulphate 
incorporation. (Figures 5.30 – 5.32) 
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Figure 5.30: Mean Patient [3H] Incorporation A-D 
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Figure 5.31: Mean Patient WGA Binding A-D 
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Figure 5.32: Mean Patient [35S] Incorporation A-D 
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In contrast, in controls, WGA binding levels altered in opposition to incorporation, 
incorporation being greatest most distally at A and lowering proximally at D whereas 
WGA binding was lowest distally, rising to its highest level proximally.  (Figures 5.33 -
5.35)  As WGA binding gives an indication of total mucin present and incorporation the 
amount of new mucin produced it could be that in controls, in the normal colon, mucin 
production is under feedback control so that a thick mucin barrier results in lower mucin 
production.  
It appears that in Hirschsprung’s disease the amount of new mucin produced is either 
unaffected by the presence of existing total mucin or new mucin formation is not under 
the same kind of negative feedback it appears to be in controls.  There may be other 
reasons why WGA binding levels were far higher in Hirschsprung’s disease patients 
than in controls. 
Bioactive factors released by mucosal immune cells can enhance mucin secretion and 
some may increase the synthesis of sialomucins.
19, 159, 160, 161 
  Release of these factors in 
vivo due to the presence of mucosal damage or infection, could lead to greater WGA 
binding levels in patients due to increased mucin production and/or increased sialylation 
of mucins.   
Mucus secretion is typically enhanced in response to intestinal
 
microbes.
156   
 Children 
with HD are known to develop enterocolitis, the exact aetiology of this condition being 
unknown but it is thought to have an infective component.
353, 358
   These children have 
also been found to have abnormal pathogen carriage when compared with age-matched 
controls.
358, 359 
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Figure 5.33: Mean Control [3H] Incorporation A-D 
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Figure 5.34: Mean Control WGA Binding A-D 
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Figure 5.35 : Mean Control [35S] Incorporation A-D 
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Although all children under going corrective surgery were asymptomatic of enterocolitis, 
and did not have diarrhoea, some may have had a recent or subclinical infection, or an 
abnormal pathogen carriage, resulting in an enhanced mucin production prior to surgery.  
Mucin retention in enterocolitis has been previously noted as a characteristic 
histopathological change.
355
  
In order to reduce any impact of an infectious agent on new mucin synthesis organ 
culture was performed in the presence of broad spectrum antibiotics. These antibiotics 
should effectively prevent any additional mucin synthesis due to any ongoing bacterial 
infection but would not affect mucin already produced in vivo.  Pre-operative exposure 
to an infectious agent could therefore explain higher levels of mucin already present, 
indicated by higher WGA binding, without corresponding higher incorporation levels. 
It would be unreasonable to assume all patients were suffering from a subclinical 
infection at the time of biopsy collection. However, there are two distinct sub-groups 
within the patient WGA binding results. (Figure 5.26) Four patients showed a greatly 
elevated total WGA binding, indicating higher amounts of mucin present. If these four 
patients had been suffering from a subclinical infection, this could go towards 
explaining this division within the patients. 
The control samples were taken under the same conditions and if an infection is the 
reason for the increased WGA binding, then any subclinical infection would show 
similar results for a control subject. Statistically four out of ten patients potentially 
having a subclinical infection, when compared to zero out of six control subjects may 
seem unlikely. However, as discussed above, HD patients have a greater susceptibility 
to infection.  
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Within the patient group were those who had developed at least one episode of EC prior 
to sample collection. It is possible that after a patient has EC colonic mucin levels are 
persistently altered for some time, either elevated in response to the microbial threat or 
alternatively depleted, and this period may have fallen within the dates of sample 
collection.  Alternatively children who develop EC may have different, perhaps lower 
levels of WGA binding to those who do not.  Therefore those patients without EC were 
compared to those with.  (Figure 5.36) 
Both patient subgroups had greater levels of WGA binding than controls at all points 
with the exception of point D where controls demonstrated higher WGA binding levels 
than patients with a previous episode of EC.  Those who had not developed EC had 
much greater WGA binding than those who had.  The reason for this difference could be 
that an episode of EC results in persistently depleted levels of mucin.  Another 
explanation is that the reason some patients did not succumb to EC was because they 
had a thicker mucin barrier, indicated by higher WGA binding levels, so were more 
resistant.  The subgroups of low and high patient values mentioned earlier were not 
explained by the presence of confirmed EC, as the individual patients did not fall into 
the same groups. 
There was no pattern discernable when comparing those patients with rectosigmoid HD 
with those with descending colon HD or those who had washouts and those who did not. 
A possible confounding factor influencing the WGA binding levels is that the age range 
for patients and controls were slightly different; controls having a median age of 199 
days compared to patients which had a median age of 137.5 days.  Children under 3 
months are known to produce the greatest amount of mucin per unit DNA and those 
children between 3 months to 3 years the lowest.
205
   Although both groups average over  
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3 months of age if there were a gradual reduction in mucin production from 3 months to 
3 years occurs this would affect the comparability of the two groups.  
 
 
As described above, WGA binding is reported to be a good indication of total mucin 
levels and it can bind to either terminal sialic acid or N-acetylglucosamine residues.
103
     
Although WGA does show specificity towards sialic acids, studies have shown that it 
preferentially binds to N-acetylglucosamine and its ß-1,4 linked oligomers.
375
 Other 
studies using different lectins have shown that the presence of an O-acetyl group can 
block their recognition of sialic acid.
376
  Alterations in terminal residues could therefore 
in influence the level of WGA binding achieved in some patients. 
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Figure 5.36: Mean Control and Patient Subgroup WGA Binding 
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Although patients appear to have greater mucin quantity, this may not correlate with a 
better defense barrier.  Pathogens bind to the outer mucus layer initially before 
penetrating through to the mucosal cells.
146
 Pathogenic bacteria are eliminated from the 
colon when mucus shedding and degradation rates exceed colonization rates.
146
   A 
thicker mucin barrier may actually represent a poor balance between the conflicting 
processes of mucin synthesis and mucin degradation, which are necessary to maintain a 
functional defensive barrier. This would allow bacterial colonization to a level where 
mucosal damage could result.
90 
   
5.5.3  Maackia Amurensis Agglutinin Binding 
MAA binds to sialic acids, specifically to α-2,3 linked sialic acids.  Sialic acids in 
mucins are usually joined to an underlying galactose or GalNAc by an α-2,3- or a α-2,6-
glycosidic linkage.
99, 100 
Therefore, in addition to the WGA binding study, MAA 
binding was performed for the cellular soluble mucin fraction.  Patients demonstrated 
higher levels of MAA binding than controls at all points A to D, peaking at point C, but 
these results were not statistically significant, although overall binding levels had a p 
value of 0.03.  (Figure 5.37)  In controls the amount of MAA binding altered in tandem 
with control levels of WGA binding within the cellular soluble fraction.  (Figure 5.38)  
If it is assumed that a large proportion of WGA binding in controls is to sialic acids, 
there appears to be a consistent proportion of α-2,3 linked sialic acids found at points A 
to D in the normal colon.  
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In patients the relative binding of MAA to WGA is found to increase proximally at 
points C and D.  (Figure 5.39)  This suggests that there is a greater proportion of α-2,3 
linked sialic acids at these points in HD. Other studies have demonstrated 50-70% 
mucin binding using MAA, with no significant differences seen between aganglionic 
bowel, ganglionic bowel near the transition zone and normal controls, however several 
of the samples analysed in that study were rectal so are not necessarily comparable.
16 
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Figure 5.37: Median MAA Binding 
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Figure 5.38: Control MAA Binding and WGA Binding  within CSF 
Fraction 
Control MAA Control WGA
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Figure 5.39: Patient MAA Binding and WGA Binding  within CSF 
Fraction 
Patient MAA Patient WGA
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Higher levels of MAA binding could be simply due to patient having greater amounts of 
α-2,3 linked sialic acids compared to controls.  As mentioned above sialic acids are 
usually joined to the oligosaccharide chain by either an α-2,3- or a α-2,6-glycosidic 
linkage.
 99, 100 
In HD, mucin oligosaccharide synthesis may be altered, patients 
producing lower levels of α-2,6 linked sialic acids compared to controls with 
corresponding greater levels of  α-2,3 linked sialic acids.  Alternatively higher MAA 
binding may be due to lower levels of terminal α-2,8-linked sialic acids in patients.  
These residues can be attached to an α-2,3 sialic acid residue,99  and if missing would 
expose the underlying  α-2,3 residues and allow greater MAA binding.   
Terminal residues are important in mucosal immunity.  They act as decoy ligands for 
microbes trying to attach to the mucosa 
19
  and can limit the rate of bacterial degradation 
of the mucin oligosaccharide chains.
90, 100
  Alterations in HD could have implications 
for the robustness of the mucin defense barrier. 
Studies using Ulex europaeus agglutinin (UEA) did not demonstrate binding in any of 
the samples. As UEA binds to fucosyl residues and decreasing levels of fucose have 
been found from ileum to rectum this was not unexpected.
24 
5.6 Limitations of the Study  
Although the control subjects were not known to have a mucosal abnormality these 
children cannot truly be considered ‘normal’ controls by virtue of the fact that they were 
born with a bowel anomaly.  It is possible, though not reported, that mucosa mucin 
production is altered in anorectal malformations.  Ideally comparison samples should 
have been taken from children with no history of any condition affecting the colon but it 
would be impossible, ethically, to justify removal of biopsies in this situation.  A 
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possible alternative would be to seek consent from parents whose children were 
undergoing a diagnostic sigmoidoscopy or colonoscopy but there are very few clinical 
indications for this in paediatric practice, especially in those children under a year of 
age. 
When removing the biopsies there was potential for error in determining the transition 
zone in patients.  In the cases of primary pull-through the colon was viewed and the 
region of the transition zone was identified by the assessing where the distended, 
ganglionic bowel met the more contracted and collapsed aganglionic bowel and also by 
changes in blood vessel configuration.  Histological specimens sent at operation for 
immediate frozen section analysis helped to more accurately delineate the position of 
the transition zone. 
In those patients who had a diverting colostomy performed prior to definitive surgery, a 
frozen section was sent to confirm that the proximal end of the stoma was ganglionic.  
The stoma was formed in the region of the distal sigmoid colon and as the majority of 
transition zones occur in the rectosigmoid, the level of the stoma would be likely to be 
very close to the transition zone.   However, this was less well established in these cases.  
Determination of the sampling sites was open to variation between subjects.  The 
uneven and unsymmetrical nature of the transition zone 
341,342
 meant that its exact 
location was difficult to ascertain with precision.  As measurements and samples were 
taken proximally from this point there is a limitation on how accurately samples 
supposedly taken at the same biopsy level in different patients can be compared like for 
like.  In addition, during the process of measuring distance along the bowel, error could 
have occurred.  In particular when taking control samples, the bowel needed to be 
telescoped to some degree on to the biopsy forceps meaning accurate measurement was 
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difficult.  All of these factors could result in one subject’s sample B, for example, being 
the equivalent of another subject’s sample C. 
There was a change in practice during the recruitment period from the more traditional 
two or three stage surgical approach to the single stage procedure.
363, 328  
 This meant 
that colonic washouts rather than a colostomy were used to deflate the colon prior to 
corrective surgery, resulting in the patient group being more mixed than intended.   The 
small sample size meant it could not be determined whether these different methods of 
surgical correction affected the results. 
There are also some reservations on how accurately a control sample can be compared 
to a patient sample.  Controls had a colostomy sited in the lower sigmoid colon and 
biopsies were taken from the proximal end of this, the part of the colon in contact with 
faeces, as studies have shown that the mucin production in a defunctioned colon is 
abnormal.
377
  As not all the transition zones in patients were in the sigmoid, the 
comparison biopsies may have been taken at a different colonic level introducing a 
certain amount of potential sampling error. 
HD is not common and therefore recruitment of sufficient subjects was difficult.  
Control numbers and the number of samples obtained from each were lower than ideal.  
It proved more difficult to recruit control subjects as parents were reluctant to agree to 
an additional procedure when any potential results would not benefit children suffering 
from a similar condition.   
Retrieving biopsies from controls was also more difficult as during the stoma closure 
the proximal colon is not as easily accessible.  Some surgeons were reluctant to biopsy 
at 15 cms from the colostomy for this reason and hence some controls only had three 
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samples taken.  In addition one sample was inadvertently placed in formalin before 
access to the theatre was gained, effectively destroying the sample. 
All the controls had a colostomy and despite the first sample being taken from inside the 
stoma, it is possible that the distal mucin production may be falsely elevated because of 
the closer proximity to the outside.   
Patients were generally of a slightly younger age than controls.  Timing of corrective 
surgery for HD and anorectal anomalies is similar 
331 
but as control samples were 
removed at colostomy closure, at a period of time after definitive surgery, these children 
were slightly older when specimens were collected. A further contributory factor is the 
increased use of the single stage pull-through procedure in Hirschsprung’s surgery 
which is performed earlier than the two or three stage procedure.
327, 328,
 
331
 
 Several results showed wide variability between different subjects.  The relatively 
small number of subjects and samples meant that it was difficult to determine whether 
some of these results were abnormal and represent some error in the methodology or if 
these were a true reflection of the spread of results.   
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Chapter 6 - Conclusions and 
Suggestions for Further Work 
The aim of this study was to further investigate the distal ganglionic colon in 
Hirschsprung’s disease to try to determine whether previously noted abnormalities were 
present and if they were limited to the region close to the transition zone. 
This study confirmed the previous work, where the most distal ganglionic colon in HD 
patients shows abnormal mucin levels.. Newly produced mucin, as assessed by 
incorporation of two precursors, was lower than control levels closest to the transition 
zone and this was due to a lack of cellular mucins.  In contrast incorporation levels 
within the secreted mucin fraction were greater at this point than controls. 
The rest of the colon studied also showed changes in mucin production.  The colon at 
point B, 5 centimetres proximal, produced much higher levels of new mucins compared 
to controls, possible demonstrating some form of compensatory reaction to the low 
distal mucin levels.  More proximally in HD patients there was also a lack of production 
of gel-forming mucins as well as a relative lack of mucin sulphation and sulphated 
secreted mucins suggesting that certain aspects of the mucin defensive barrier remains 
abnormal up to 15 centimetres from the transition zone. 
In contrast existing in vivo mucin production seemed to be much greater in patients, as 
indicated by WGA binding levels, and there appeared to be two different groups of 
patients with either very high binding levels or lower levels, similar to controls.  The 
terminal residues found in Hirschsprung’s also appear different to controls with a 
greater proportion of α-2,3 sialic acids as demonstrated by greater levels of MAA 
binding. 
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Although Hirschsprung’s disease is a rare condition,207  the associated problem of 
enterocolitis still causes significant morbidity and mortality 
331, 348
  and the fact that the 
ability to produce new mucins is diminished in the distal ganglionic colon suggests that 
this could be a contributing factor. Extended surgical resection of the distal 5 
centimetres of the ganglionic colon at pull-through surgery would remove this region. 
However, the next 15 centimetres of ganglionic colon would retain these identified 
mucin abnormalities which may affect the defensive capacity of the colon and still 
render patients susceptible to infective complications including enterocolitis. 
Suggestions for further work 
Due to the uncommon nature of Hirschsprung’s disease 207 and the wide spread of 
results obtained, a large multicentre study is needed in order to recruit enough patients 
and controls to generate more definitive results.  This would also allow patient 
subgroups to be studied; for example, those who developed pre and/or post operative 
enterocolitis, to determine whether they had different mucin profiles, in order to better 
establish a link between aspects of mucin production and risk.    
Better correlation between the site of patient and control samples is also needed.  This 
may require more stringent inclusion and exclusion criteria. In laparoscopic assisted 
pull-through surgery, which is becoming the more common form of corrective surgery, 
intra-operative colon mapping is performed, where biopsies are removed from different 
sites and sent for immediate frozen section analysis. This allows a more exact placement 
of the transition zone and could be utilized in further studies with only those children 
undergoing this form of procedure included. 
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Controls were children who had a sigmoid colostomy placed and it is difficult to find a 
more comparable group from which biopsies could be easily and ethically removed.  
Placing a stoma in this group is essentially a blind procedure and it would be difficult to 
determine exactly where along the sigmoid the proximal end was.  Before stoma 
closure, these children often have a distal contrast study performed where radio opaque 
fluid is instilled from either the distal colostomy loop or from the rectum and 
radiological imaging taken.  It may be possible to estimate the length of colon distally to 
the stoma as well as estimating this distance intra-operatively in patients and aim to 
match controls and patients better.   
A further way of establishing the site of the colostomy in controls would be to perform 
the addition procedure of an on table sigmoidoscopy/colonoscopy and estimate the 
distance from a definable landmark such as the splenic flexure in order to better match 
biopsy samples.  However, it may be difficult to justify this on ethical grounds.  
Concurrent analysis on biopsies looking at the levels of neuropeptide markers and the 
arrangement of neuropeptide nerves within the specimens could help determine a 
correlation between poor mucin production and ENS abnormalities. 
Previous studies on the distal ganglionic bowel and aganglionic bowel have not shown 
differences in MUC mRNA levels but this has not been established at higher levels.  It 
would also be useful to try to establish exactly which mucins are found in the secreted 
soluble, cellular soluble and cellular insoluble fractions to see if mucin expression is 
altered in HD. 
The results from the slot blots were very interesting.  A larger study would help to 
establish whether there are two subgroups of patients with very high or low WGA 
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binding levels. Due to the time constraints of establishing a working methodology, the 
cellular insoluble and secreted soluble fractions were not analysed for MAA binding. 
This could provide useful information.   
The mucin peak samples could be further analysed to ascertain the length of 
oligosaccharide chains
 
and to determine the nature of the terminal residues.  Blood 
group probes could be used and levels of O-acetylation of sialic acids could be assessed 
to see if this varies higher up the colon.  This would also help to clarify whether 
differences in WGA binding levels are due to greater amounts of mucin present or 
greater sialylation.  It may also be possible to determine levels of α-2,8, linked sialic 
acids, to see if these are deficient in Hirschsprung’s disease and whether this accounts 
for greater MAA binding.
378
 
The theory mentioned previously that greater WGA binding may be due to subclinical 
infection in some patients could be further researched by collecting stool samples in 
subjects to see if they showed evidence of pathogen carriage or by carrying out further 
studies on part of the biopsy specimen, in tandem with organ culture, to determine 
whether pathogens are present.  
Analysis of the constituents of the back peak would also yield useful information to 
ascertain whether low mucin production is associated with more widespread mucosal 
synthesis problems or if the back peak is mainly composed of mucin precursors.   
The lower relative sulphation in the proximal Hirschsprung’s colon could be further 
investigated by assessing the expression of sulphotransferases to see if these are also 
altered in HD.   
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The interesting findings of much high new mucin production in the colon next to the 
area of low production is worthy of further study but it is difficult to suggest a strategy 
for this.  Whether colonic conditions can be simulated in the laboratory, with a section 
of colon placed in organ culture and mucin production in one area actively suppressed 
and the mucin production in response to this determined, would need careful 
consideration. 
This research has resulted in some very interesting results but much more work is 
required to fully understand the changes in mucin production in the ganglionic colon in 
Hirschsprung’s disease patients. 
 
.   
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PARENT INFORMATION SHEET    Version 03/121 
 
 
A Study of the Large Bowel’s Defence against Inflammation in Hirschsprung’s 
Disease 
 
 
What is Hirschsprung’s Disease? 
Hirschprung’s disease is a congenital condition where nerve cells in the bowel are 
absent.  This means that the bowel does not work properly and becomes blocked.  The 
‘pull through’ operation removes the part of the bowel without nerve cells and joins 
normal bowel to normal bowel.   
 
 
What is this project about? 
Unfortunately some children develop inflammation of the bowel (enterocolitis)after this 
operation which can prolong their recovery and in some cases make them very unwell.  
Previous studies have shown that the so-called ‘normal’ bowel in these children, has a 
defective barrier to infection and that this correlates with their chance of developing 
enterocolitis.  What we currently do not know is whether this defective barrier extends 
throughout the whole bowel or whether it only occurs near where the abnormal and 
‘normal’bowel meet. 
 
 
What is the aim of this study? 
The aim of this study is to find this out.  If we can tell how much bowel is affected in 
this way we could remove it during the operation and therefore reduce the number of 
children suffering with enterocolitis in the future.  We are asking you, as the parent of a 
child with Hirschsprung’s disease, whether you would like to participate in this 
research.  If you decide to decline this will NOT affect the treatment your child receives 
in any way. 
 
 
Who is organising the study? 
The research project is being carried out within the Paediatric surgery department. The 
principal research investigator is Miss Ruth Groves, a clinical research fellow working 
within the department under the close supervision of Mr Aslam, consultant paediatric 
surgeon. 
  
 
What is involved? 
During the ‘pull through’ operation 4 small (4mm2) samples of tissue (biopsies) would 
be taken from the large bowel.  These would be removed by the surgeon performing the 
operation.  The extra time taken would be a matter of a couple of minutes.  The samples 
are then sent to the laboratory for analysis.  The samples will NOT be used for any other 
research.  All you have to do in order to take part is to sign a consent form giving your 
permission for the samples to be taken. 
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Are there any risks involved? 
At the time of taking a biopsy there is a small chance that a hole could be made in the 
bowel.  As the surgeon is able to see the bowel as s/he takes the samples, this is made 
very unlikely, but if this did occur this would be noticed at the time and the hole 
repaired with a stitch.  There can also be a small amount of bleeding from the biopsy 
site but this should be minimal within the context of the operation as a whole.   
 
 
Are there any compensation arrangements if anything did go wrong? 
In the unlikely event of something going wrong, if this is due to medical negligence this 
will be covered by the hospital trust.  There are no arrangements for non-negligent 
compensation. 
 
 
Who will have access to my child’s notes? 
Only the principal investigator will use medical records for the purpose of the study.  
Data collected will be anonyomised.  Your GP will be informed of your participation. 
 
 
What happens at the end of the study? 
The results will be processed and analysed and the data will be sent for publication.  
Depending on the results current surgical practice in dealing with these children may be 
altered to reduce complications for future children.  
 
 
 
Thank you for agreeing to take part in this valuable piece of research.  Remember 
that you can withdraw from this study at anytime, WITHOUT explanation and 
WITHOUT affecting your child’s current or future treatment. 
 
 
 
Contact person: Ruth Groves 
   Department of Paediatric Surgery, 
   Box 201. 
   01223 245151 ext 4455 (Mr Aslam’s secretary) 
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PARENT INFORMATION SHEET:CONTROL SUBJECT Version 1 
 
 
A Study of the Large Bowel’s Defence against Inflammation in Hirschsprung’s 
Disease 
 
 
 
What is Hirschsprung’s Disease? 
Hirschprung’s disease is a congenital condition where nerve cells in the bowel are 
absent.  This means that the bowel does not work properly and becomes blocked.  The 
‘pull through’ operation removes the part of the bowel without nerve cells and joins 
normal bowel to normal bowel.   
 
 
What is this project about? 
Unfortunately some children develop inflammation of the bowel (enterocolitis)after this 
operation which can prolong their recovery and in some cases make them very unwell.  
Previous studies have shown that the so-called ‘normal’ bowel in these children, has a 
defective barrier to infection and that this correlates with their chance of developing 
enterocolitis.  What we currently do not know is whether this defective barrier extends 
throughout the whole bowel or whether it only occurs near where the abnormal and 
‘normal’bowel meet. 
 
 
What is the aim of this study? 
The aim of this study is to find this out.  If we can tell how much bowel is affected in 
this way we could remove it during the operation and therefore reduce the number of 
children suffering with enterocolitis in the future.  We are asking you, as the parent of a 
child who has a colostomy which is to be reversed, whether you would like to 
participate in this research.  The information we gather from your child is extremely 
important in order for us to draw meaningful conclusions from the data we collect from 
children with Hirschsprung’s disease. Your child will be acting as a control subject.  If 
you decide to decline this will NOT affect the treatment your child receives in any way. 
 
 
Who is organising the study? 
The research project is being carried out within the Paediatric surgery department. The 
principal research investigator is Miss Ruth Groves, a clinical research fellow working 
within the department under the close supervision of Mr Aslam, consultant paediatric 
surgeon. 
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What is involved? 
During the closure of colostomy operation, 4 small (4mm
2
) samples of tissue (biopsies) 
would be taken from the large bowel.  These would be removed by the surgeon 
performing the operation.  The extra time taken would be a matter of a couple of 
minutes.  The samples are then sent to the laboratory for analysis.  The samples will 
NOT be used for any other research.  All you have to do in order to take part is to sign a 
consent form giving your permission for the samples to be taken. 
 
 
Are there any risks involved? 
At the time of taking a biopsy there is a small chance that a hole could be made in the 
bowel.  As the surgeon is able to see the bowel as s/he takes the samples, this is made 
very unlikely, but if this did occur this would be noticed at the time and the hole 
repaired with a stitch.  There can also be a small amount of bleeding from the biopsy 
site but this should be minimal within the context of the operation as a whole.   
 
 
Are there any compensation arrangements if anything did go wrong? 
In the unlikely event of something going wrong, if this is due to medical negligence this 
will be covered by the hospital trust.  There are no arrangements for non-negligent 
compensation. 
 
 
Who will have access to my child’s notes? 
Only the principal investigator will use medical records for the purpose of the study.  
Data collected will be anonymised.  Your GP will be informed of your participation. 
 
 
What happens at the end of the study? 
The results will be processed and analysed and the data will be sent for publication.  
Depending on the results current surgical practice in dealing with these children may be 
altered to reduce complications for future children.  
 
 
 
Thank you for agreeing to take part in this valuable piece of research.  Remember 
that you can withdraw from this study at anytime, WITHOUT explanation and 
WITHOUT affecting your child’s current or future treatment. 
 
 
 
Contact person: Ruth Groves 
   Department of Paediatric Surgery, 
   Box 201. 
   01223 245151 ext 4455 (Mr Aslam’s secretary) 
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CONSENT FORM 
 
A Study of the Large Bowel’s Defence against Inflammation in Hirschsprung’s 
Disease. 
 
LREC Reference Number: 03/121 
 
Lead investigator Ruth Groves. 
 
 
Please read the following statements, initial the boxes accordingly and sign at the 
bottom. 
 
 
      1.    I confirm that I have read and understood the information sheet (version 1 ) for the 
 above study and have had the opportunity to ask questions. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of my child’s notes may be looked at by responsible 
individuals employed by the hospital trust, where it is relevant to my taking part 
in research.  I give permission for these individuals to have access to my child’s 
records. 
 
4. I am willing that my general practitioner is notified of my participation in this  
research. 
 
 
5. I agree that my child is to take part in the above study. 
 
 
                                                
Name of child   Date   Signature 
 
      Relationship to child:      
 
                                  
Name of Witness to Signature  Date   Signature 
 
                       
Name of Research Team Member Date   Signature 
 
(3 copies, one for parent, one for researcher, one for medical notes) 
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LETTER TO GENERAL PRACTITIONER 
Department of Paediatric Surgery, 
Box 267, 
Addenbrookes Hospital, 
Hills Road, 
Cambridge. 
CB2 2QQ           
 
 
Re: A Study of the Mucus Defensive Barrier in the Pulled-through Bowel in 
Hirschsprung’s disease         
 
                                   (Child’s name) 
 
 
 
Dear Dr    , 
 
I am writing to inform you that    (child’s name) parents have kindly 
agreed to participate in a research project run by the Paediatric Surgery department. 
 
Previous research in this field has demonstrated that the ganglionic bowel in 
Hirschsprung’s disease has a defective mucus defence barrier and that this correlates 
with the risk of these children developing enterocolitis after ‘pull through’ surgery.  
What is not known is whether this deficiency extends throughout the bowel or is limited 
to an area close to the aganglionic bowel which could, therefore, potentially be resected 
at surgery, thus reducing the post-operative incidence of enterocolitis.  
 
The current research project involves taking 4 small biopsies at different sites from the 
colon at the time of ‘pull-through’ surgery, or, in the case of  controls, at the time of 
closure of colostomy, and analysing these for mucin turnover. 
 
This should make no different to the usual post-operative course for these children and 
there are no anticipated problems. 
 
Please feel free to contact me if you have any questions or concerns. 
 
 
Yours Sincerely, 
 
 
Miss Ruth Groves 
Clinical Research Fellow 
Department of Paediatric Surgery 
01223 245 151  bleep 152-681 
 
